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G protein-coupled receptors (GPCRs) 
G protein-coupled receptors (GPCRs) make up a large family of cell surface receptors. So far, 
more than a thousand GPCR family members have been identified, including the receptors for 
many neurotransmitters, neuropeptides, peptide hormones and small molecules such as ions 
and protons (Bartfai et al., 2004). These proteins derive their name from their interaction with 
guanine nucleotide-binding proteins (G proteins). 
The members of GPCRs share two major structural and functional similarities. Firstly, they 
are transmembrane proteins characterized by seven membrane-spanning  helices connected 
by intra- and extracellular loops. Secondly, the binding of agonistic ligands to the receptors 
elicits conformational changes of the receptor and activates the G protein. In this manner the 
receptors transfer extracellular signals to intracellular targets. 
G proteins consist of three subunits: , , and . The binding of guanine nucleotides to the 
subunit regulates G protein activity. In the resting state, GDP is bound to the  subunit which 
forms a complex with the  and  subunit. Agonist binding to a GPCR induces a 
conformational change in the receptor, enabling the cytosolic domain of the receptor to 
interact with the G protein and stimulate the exchange of bound GDP for GTP. Next, the 
and  subunits, which remain together and function as a  complex, dissociate from the 
activated GTP-bound  subunit. Subsequently, both the active GTP-bound  subunit and the 
 complex interact with their targets to activate downstream responses. The activity of the 
subunit is terminated by the hydrolysis of the bound GTP, and the inactive  subunit (now 
with GDP bound) reassociates with the  complex, making the G protein ready for a new 
activation cycle (Patrick, 2001). 
G proteins have been classified into four protein families based on their -subunit
composition: Gs, Gi, Gq/11 and G12/13. The major effectors regulated by G include adenylyl 
cyclase (stimulated by Gs and inhibited by Gi), phospholipase C (PLC) (stimulated by Gq/11)
and K+ channels (stimulated by Gi). The second messengers produced by these enzymes 
trigger the complex downstream signaling cascades. So far, 16 , 5  and 14  isoforms have 
been identified which implies the potential to create many different G protein complexes 
(Milligan and Kostenis, 2006).
Classification of GPCR Ligands  
Two classic GPCR ligands are well known: ligands that produce physiological responses 
through activation of receptors are referred to as agonist while molecules which interfere with 
the interaction between agonists and the receptors are denoted as antagonists. 
From a more recent pharmacological point of view, it is accepted that antagonists can be 
further classified as neutral antagonists and inverse agonists based on their ability to reduce 
the agonist-independent activity of receptors (Neubig et al., 2003; Milligan, 2003). 
Antagonists that reduce the level of agonist-independent functional responses are called 
inverse agonists or ligands with negative intrinsic activity whereas antagonists that do not 
reduce agonist-independent activity are referred to as neutral antagonists. Most endogenous 
ligands are agonists, but on a few constitutively active receptors endogenous inverse agonists 
have been identified such as retinal for rhodopsin and agouti-related protein for the 
melanocortin-4 receptor (Fishkin et al., 2004; Adan et al., 2003). Moreover, chemokines may 
be agonist ligands for one subtype of receptors while interacting as inverse agonists with other 
chemokine receptors (Petkovic et al., 2004). 
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Constitutive activity or the spontaneous activation of receptors is a feature of quite a few 
GPCRs and was initially reported for the  opioid receptor (Koski et al., 1982) and the 2-
adrenoceptor (Cerione et al., 1984). Increased constitutive GPCR activity is one of the causes 
of GPCR-related diseases, a prominent example being the increased constitutive activity of 
rhodopsin resulting in night blindness (Rao et al, 1994). Since inverse agonists are the only 
ligands which can reduce the constitutive activity of GPCRs, the therapeutic relevance of 
these ligands is implied in diseases stemming from increased constitutive activity. So far, the 
majority of clinically used compounds, which were originally reported to be antagonists, have 
been reclassified as inverse agonists (Bond and IJzerman, 2006; Milligan, 2003).  
Negative intrinsic efficacy is a property of the ligand but its magnitude depends on receptor 
test systems (Kenakin, 2004b). In theory, inverse agonism or positive partial agonism should 
predominate in the world of antagonists and true neutral antagonists should be rare (Kenakin, 
2004b). However, as will be described in Chapter 3, the experimental window determines 
whether partial (inverse) agonism can be detected. 
The site where these endogenous ligands bind is referred to as the orthosteric binding site. 
Allosteric ligands or allosteric modulators on the other hand bind to a site different from this 
orthosteric site, the so-called allosteric site, to modulate the binding and/or signaling 
properties of the endogenous ligand (May et al., 2007). (Kinetic) radioligand binding assays 
are powerful tools to identify allosteric ligands. 
Receptor models 
Mathematical models have proven instrumental to link experimental observations to 
theoretical predictions of receptor-ligand interactions at the molecular level (Kenakin, 2003). 
To understand the relationship between receptor-ligand interactions and physiological 
responses, various receptor models have been developed and tested. The most important 
models are discussed below. 
Two-state receptor model 
The two-state receptor model is a receptor activation model which originated from a model 
explaining ion channel activation and which was adapted for receptors (Kenakin, 2003). The 
two-state model assumes that the receptors exist in equilibrium between two states, the active 
R* and inactive R states. The isomerization constant (L) determines the ratio between the two 
receptor populations and the intrinsic efficacy  determines the affinity of a ligand to R* and 
R state receptors (see Figure 1). This model assumes that ligands have biased affinity for  
Figure 1. Two-state receptor model.
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either one of the two receptor states. It provides a useful tool to explain receptor 
activation/inactivation in the presence or absence of a ligand. This model will be discussed in 
detail in Chapter 3 and Chapter 4.
Ternary complex model 
The ternary complex model was introduced to recognize the ability of guanine nucleotides to 
affect the affinities of agonists. This model assumes the existence of two stages in ligand 
binding: firstly ligands bind to receptors, and then the receptor-ligand complex binds to a G 
protein (De Lean et al., 1980). This model accounts for a novel concept in receptor activation, 
which defines that the responsivity of a system is subject to the availability of G proteins 
(Kenakin, 2004a). The ternary complex model is rather simple but illustrates that a signalling 
molecule functions via a receptor to activate a G-protein (see Figure 2). The limitation of this 
model lies in the fact that a receptor is allowed to exist in only one of two ligand-dependent 
states, an inactive (agonist free) and an active (agonist bound) state. 
Figure 2. Ternary complex model. 
Extended ternary complex model
To explain experimental observations such as ligand independent G protein activation or 
constitutive activation (Costa and Herz, 1989), the extended ternary complex model, or ETC 
model was developed (Samama et al., 1993). The ETC model incorporates an important 
concept from the two-state receptor model, namely the assumption that ligands have biased 
affinity for different receptor species. This model is therefore able to explain how a receptor 
functions in both an agonist-dependent and an agonist-independent manner and is also able to 
explain antagonist-mediated and inverse agonist-mediated effects (see Figure 3). On the other 
hand, in contrast to the two state receptor model and the ternary complex model, the ETC 
model assumes the existence of an infinite number of receptor states rather than just two states. 
Parameter  in the ETC model confers different affinities for G proteins interacting with 
ligand-receptor complexes than for G proteins interacting with unliganded receptors (Kenakin, 
2004a). This model, however, does not consider an association of G-proteins with receptors in 
the inactive state.  
Figure 3. Extended ternary complex model. 
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Cubic ternary complex model  
To account for an association of G-proteins with inactive state receptors, the cubic ternary 
complex model (CTC model) was created (Weiss et al., 1996). This model allows both 
ligands and G-proteins to interact independently with either the active or inactive state of a 
receptor. As a result this model can explain both ligand-independent signalling, as well as the 
influence of G-proteins on ligand binding and vice versa the influence of ligands on G-protein 
interactions (see Figure 4).
Figure 4. Cubic ternary complex model. 
Allosteric two-state model 
Accommodation of allosteric ligand interactions into the two-state model resulted in yet 
another cubic model known as the allosteric two-state model (Hall, 2000). In this model, 
effects of the allosteric ligand on orthosteric ligand binding as well as effects of allosteric 
ligands on the receptor by themselves are considered (see Figure 5). This allosteric two-state
model successfully explained the allosteric effects of PD 81,723 on the adenosine A1 receptor 
(Hall, 2000). The parameters of this model will be discussed in Chapter 6.
Figure 5. Two-state allosteric receptor model.
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Classification of GPCRs 
GPCRs have been classified into three major subfamilies on the basis of their similarity to 
rhodopsin (class A), secretin receptors (class B) and glutamate receptors (class C) (Probst et 
al., 1992). This classification is based on the chemical nature of their natural ligands (Morris 
and Malbon , 1999). Class A (rhodopsin-like) GPCRs are by far the largest group, and include 
besides rhodopsin e.g. the olfactory receptors, amine receptors and nucleotide-like receptors. 
Class B GPCRs consist of only 25 members, including the receptors for the gastrointestinal 
peptide hormone family. Class C is also relatively small, and contains the metabotropic 
glutamate receptor family, the GABAB receptor, and the calcium-sensing receptor, as well as 
some taste receptors. All Class C members are characterized by a very large extracellular 
amino terminus which seems to be crucial for ligand binding and activation. There are two 
minor subfamilies of GPCRs as well. Yeast pheromone receptor and cAMP receptor have 
been classified as Class D and Class E GPCRs, respectively. So far, the existence of 
frizzled/smoothened family is still debated. 
Adenosine receptors and their subtypes 
Adenosine receptors were named after their endogenous ligand adenosine, which is a purine 
produced in our body with a short half life (Moser et al., 1989). Adenosine receptors belong to 
Class A GPCRs and can be divided into four subtypes: A1, A2A, A2B and A3. This 
nomenclature is based on several discoveries: Van Calker found different effects of adenosine 
on cAMP production, and discriminated between inhibitory A1 (or Ri) and stimulatory A2 (or 
Rs) receptors (Van Calker et al., 1979). Daly and Bruns further subdivided the A2 receptors 
into two groups based on the identification of high (A2A) and low (A2B) affinity binding sites 
(Daly et al., 1983; Bruns et al., 1986). In contrast to these adenosine receptors the A3 receptor 
was first cloned and then pharmacologically characterized (Meyerhof et al. 1991; Zhou, et al., 
1992).
Adenosine A2B receptor 
Cloning
Adenosine A2B receptors were first cloned from rat hypothalamus (Rivkees and Reppert, 1992) 
and human hippocampus (Pierce et al., 1992). Two years later, in 1994, this receptor was 
cloned from mouse mast cells (Marquardt et al., 1994). In 1997, the adenosine A2B receptor 
was identified and cloned from chicken cell lines and tissues (Worpenberg et al., 1997). It is 
noticeable that A2B receptors are rather conserved among mammalian species: A2B receptors 
from closely related species rat and mouse share 96% amino acid sequence homology; and 
human A2B receptors share 86 to 87% amino acid sequence homology with the rat and mouse 
A2B receptors individually (Feoktistov and Biaggioni, 1997). 
Distribution 
The mRNA of the adenosine A2B receptor was originally detected in a limited number of rat 
tissues by Northern blot, such as cecum, bowel, bladder, brain, spinal cord, lung, epididymis, 
vas deferens, and pituitary (Stehle et al., 1992). Later, a more sensitive reverse transcriptase-
polymerase chain reaction (RT-PCR) technique revealed a ubiquitous distribution of
adenosine A2B receptors, with the highest levels found in the proximal colon and the lowest 
levels in rat liver (Dixon et al., 1996). The wide-spread distribution of adenosine A2B
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receptors was further confirmed by western blotting and immuno-staining with an anti-A2B
receptor antibody in human and murine tissues (Puffinbarger et al., 1995). 
Structure
Being a member of the GPCR family, adenosine A2B receptors consist of 7 transmembrane 
regions linked by intra- and extracellular loops and flanked by an N terminal and a C-terminal. 
Two potential N-glycosylation sites were found in the 2nd extracellular loop of the A2B
receptors (Rivkees and Reppert, 1992; Pierce et al., 1992; Marquardt et al., 1994), which 
accounts for the 50-52 kD protein bands on western blot observed for a 36-37 kD receptor 
(Feoktistov et al., 2003a). However, the functional role of glycosylation is still unknown.
So far, the crystal structure of the A2B receptor has not yet been experimentally elucidated, 
however a number of homology models according to the crystal structure of bovine rhodopsin 
and the human 2-adrenoceptor have been built (Ivanov et al., 2005; Chapter 5).
Signaling pathway 
It is well known that A2B receptors are coupled to Gs proteins and activate adenylyl cyclase 
(Linden, 2001). Activation of this pathway results in accumulation of cAMP and stimulation 
of protein kinase A (PKA); the latter in turn phosphorylates other proteins in the cells. 
Another important signalling pathway of A2B receptors is the phospholipase C (PLC) pathway 
via Gq/11, which was found in mast cells and HEK293A2B cells (Marquardt et al., 1994; 
Feoktistov and Biaggioni, 1995; Auchampach et al., 1997; Linden 1999). Activation of this 
pathway results in an increased production of diacylglycerol (DAG) and inositol trisphosphate 
(IP3). Both molecules activate downstream signaling cascades. DAG activates protein kinase 
C (PKC), which phosphorylates other cellular proteins and modulates cellular Ca2+
concentrations (Feoktistov et al., 1997). IP3 activates the mobilization of calcium from 
intracellular stores. Except for modulating cellular Ca2+ concentrations via Gq, A2B receptors 
were also suggested to increase intracellular calcium by directly activating ion channels in 
human erythroleukemia (HEL) cells via Gs (Feoktistov et al., 1994). In addition, recombinant 
rat A2B receptors were reported to increase a calcium-dependent chloride conductance in 
Xenopus oocytes presumably via the PLC pathway (Yakel et al., 1993). A few studies 
revealed the ability of adenosine A2B receptors to regulate guanylate cyclase in various tissues. 
Shin indicated that adenosine A2B receptors induced vasodilation through cGMP in the pial 
artery (Shin et al., 2000). Kang suggested that stimulation of the A2B receptor plays an 
inhibitory role in central cardiovascular regulation via the cGMP pathway (Kang et al., 2007). 
cGMP-mediated signaling via the adenosine A2B receptor was also reported by Olanrewaju 
and Mustafa in porcine coronary artery endothelial cells resulting in NO release (Olanrewaju 
and Mustafa, 2000). 
To study desensitisation of the A2B receptor, several heterologous expression systems have 
been used (Mundell et al., 1997; Peters et al., 1998; Sitaraman et al., 2000; Haynes et al., 
1999). Experiments in COS-7 cells showed the A2B receptor to be subject to agonist-induced 
desensitization. In addition, restoration of activity was observed after recovery of COS-7 cells 
in growth medium for 24 hr (Peters et al., 1998). Desensitisation of endogenously expressed 
A2B receptors has been investigated as well. In rat lung microcirculation preconstricted with a 
hypoxic gas, initial administration of NECA caused a normal vasodilatory response after 3-4 
min while readministration of NECA after 45 min resulted in minimal vasodilation, which is 
caused by the internalization of A2B receptor (Haynes et al., 1999). In a further study, G 
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protein-coupled receptor kinase 2 (GRK2) was suggested to be involved in A2B receptor 
phosphorylation and internalization in NG108-15 mouse neuroblastoma X rat glioma cells. In 
these experiments the NG108-15 cells transfected with the inactive K220R mutant GRK2, 
demonstrated significantly reduced NECA-induced A2B receptor desensitization compared 
with control (Mundell et al., 1997).
More recent mutation studies revealed involvement of arrestin-2 and showed that the C 
terminus of A2B receptor is critical for the receptor desensitization and internalization 
(Matharu et al., 2001). F328stop and the Q325stop mutant A2B receptors were resistant to 
rapid agonist-induced desensitization and internalization although both mutants were able to 
induce cAMP accumulation. Fluorescently labeled arrestin-2-GFP showed a rapid 
translocation when co-expressed with WT A2B receptor in the presence of agonist. However, 
when coexpressed with these two truncated mutants, no translocation was observed. Within 
the C-terminus, S329 is a critical residue for A2B receptor internalization, as this mutant could 
not undergo rapid agonist-induced desensitization and internalization. 
Physiological effects and therapeutic relevance
Due to the fact that selective agonists for the A2B adenosine receptors were lacking in the past 
decades, the functional significance of this receptor is not fully understood despite intensive 
experimental efforts. However, by using combinatorial pharmacological approaches with 
nonselective A2B agonists and selective receptor antagonists, the involvement of the adenosine 
A2B receptor in several biological systems has been revealed. The emergence of more 
selective A2B agonists in latest years provided useful tools to further study physiologic roles 
of A2B receptors (Kuno et al., 2007; Eckle et al., 2007). 
Vascular and cardiac function
Adenosine elicits relaxation in smooth muscle cells in the cardiovascular system via 
adenosine A2A and/or A2B receptors, which results in vasodilation (Feoktistov et al., 1997). 
The involvement of either A2A or A2B receptors in vasodilation is species-dependent. The role 
of A2B receptors in vasodilation in the vascular beds of guinea pig aorta, dog saphenous vein 
and coronary arteries was proven quite inconclusively by the fact that this effect was mediated 
by the nonselective agonist NECA rather than the selective A2A receptor agonist CGS 21680 
(Martin, 1992; Balwierczak et al., 1991).
In addition, several studies suggest a vascular and cardioprotective role of adenosine A2B
receptors. The adenosine A2B receptor was suggested to play a critical role in regulating 
vascular remodelling associated with endothelial cell proliferation in angiogenesis, collateral 
vessel development, and recovery after vascular injury since activation of A2B receptors was 
observed to induce endothelial cell growth (Dubey et al., 2002). In addition, long-term 
stimulation of adenosine A2B receptors after myocardial infarction was shown to attenuate 
cardiac fibrosis in the non-infarcted myocardium and to improve cardiac function (Wakeno et 
al., 2006). Moreover, a recently published study reveals a cardioprotective function of 
adenosine A2B receptors during myocardial ischemia based on two observations: 1) mice with 
deficiencies in adenosine A2B receptors showed increased susceptibility to acute myocardial 
ischemia; 2) treatment with the selective A2B receptor agonist BAY 60–6583 significantly 
attenuated infarct sizes after ischemia (Eckle et al., 2007). This protective effect was 
confirmed upon reperfusion of rabbit heart by application of BAY 60-6583 (Kuno et al.,
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2007). Finally,  a study in A2B receptor knockout (KO) mice model, suggests a mechanism of 
action as the A2B receptor was found to regulate CXCR4 expression in vivo thereby protecting 
against vascular lesion formation (Yang et al., 2008).
Next to this interaction with a chemokine receptor, the adenosine A2B receptors have also 
been reported to act in a functionally cooperative fashion with other adenosine receptor 
subtypes in the cardiovascular system. For example, A2B receptors cooperatively act with A3
receptors to promote angiogenesis by stimulating human umbilical vein endothelial cell 
proliferation and migration, and to induce capillary tube formation (Feoktistov et al., 2003b). 
Role in inflammation and lung diseases 
Due to low affinity to adenosine, A2B receptors are assumed to remain silent under normal 
physiological conditions, and become important only during conditions such as inflammation 
when concentrations of adenosine increase (Fredholm et al., 2001).  
Evidence for a potential role of adenosine in the pathogenesis of asthma has been growing 
steadily since the early observation of its bronchoconstrictor effect in human asthmatics. In 
the early 1980s, it was shown that adenosine or AMP induces bronchoconstriction in 
asthmatics but not in normal subjects (Cushley et al., 1983). 
Activation of the adenosine A2B receptor has been shown to result in degranulation in canine 
mastocytoma mast cells (BR line) and to increase the release of inflammatory cytokines IL-3, 
IL-4, IL-8 and IL-13 in human leukemia mast cells (HMC-1) (Feoktistov and Biaggioni, 1995; 
Auchampach et al., 1997; Feoktistov et al., 2003b; Ryzhov et al., 2004). The release of these 
cytokines can induce IgE synthesis by B lymphocytes (Ryzhov et al., 2004). Likewise, 
adenosine-mediated activation of A2B receptors increases the release of inflammatory 
cytokines from human bronchial smooth muscle cells, human lung fibroblasts, and human
airway epithelial cells (Zhong et al., 2004; Zhong et al., 2005). These cytokines, in turn, 
induce differentiation of lung fibroblasts into myofibroblasts (Zhong et al., 2005) and increase 
the release of tumor necrosis factor  (TNF) from monocytes (Zhong et al., 2006). These 
effects of adenosine have been shown to be inhibited by selective antagonists of the A2B
receptors (Feoktistov and Biaggioni, 1995; Feoktistov et al., 2001; Ryzhov et al., 2004; Zhong 
et al., 2004; Zhong et al., 2005; Zhong et al., 2006). 
In a more recent study, an allergic mouse model was set up and used to study the role of A2B
receptors on airway reactivity and inflammation in asthma (Mustafa et al., 2007). In this study, 
the A2B selective antagonist CVT-6883 significantly inhibited airway inflammation. In 
another study with adenosine deaminase-deficient (ADA-deficient) mice, which develop 
pulmonary inflammation and injury due to increased lung adenosine levels, the A2B selective 
antagonist CVT-6883 was found to prevent the development of pulmonary inflammation, 
airspace enlargement, and airway fibrosis in the lungs (Sun et al., 2006). All this evidence 
points to an important role for adenosine A2B receptors in the pathophysiology of asthma and 
suggests that this receptor is a key player in lung diseases. 
Neurosecretion and Neurotransmission 
Adenosine inhibits norepinephrine release from peripheral noradrenergic nerve terminals 
(Wakade and Wakade, 1978). According to the rank order of potencies of agonists, the 
inhibition of norepinephrine release in isolated canine pulmonary arteries was attributed to 
A2B receptors (Tamaoki et al., 1997). In a similar way, adenosine-induced inhibition of 
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neurotransmission in rabbit corpus cavernosum is also mediated via A2B receptors (Chiang et 
al., 1994).
Various
Next to the above-mentioned physiological and therapeutic applications of the adenosine  
A2B receptor, this receptor has been shown to affect the expression of a series of genes  
and even other receptors to modulate other cellular effects. For example, stimulation of A2B
receptors elevated cAMP levels, which in turn decreased collagenase gene expression in 
interleukin-1-stimulated cultured fibroblast-like synoviocytes (Boyle et al., 1996). On the 
contrary, fibroblast growth factor-7 (FGF-7) was observed to be upregulated by A2B receptors 
(Iino et al., 2007). In a recent report, A2B receptors were observed to up-regulate the cell 
surface expression of CXCR4  receptor (yang et al., 2008) and to down-regulate the netrin 
UNC5A receptor (McKenna, et al., 2008). In addition to receptor expression levels, the 
adenosine A2B receptor was also demonstrated to recruit apoptosis-inducing DCC (deleted in 
colon cancer) receptors from an intracellular pool to the cell surface (Bouchard et al., 2004).
Other physiological role of A2B receptors includes being implied in epithelial chloride 
secretion (Strohmeier et al., 1995), to prevent loss of the endothelial barrier’s integrity in 
corneal endothelial cells (D’hondt et al., 2007). 
Therapeutic application of agonists and antagonists 
A2B receptor is able to induce angiogenesis, to reduce vascular permeabilization and to 
increase anti-inflammatory cytokine (Volpini et al., 2003; Clancy et al., 1999; Dubey et al., 
2005; Mohsenin and Blackburn, 2006). Thus A2B receptor selective agonists were proposed 
for the treatment of septic shock, cystic fibrosis, and cardiac, kidney and pulmonary diseases 
associated with remodeling and hyperplasia.  
Adenosine A2B receptor antagonists, on the other hand, may play an important role in the 
treatment of inflammatory disorders and lung diseases (Feoktistov et al., 1998; Rosi et al., 
2003; Mustafa et al., 2007; Sun et al., 2006), The therapeutic benefit of A2B antagonists 
includes the treatment of asthma (Landells et al., 2000), type-II diabetes (Volpini et al., 2003), 
and Alzheimer’s disease (Rosi et al., 2003). 
Pharmacology of adenosine A2B Receptors 
Due to the therapeutic relevance, intensive synthesis efforts have been devoted in the past 
decades to identify selective, high affinity adenosine A2B receptors ligands. The search for 
antagonists was very successful and led to the identification of selective compounds 
belonging to various chemical classes. Just recently also selective agonists have been 
identified. A brief overview of the identification of selective ligands is presented below, more 
details are to be found in a recently published review (Beukers et al., 2006). 
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Table 1.  EC50 of A2B agonists and Ki of A2B antagonists commonly used to study the A2B receptor 
* KD instead of Ki
Agonists
For several decades, NECA was considered to be the most potent known agonist at the A2B
receptor, with an EC50 of around 104 nM to 1140 µM (Hide et al., 1992; Klotz et al., 1998; 
Varani et al., 2005; Beukers et al., 2004; Schulte and Fredholm, 2000). However, NECA is by 
no means selective, in fact it acts as a universal agonist to all adenosine receptor subtypes. 
NECA                       (S) PHPNECA  
Figure 6. Chemical structure of two adenosine derived A2B agonists: NECA and (S) PHPNECA.
In order to identify selective and high affinity agonists for the adenosine A2B receptor, 
laborious synthesis efforts have been devoted to modify the purine ring and ribose moiety of 
adenosine (De Zwart et al., 1998). Nevertheless, NECA still remained the most potent agonist 
for A2B receptors in this class of compounds. Finally, an equally potent, but more selective 
C2-substituted analog of NECA was obtained. This compound, (S)-PHPNECA has an EC50
value for the adenosine A2B receptor of 0.22 µM and showed 3- to 10-fold selectivity towards 
the other adenosine receptors (Volpini et al., 2002). The structures of both compounds are 
presented in figure 6. 
A major breakthrough resulting in an improved affinity and selectivity for the A2B receptors 
was achieved with the discovery of a new series of non-ribose compounds, the 
EC50  (nM) references 
agonists
hA2B hA1 hA2A hA3
NECA
(S)-PHPNECA
LUF5835
BAY 60-6583 
104 - 1140 
220
10
3-10
26
>10,000
26.1
>10,000
129
>10,000
Varani et al., 2005 
Beukers et al., 2004 
Schulte and  Fredholm, 2000 
Volpini et al., 2002 
Beukers et al., 2006 
Eckle et al., 2007 
antagonists Ki (nM) 
DPCPX 
ZM241385
CGS15943
MRE2029F20
MRS1754
MRS1706
OSIP339391
18.4
50
65.8
5.5
2
1.4
0.5
3.9*
255
3.5
200
403
157
37
129
0.8
4.18
>1000
503
112
        328 
3960
    >10,000 
50.8
>1000
570
230
        450 
Klotz et al., 1998 
De Zwart et al., 1999 
Klotz et al., 1998 
Baraldi et al., 2004 
Kim et al., 2000 
Kim et al., 2000 
Stewart, 2004 
N
NN
N
O
OH OH
NH2
N
H
O
OH
N
NN
N
O
OH OH
NH2
N
H
O
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dicarbonitrilepyridines (Rosentreter et al., 2001; Rosentreter et al., 2003; Beukers et al., 
2004a). Several ligands belonging to this class displayed low nanomolar affinity for adenosine 
A2B receptors expressed in CHO cells (Beukers et al., 2004a; Beukers et al., 2006). The most 
potent and selective ligand among this series was LUF5835 (see Figure 7). These compounds, 
however, still lacked selectivity with respect to the adenosine A1 receptor. Recently, a new 
adenosine A2B receptor agonist BAY 60-6583 was patented by Bayer HealthCare and was 
used to study the cardioprotective function of A2B receptors (Kuno et al., 2007; Eckle et al., 
2007). This compound is very selective for the A2B receptor with an EC50 value of 3–10 nM 
for the human A2B receptor and EC50 values > 10 M for the A1, A2A and A3 receptors (Kuno 
et al., 2007; Eckle et al., 2007). The structure of BAY 60-6583 is shown in figure 7. 
LUF5835    BAY60-6583 
Figure 7. Chemical structure of two non-ribose adenosine A2B receptor agonists: LUF5835 and BAY 60-
6583. 
Antagonists
The prototypic high affinity, but not selective, adenosine A2B receptor antagonists are DPCPX,  
DPCPX              ZM241385 
CGS15943      
Figure 8. Structure of four prototypic adenosine receptor antagonists: DPCPX, ZM241385, and CGS15943.  
used as lead compounds to synthesize antagonists with even higher affinity (Kim et al., 1998; De Zwart et 
al., 1999). 
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ZM241385 and CGS15943 (see Figure 8). They have nanomolar affinities for the A2B
receptors and are frequently used to study adenosine A2B receptors (Klotz et al., 1998; Ongini
et al., 1999; Beukers et al., 2000). Moreover, DPCPX, ZM241385, and CGS15943 have been 
Intensive synthesis efforts have been devoted to five different classes of antagonists: 
xanthines, pyrrolopyrimidines, triazoles, aminothiazoles, and quinazolines (Moro et al., 2006; 
Beukers et al., 2006). Among these five classes of compounds, the best results were achieved 
with the xanthine and pyrrolopyrimidine scaffolds. Substitutions at the 1, 3, and 8 positions of 
the xanthine core yielded quite a few highly selective and potent antagonists. For example, 
MRE2029F20, MRS1754 and MRS1706 have affinities of 5.5, 2 and 1.4 nM for the human 
adenosine A2B receptor, respectively. Moreover, these compounds were over 180, 200 and 78 
fold selective on the human A1, A2A and A3 receptors (Baraldi et al., 2004; Kim et al., 2000). 
Modifying pyrrolopyrimidines resulted in an even more potent antagonist with a decent 
selectivity, OSIP339391. It has an affinity of 0.5 nM toward the human adenosine A2B
receptor, which is more than 70-fold selective with respect to the human A1, A2A and A3
receptors (Stewart, 2004). Such antagonists with both high affinity and selectivity have not 
been identified using triazoles, aminothiazoles, or quinazolines as a scaffold (Beukers et al., 
2006).
MRE2029F20, MRS1754 and OSIP339391 have been tritiated to perform radioligand binding 
studies (Baraldi et al., 2004a; Ji, 2001). [3H]-MRE 2029F20 showed a Kd value of 1.65 nM to 
human A2B receptors expressed in CHO cells and [3H]MRS 1754 showed a Kd value of 1.13 
nM to human A2B receptors expressed in HEK293 cells. Among these three antagonists, [3H]
OSIP339391 is the most potent with a Kd value of 0.41 nM for the human A2B receptor as 
present on HEK293 cell membranes (Stewart, 2004). 
Inverse agonists  
Constitutive receptor activity is a prerequisite to discriminate inverse agonists from 
antagonists. Since wild-type (wt) adenosine A2B receptors lack constitutive activity no inverse 
agonists were known and all ligands were classified as antagonists. The construction of 
constitutively active mutant adenosine A2B receptors enabled us to determine the intrinsic 
efficacy of these compounds. In fact, ZM241385, DPCPX and MRS1706 were shown to 
possess inverse agonistic properties, with a rank order of potency of ZM241385 > DPCPC > 
MRS1706 (Li et al., 2007). 
Progress on A2B receptor research and aim of the present thesis 
Much effort is put on investigating the physiological function of A2B receptors and on the 
identification of selective, high affinity ligands. In the mean time, studies were performed to 
elucidate the activation mechanism and receptor-ligand interactions of A2B receptors through 
the use of mutant A2B receptors. In our group, the human adenosine A2B receptor has been 
studied in both CHO cells and yeast cells (Beukers et al., 2000; Beukers et al., 2004b; Li et al., 
2007). Compared to mammalian cells, yeast cells are more convenient in both random and 
site-directed mutagenesis studies as these cells take up a single plasmid. When such a 
mutagenesis approach is combined with a robust screening assay, a great tool arises to 
investigate receptor activation (a review is presented in Chapter 2). This yeast screening 
method has been applied to identify inverse agonists (Chapter 3), leading to the conclusion 
that the antagonists ZM241385, DPCPX and MRS1706 are inverse agonists for human 
adenosine A2B receptors. In Chapter 4 we quantified the relationship between the intrinsic 
efficacy of an inverse agonist and the constitutive activity level of a receptor. Rather than 
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random mutagenesis we applied site-directed approaches in Chapter 5, particularly focussing 
on the role of conserved receptor motifs such as the NxxxNPxxY motif and the adenosine 
receptor specific salt bridges in receptor activation. We learned that both motifs are critical in 
receptor activation due to the fact that mutation of both the NxxxNPxxY motif and the salt 
bridge generally results in loss-of–function receptors. Finally, in Chapter 6 we summarized 
evidence for the advantage of allosteric modulators over inverse agonists to treat disease-
related receptor mutations causing constitutive activity. 
In conclusion, in this thesis the concepts of constitutive activity and inverse agonism are 
applied to the otherwise silent adenosine A2B receptor. The results of our investigations on the 
A2B receptor are extended to somatic mutations within the entire superfamily of GPCRs that 
cause unwanted constitutive activity, emphasizing that allosteric modulators may be more 
privileged as future therapeutics than inverse agonists . 
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ummar  
G protein-coupled receptors (GPCRs) are the major targets of today's medicines. To elucidate 
the mechanism of activation and the interaction of these receptors with their G proteins, 
mutagenesis studies have proven to be a powerful tool and have provided insight in their 
structure and function. Random mutagenesis is very useful in this respect especially when it is 
combined with a robust screening assay that is based on the functional properties of the mutants. 
In this chapter, the use of random mutagenesis combined with a functional screening assay in 
yeast will be described and compared with alternative approaches such as site-directed 
mutagenesis per se and alanine/cysteine scanning. In addition, applications of the screening 
assay in yeast will be discussed. 
G protein-coupled receptors  
G protein-coupled receptors, GPCRs, constitute one of the larger classes of proteins. 
Information on these proteins is collected in a target specific database, the GPCRDB 
(www.gpcr.org/7tm). In humans approximately 650 members of this protein class have been 
identified (Lander et al., 2001; Venter et al., 2001). In addition also other eukaryotes, such as 
the model organisms C. Elegans, Drosophila, Zebrafish and even the unicellular yeast 
Saccharomyces cerevisiae, express GPCRs (Inoue et al., 2004). In all these organisms, 
GPCRs are involved in crucial signal transduction pathways including such vital processes as 
reproduction. Among them, yeast cells in particular provide a very convenient model system 
due to their short generation time. In addition, they are cheap to culture, their physiology is 
well-known and they are amenable to rapid molecular genetic manipulation. The functional 
similarity between the yeast pheromone pathway and the mammalian signaling cascade 
allows signaling of mammalian GPCRs via the yeast pathway (Slessareva and Dohlman, 
2006). Yeast cells express only two endogenous GPCRs (see Box 1 and Figure 1A). 
Box 1: GPCR signaling in yeast: 
Two GPCR signaling pathways have been identified in yeast. One is involved in mating, the other in glucose 
sensing. Mating is activated by the -factor and a-factor via the structurally unrelated Ste2 and Ste3 pheromone 
receptors, respectively. Yeast cells expressing the Ste2 receptor secrete the opposite sex hormone, the a-factor 
and vice versa (Versele et al., 2001). Both receptors activate the MAP kinase pathway via the yeast Gpa1 G 
protein. 
The second signaling pathway is activated through glucose via the Gpr1 receptor and couples to the Gpa2 G 
protein. Stimulation with glucose activates a yeast adenylate cyclase resulting in the production of intracellular 
cAMP followed (Eilers et al., 2005) by several phenotypic responses such as a loss of carbohydrate storage, of 
stress resistance and a reduced life-span as well as an increase in growth and pseudohyphal differentiation 
(Versele et al., 2001; Lemaire et al., 2004; Tamaki et al., 2005) 
A comparison of the GPCR signaling pathways in mammalian and yeast cells is schematically shown (Figure 
1A). On a structural level, yeast and mammalian GPCRs share essential proline residues in TM6 and TM7, 
helix-helix interactions are mediated by polar residues and tight helix packing is mediated by small, weakly polar 
residues in both receptor classes (Eilers et al., 2005). 
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Figure 1. A) Schematic drawing of GPCR activation in yeast and mammalian cells. B) Schematic drawing 
of GPCR activation in genetically modified yeasts. When heterologously expressed mammalian receptors 
were activated by agonists, yeast  and  subunits disassemble from the  subunit and activate the Fus 
promoter which in turn activates the transcription of reporter genes, for example imidazole 
glycerolphosphatedehydratase. This enzyme enables yeast cells to synthesize histidine allowing them to 
grow in histidine-deficient medium.  
Gpa: G protein alpha, Gpr: G protein-coupled receptor, RGS/Rgs: regulators of G protein signaling, Sst2: 
supersensitivity to pheromone, Ste: sterility 
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Knocking these genes out in the yeast system provides a null background to study mammalian 
GPCRs (Minic et al., 2005b). Quite a few yeast vectors have been developed, which enables 
one to functionally express heterologous GPCRs in yeast (Minic et al., 2005b). So far, more 
than 20 mammalian receptors have been successfully expressed in the yeast S. cerevisiae (for
a review, see Minic, 2005). In several reports receptor expression in yeast was compared with 
expression in mammalian hosts. With respect to ligand binding, the 2-adrenergic receptor, 
somatostatin receptor SST2 and adenosine A2A receptor were shown to behave similarly upon 
expression in mammalian cells or in yeasts (King et al., 1990; Price et al., 1995; Price et al., 
1996). In addition, receptor activation of the adenosine A2B receptor was shown to be similar 
upon expression in mammalian cells or in yeast cells (Li et al., 2007b). 
Interest in GPCRs is further substantiated by the fact that they are very successful drug targets. 
In fact about 50% of today's medicines act via this class of proteins (Drews, 2000). To 
elucidate the mechanism of activation of the receptors and their interaction with G proteins at 
a molecular level, mutagenesis studies are a very powerful tool. The GPCRDB provides 
access to mutation data on GPCRs via the tinyGRAP database and via an automatic tool to 
extract mutation data from the literature, MuteXt (Horn et al., 1998; Edvardsen et al., 2002; 
Horn et al., 2004) (www.gpcr.org/7tm). In addition, very recently a database on natural 
variants of GPCRs has been created (http://nava.liacs.nl/; Kazius et al., 2008). 
uta enesis techni ues 
To elucidate the mechanism of activation of GPCRs and their interactions with G proteins at a 
molecular level, mutagenesis studies are a powerful tool. 
Available techniques to introduce mutations range from site-directed to random mutagenesis 
in decreasing order of specificity. Site-directed mutagenesis refers to the site-specific 
introduction of point mutations. In addition, a less specific mutagenesis approach can be 
undertaken such as a simultaneous replacement of multiple amino acids e.g. through the 
construction of chimeras or the use of techniques such as alanine scanning. A keyword search 
in PubMed reveals that site-directed mutagenesis is the most commonly used tool 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB pubmed). More recently, however, the use of 
random mutagenesis techniques has been gaining popularity. 
The latter approach yields large numbers of mutant proteins for which additional techniques 
are required to select for the mutants of interest (Figure 2).  
ite-directed mutagenesis 
Selection of an amino acid for mutation assumes a certain perception of its importance and 
role in the protein. From the triad sequence – structure – function it follows that both structure 
and sequence might already hint to or even reveal the role of an individual amino acid. The 
3D structure of only two GPCRs, rhodopsin and the 2-adrenoceptor, have been elucidated 
(Cherezov et al, 2007; Rosenbaum et al., 2007a; Rosenbaum et al., 2007b), and hence structural 
information is scarce (Palczewski et al., 2000). Fortunately, the large number of GPCR 
sequences available allows bioinformatics approaches to derive clues for the function of 
individual amino acids. The importance of bioinformatics in mutagenesis studies has been 
recently reviewed (Lu et al., 2002; Kristiansen, 2004). In addition, various authors compared 
the occurrence of residues within GPCR subfamilies versus the GPCR family as a whole 
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(Oliveira et al., 2003; Ye et al., 2006), these studies provide clues on residues that may be 
involved in for instance ligand binding. 
Figure 2. Strategies to generate and subsequently investigate mutated GPCRs. 
Techniques to introduce mutations range from site-directed to random mutagenesis. To select amino acids 
for mutation, prior knowledge on the receptor itself or related receptors is required. Examples include 
information from an experimentally determined or computer-modeling derived structure, sequence 
alignments and (other) mutation data. Random mutagenesis generates a large number of mutants, in 
contrast to site-directed mutagenesis and alanine/cysteine scanning.  
Data obtained through site-directed mutagenesis are most easily interpreted. Still, careful 
analysis of experimental data is required since the replacement of an amino acid can result in 
a local effect due to a gain or loss of interaction with neighboring residues or in a global effect 
such as an alteration of protein folding or protein stability. 
An extended application of site-directed mutagenesis is to create the reciprocal mutant pair. 
For instance if an interaction between two residues is considered to be critical for receptor 
function, mutation of one of the residues must impair receptor function, whereas the 
reciprocal mutant may display wild-type activity. In addition, a mutation of a critical amino 
acid may be compensated for by mutating interacting residues as was shown for the yeast 
Ste2p receptor (Lee et al., 2006). Three approaches have been reported to show that residues 
are interacting with one another. Through introduction of a histidine pair, pH dependence can 
be introduced. Alternatively, an ion pair such as lysine-aspartate may be introduced. Finally, 
the introduction of a pair of cysteines may result in disulfide bond formation provided that the 
residues are in each other’s vicinity (Lee et al., 2006). To aid in the selection of amino acids 
to be subjected to site-directed mutagenesis a double mutant cycle analysis was developed. 
This method combines site-directed mutagenesis with free-energy calculations. It enables one 
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to calculate how a mutation of a selected residue may affect the properties of a second residue 
(Vogel et al., 1999). In this approach, the binding free energy is calculated for the ligand/wt 
receptor, for both ligand/single mutant receptors and for the ligand/double mutant receptor. If 
the effect on the binding free energy of the double mutant is not equal to the sum of that of the 
two single mutants, then the two residues must affect each other either favourably (the double 
mutant has the smaller binding free energy) or unfavourably (the sum of the single mutants 
has the smaller binding free energy). In a study on M2 muscarinic acetylcholine receptors, the 
double mutant cycle analysis revealed the absence of an interaction among three asparagine 
residues in the transmembrane area (N69, N97 and N103) since they showed an independent 
effect on the free energy of ligand binding as well as independent effects in a phospholipase C 
stimulation assay (Vogel et al., 1999). Using this approach Naider et al. (2007) proved that for 
the Ste2p receptor and its –factor ligand in yeast, N205 and Y266 interact strongly with 
residues at the amino terminus but not with amino acids at the carboxyl terminus of the 
receptor.  
Alanine cysteine scanning mutagenesis 
A less specific mutagenesis strategy is often undertaken when clear indications on exactly 
which amino acid to mutate are absent. A frequently applied technique is a scanning analysis, 
e.g. alanine scanning. In this approach, residues are replaced with alanine because of its small 
size (the side chain is a methyl group) and its relative inertness (it is non-charged). Recently, 
this method has been applied to two GPCRs, the Ca2+ -sensing and the metabotropic 
glutamate receptor to study ligand binding and G protein-coupling, respectively (Dhami et al., 
2005; Hu et al., 2005). Besides alanine also cysteine replacements have been carried out. The 
advantage of the latter method is that cysteine residues can be modified with 
sulfhydryl-specific alkylating reagents, such as methanethiosulfonate-ethylammonium. When 
the chemical modification of native cysteines does not affect ligand binding, cysteine residues 
can be introduced at the putative ligand binding site and after treatment of the receptor with 
the reagent, the ability of the ligand to bind to the receptor is determined (Hubbell et al., 
2003).
A recent extension of the alanine scanning technique is the shotgun approach (Weiss et al., 
2000). This method introduces residues at selected positions within the target protein through 
the use of a so-called shotgun codon and employs a phage display assay based on 
protein-protein interactions to analyze the large numbers of mutants generated (Kunkel et al., 
1987; Smothers et al., 2002; Szardenings, 2003). The shotgun approach has not yet been 
applied to GPCRs but might be used to study those receptors that recognize a protein ligand. 
Random mutagenesis 
Random introduction of mutations can be achieved through the use of spiked oligonucleotides 
or by manipulating the polymerase chain reaction, PCR. The former method is limited to the 
introduction of mutations within the synthetic oligonucleotide and is therefore restricted to 
domains up to approx. 90 basepairs (bp). During synthesis a low percentage of incorrect bases 
are introduced at each position resulting in mutations. This method has been applied to the 
yeast  factor receptor (Sommers and Dumont, 1997; Martin et al., 2002; Celic et al., 2003), 
the cAMP receptor from Dictyostelium (Milne et al., 1997) and the human C5a (Baranski et 
al., 1999; Geva et al., 2000; Klco et al., 2005; Klco et al., 2006) and vasopressin V2 receptors 
(Erlenbach et al., 2001b), and has been recently reviewed (Celic et al., 2004). The latter, 
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error-prone PCR method is based on the substitution of Mg2+ with Mn2+ ions resulting in a 
compromised fidelity of the DNA polymerase enzyme. Furthermore, the introduction of 
mutations can be guided by adding excess of one of the nucleotides. The use of this technique 
to mutate large DNA fragments was initially described and compared to existing methods in 
1995, and has been further optimized to introduce mutations in fragments up to 400 bp length 
(Fromant et al., 1995; Beukers et al., 2004). The use of a combination of polymerases, the 
so-called genemorph technique has been reported to enable random mutagenesis of fragments 
up to 6000 bp length (Chao et al., 2004). 
Although an error-prone PCR will yield mutated proteins, not every single amino acid 
substitution can be achieved. The likelihood of a simultaneous substitution of more than one 
nucleotide within a single codon is very small especially since the PCR conditions are 
optimized to limit the number of introduced mutations. As a result in practice only one-base 
substitutions occur, limiting the number of possible amino acid substitutions (see 
supplementary information). The mutant library should be large enough to contain as many 
substitutions as possible. As a consequence, analysis of all the mutants is very laborious 
unless a powerful selection assay is available to identify the mutations of interest. 
Combined mutagenesis 
To thoroughly investigate the receptor activation/inactivation mechanism, combined 
mutagenesis methods have been frequently applied. For example, in a study to identify critical 
amino acids in the function of the yeast Ste2p receptor, N205 and Y266 were found in an 
alanine mutagenesis assay (Lee et al., 2002). Subsequently, various mutants were made and a 
double-mutant cycle study was performed to prove the interaction between these two residues 
(Lee et al., 2006). As mentioned above, the double-mutant cycle approach was used to 
investigate the interaction between these two residues and the residues in the -factor peptide 
(Naider et al., 2007).  
In addition, in several reports random and single-point mutagenesis have been combined. In 
the study of the M3 muscarinic receptor, random mutagenesis was followed by site-directed 
mutagenesis to reveal the critical amino acids involved in the stabilization of the active state 
of the receptor (Scarselli et al., 2007). Another example is the human UDP-glucose (P2Y14) 
receptor where two rounds of mutagenesis were performed to determine the amino acid 
residues involved in ligand binding (Ault and Broach, 2006). 
To evaluate the effect of the mutagenesis studies on receptor function, engineered yeast cells 
in which the endogenous pheromone signal transduction route was coupled to mammalian 
GPCRs have thus been very instrumental. A further coupling of the pheromone signal 
transduction route to a reporter gene yielded very robust screening assays.  
east screenin  assa  
Endogenous GPCRs of yeast activate the pheromone pathway via the yeast Gpa1 protein. For 
human GPCRs to interact with this pathway, the yeast G protein needs to be 'humanized'. A 
major breakthrough in the study of functional expression of human GPCRs in yeast cells was 
the creation of a chimeric G protein between the yeast Gpa1 and human Gi2 proteins (Pausch, 
1997; Klein et al., 1998; Baranski et al., 1999). The coupling of human GPCRs to the 
endogenous yeast G protein or these chimeric G proteins was, however, successful for a 
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limited number of receptors only. The construction of G protein chimeras of Gpa1 containing 
the C-terminal five amino acids of mammalian G proteins, the so-called G protein transplants, 
alleviated this limitation to a large extent (Olesnicky et al., 1999; Brown et al., 2000).  
Methods were not only developed to enhance G protein coupling, but also to improve the 
measurement and read-out of receptor activation. To this end the yeast cell was equipped with 
a reporter gene. 
Read-out
Reporter gene 
To assess receptor activity several reporter genes have been used, the most frequently being 
LacZ and HIS3. LacZ encodes -galactosidase, the production of which can be monitored 
through the conversion of a colorless substrate such as X-gal to a colored product. The HIS3
gene encodes imidazole glycerolphosphate dehydratase, the key enzyme for the production of 
histidine, an essential amino acid for yeast growth. Whereas some authors based their findings 
on the -galactosidase assay only (Sommers et al., 2000), others combined both methods and 
measured -galactosidase activity as well as growth (Zhang et al., 2002; Arias et al., 2003). In 
some cases, however, yeast growth turned out to be a more reproducible measure than the 
production of -galactosidase (Beukers et al., 2004). 
To measure histidine-dependent growth, 3-aminotriazole (3-AT), an inhibitor of imidazole 
glycerolphosphate dehydratase, is added to the cells to block receptor-independent growth. To 
discriminate among mutants of the C5a receptor yeast growth was studied at a fixed 
concentration of agonist and a range of 3-AT concentrations (Baranski et al., 1999; Geva et al., 
2000; Klco et al., 2005). Alternatively, growth upon activation of the adenosine A2B receptor 
was investigated with different agonist concentrations in the presence of an optimized amount 
of 3-AT (Beukers et al., 2004; Li et al., 2007b). This method allows the characterization of 
ligand-dependent as well as constitutive growth. 
Whereas the studies mentioned above examined growth at a single, optimized, time-point, 
others monitored growth in time (Erlenbach et al., 2001a; Erlenbach et al., 2001b; Schmidt et 
al., 2003). The latter method provides a more detailed insight in growth and allows the 
determination of the growth rate (see also Figure 3A and 3B with details from our own work). 
Interestingly, recent data suggest that the sensitivity of the read-out can be improved by 
simultaneously using both reporters because the increased yeast growth is able to produce a 
more extensive color after stimulation. Thus the use of two reporters may result in strong 
signal amplification. Das et al. reported that stimulation of the genetically modified fission 
yeast S. pombe with 1 µM P factor with a double reporter increased the signal: background 
ratio to almost 2500:1, while this ratio was 35:1 for a single LacZ reporter (Das et al., 2006). 
Next to the LacZ and the HIS3 reporter, luc, the gene encoding for luciferase has been placed 
under the control of an inducible Fus1 promoter. With this reporter gene assay, receptor 
activation can be measured upon addition of luciferin and ATP (Minic et al., 2005a). An 
advantage of the luciferase assay with respect to the HIS3 gene assay is the amount of time 
required to perform the assay. Yeast growth assays are time consuming as they include a delay 
of 2 – 4 days in response (Minic, et al., 2005a). Luciferase assays on the other hand can be 
performed within hours (Pajot-Augy et al., 2005). If the assay is measured with fluorescence, 
the ligands for the luciferase assay are cheaper than those for the LacZ reporter gene assay. 
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Figure 3. A) Growth curves of yeast cells expressing wild-type human adenosine A2B receptors. Each curve 
represents the growth of yeast cells as a response to [NECA] in an individual well of a 96-well microtiter 
plate (liquid medium assay). Based on the yeast growth in various wells with different concentrations of 
NECA, a dose-response curve B) can be obtained, in this case at 35 h of growth. C) Yeast growth assay 
(solid medium assay) to detect constitutive and agonist-induced receptor activation. Growth of yeast cells 
expressing the wild-type and the F84S mutant adenosine A2B receptor is shown. The agonist NECA is 
required to induce growth of yeast cells expressing the wild-type receptor. The F84S mutant receptor is 
constitutively active as indicated by the fact that yeast growth occurs in the absence of NECA. Upon 
addition of NECA the growth of yeast cells expressing this mutant receptor is further enhanced.  
Yet another reporter gene is the Hph reporter gene. Expression of the Hph reporter gene 
confers the yeast to be resistant to hygromycin. Thus, similar to the HIS3 reporter gene assay, 
activation of the Hph reporter gene permits yeast growth on a selective hygromycin medium. 
A word of caution, however, must be mentioned, as tolerance to hygromycin might be 
dependent on the incubation temperature (Pajot-Augy et al., 2003). 
Contrary to the above strategies for positive selection, i.e. gain-of-function’, fusing the 
inducible Fus1 promoter with can1 leads to negative selection. The Can1 gene encodes for 
arginine permease, which allows the yeast cells to take up a toxic arginine analogue 
canavanine. Thus in the presence of canavanine, yeast cells expressing functional receptors 
are unable to grow. This negative selection can be used to screen for inactivating mutants or 
to screen for antagonists and/or inverse agonists. This method was successfully applied to 
reveal the importance of the second extracellular loop in the activation of the M3 muscarinic 
acetylcholine receptor (Li et al., 2007a; Scarselli et al., 2007). 
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The reporter gene assays listed above can be performed in liquid media or on agar plates. 
With respect to the liquid assay, the yeast cells are usually cultured in microtiter dishes for 20 
to 35 hours and yeast growth is determined by measuring the optical density at 600 nm. 
Microtiter cultivation of yeast cells displayed overall growth features and protein expression 
patterns similar to growth in medium-scale cultures (10 ml) although higher levels of 
stress-induced proteins were observed in the former culture probably due to a lack of oxygen 
(Warringer and Blomberg, 2003). Violent shaking at the highest intensity for 60 seconds prior 
to measurements helps to homogenize cells and improves the reproducibility of the assays. 
The output from the platereader in Excel files can be directly used to generate yeast 
growth-time curves or dose-response curves. For the solid medium assay, drops containing 
the same amount of yeasts are seeded on agar plates. After 24 to 50 hours incubation, the 
plates are scanned and the growth of yeasts can be quantified by software. Since the outcome 
is not automatically reported, solid medium assays are more laborious to perform than the 
liquid ones. 
To verify whether abnormal binding or functioning is a result of altered expression levels, 
folding or localization, GFP has been used as a marker in mammalian cells (Gimpl and 
Fahrenholz, 2000) and yeast cells (Sarramegna et al., 2002; Butz et al., 2003; Niebauer and 
Robinson, 2006). Reports in the literature suggest that high quantum GFP fluorescence is able 
to reveal relatively low expression levels of GPCRs (Niebauer and Robinson, 2006). For a 
receptor-GFP fusion protein, the expression level can be determined either by comparing the 
intensity of the receptor-GFP band in a western blot with the expression level of a standard or 
by comparing whole cell GFP fluorescence with a standard GFP curve. Disadvantages of both 
methods were reported in a study on the functional expression of human adenosine A2A
receptors in yeast (Niebauer and Robinson, 2006). Western blot analysis may induce large 
standard deviations due to the multiple experimental steps that are involved in the preparation 
of the sample. GFP fluorescence on the other hand is very sensitive to pH which may affect 
whole cell GFP fluorescence measurements. Confocal microscopy is able to reveal the 
cellular localization of receptor-GFP fusion proteins. When a GFP tagged receptor is used 
together with a vacuolar dye or with a co-expressed subcellular apparatus marker, for example 
Golgi marker Sec7-DsRed2, confocal microscopy is even able to reveal receptor 
transportation (Butz et al., 2003). A drawback of these (GFP-) tagged receptors is that these 
methods reveal the presence of the tag, but do not provide information on functional 
expression levels. 
Application of yeast screening assay 
The engineered yeast cells have been successfully used not only to screen for mutants of 
interest but also in several other applications. Examples of these will be provided below.  
High throughput screening (HTS) 
To transform the yeast screening assay into a high throughput format a convenient read-out is 
essential. The coupling of the pheromone pathway to yeast growth via the HIS-3 gene fuelled 
the use of engineered yeast cells in high-throughput screening (Pausch, 1997; Dowell and 
Brown, 2002). Application of this method includes the identification of novel agonists for the 
yeast -mating type receptor, of antagonists for heterologously expressed somatostatin 
receptors and of odorants (Bass et al., 1996; Manfredi et al., 1996; Dowell and Brown, 2002; 
Pajot-Augy et al., 2003). 
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Orphan receptors 
Orphan receptors are GPCRs for which the endogenous ligand is unknown. The yeast assay 
has proven successful in the identification of surrogate ligands for these orphan receptors 
(Klein et al., 1998; Brown et al., 2003). For example, an orphan receptor structurally related 
to the formyl peptide receptor was successfully expressed in yeast cells together with a library 
encoding random peptides [Klein et al., 1998]. Growth in the absence of histidine identified 
six peptides that were able to activate this receptor. Similarly, the GPR41 and GPR43 
receptors were expressed in yeast and shown to be activated by short chain carboxylic acids 
such as propionate [Brown et al., 2003]. The advantage of these yeast cells over other higher 
eukaryotic expression systems is the zero background they provide. The cells themselves do 
not release endogenous ligands in contrast to e.g. human embryonic kidney cells. Moreover 
the yeast cells have been engineered to lack endogenous GPCRs (Wise et al., 2002). 
G protein-coupling 
Although the involvement of the intracellular domains of GPCRs in G protein-coupling is 
known, random mutagenesis together with screening in yeast has proven a useful strategy to 
identify the relevant amino acids. The communication of muscarinic receptors with yeast G 
proteins (endogenous as well as humanized) was shown to depend on the large third 
intracellular domain of these receptors (Erlenbach et al., 2001a). Vasopressin V2 receptors 
were also studied for their interaction with G proteins. Random mutagenesis of the second 
intracellular loop identified a critical methionine residue in the central part of this domain. 
Mutation of this amino acid turned out to alter G-protein selectivity as was confirmed through 
subsequent site-directed mutagenesis experiments (Erlenbach et al., 2001b). 
Receptor activation/inactivation 
The endogenous yeast GPCR gene, Ste2, encoding the  factor receptor was subjected to 
random mutagenesis to identify amino acids involved in constitutive activity (Sommers et al., 
2000). Within the large library of mutant receptors 14 amino acids were discovered that 
caused constitutive activity. The endogenous agonist, the  factor, was still able to further 
activate these mutants. Interestingly, in 10 of these mutants a peptide analog of the  factor 
that is an antagonist on the wild type receptor behaved as an agonist. Due to the lack of 
sequence homology between yeast GPCRs and GPCRs of higher eukaryotes, these findings 
cannot be readily extrapolated to e.g. mammalian GPCRs. Subsequent experiments on human 
GPCRs have provided insight though in the amino acids involved in receptor activation in 
higher eukaryotes. An example is the random mutagenesis and screening of the C5a receptor 
(Baranski et al., 1999; Geva et al., 2000; Klco et al., 2005). Random mutagenesis of the 
transmembrane domains and the second extracellular loop yielded a large number of receptor 
mutants that were activated at lower concentrations of C5a than needed for the wild type 
receptor. In addition, several constitutively active mutants were identified. Although these 
studies yielded very few point mutants, regions of the receptor involved in ligand-induced 
activation as well as constitutive activity of the receptor could be identified. 
Constitutively active receptor mutants can also be used to discriminate between neutral 
antagonists and inverse agonists. Analysis of constitutively active mutant CXCR4 receptors 
revealed that antagonists (for the wild type receptor) possessed intrinsic activities varying 
from inverse agonism to weak partial agonism (Zhang et al., 2002). A similar study was 
performed with constitutively active mutant human adenosine A2B receptors and revealed a 
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parabolic relationship between intrinsic efficacy of inverse agonists and the levels of 
constitutive activity of the mutant receptor tested (Li et al., 2007b).  
Furthermore, constitutively active receptors have been used to identify silencing mutations. 
Residues reverting the constitutive activity of a mutant muscarinic M3 receptor were also 
shown to be involved in receptor/G protein coupling in the wild-type receptor (Schmidt et al., 
2003). A similar strategy was applied to compensate for the loss of function of the D113N 
mutant rat muscarinic M3 receptor, D113 being the highly conserved aspartate in TM2. 
Through random mutagenesis three mutations of two highly conserved residues, R165W, 
R165M and Y250D in TM3 and TM5, respectively, were able to restore the function of the 
mutated receptor (Li et al., 2005). 
The above-mentioned examples to study receptor activation all focused on a rather small 
amino acid sequence, either a transmembrane domain or an intracellular loop. To increase the 
domain subjected to mutagenesis without increasing the number of introduced mutations, the 
random mutagenesis PCR approach needed to be optimized (Beukers et al., 2004). In addition, 
the screening assay in yeast was adapted to identify and select for constitutively active 
receptors as well as receptors that are more easily activated than the wild-type receptor. By 
fine-tuning the assay conditions, such a selection was achieved yielding mutants of the human 
adenosine A2B receptor with varying degrees of constitutive and agonist-induced activity 
(Figure 3C). 
Most mutagenesis experiments are aimed at the discovery of an activating mutation. However, 
inactivating mutations can also provide important clues for the mechanism of receptor 
activation. A screen for loss-of-function mutants of the muscarinic acetylcholine M3 receptor 
from a random mutation bank revealed 20 point mutants which had lost their function. 
Interestingly, these 20 mutated residues were all located in extracellular loop 2 which 
suggests that extracellular loop 2 plays an important role in agonist-induced activation 
(Scarselli et al., 2007). 
Evaluation of yeast screening assay together with random mutagenesis 
The success of a random mutagenesis study depends on the error-prone PCR protocol and on 
the number of mutants generated. Optimization of the PCR conditions should ideally yield 
single point mutants or at least a limited number of multiple point mutants. The use of a slight 
amount of MnCl2 together with excess of one of the nucleotides, the forcing nucleotide, has 
proven very successful yielding relatively large numbers of single point mutants (Sommers 
and Dumont, 1997; Sommers et al., 2000; Schmidt et al., 2003; Beukers et al., 2004). Table 1 
presents an overview of random mutagenesis studies of GPCRs, through the use of spiked 
oligonucleotides or error-prone PCR, followed by expression in yeast. As mentioned before, 
spiked oligonucleotides can be used to mutate domains up to 90 bps, whereas error-prone 
PCR is applicable to larger sequences too.  
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Table 1. Evaluation of error-prone PCR and spiked oligonucleotides methods to introduce random 
mutations. 
Investigated
domain;
receptor 
Domain
size 
(amino
acids) 
Number of 
mutants 
Number of single 
point mutants of 
selected mutants of 
interest 
Mutagenesis method Ref. 
TMIII;  -factor 15 9,000- 
15,000
12 out of 29 Spiked oligonucleotide: 
0.7% non wild-type 
Sommers and 
Dumont, 1997 
TMI to TMII 
TMIII to TMIV 
TMVI to 
TMVII; all 
-factor
69
71
48
5000 2 out of 7 Error-prone PCR: 
3 mM MgCl2, 0.6 mM 
MnCl2
1 mM forcing NTP, 0.2 
mM for either dATP or 
dGTP
Sommers and 
Dumont, 1997 
TMIII, TMV, 
TMVI, TMVII; 
C5a
21-25 50,000- 
1000,000
TMIII 0 out of 30 
TMV: 0 out of 40 
TMVI: 0 out of 25 
TMVII: 1 out of 28 
Spiked oligonucleotide: 
 20% non wild-type 
Baranski
et al., 1999 
TMI, TMII, 
TMIV; C5a 
19-25 50,000- 
1000,000
TM1: 0 out of 25 
TMII: 0 out of 22 
TMIV: 1 out of37 
Spiked oligonucleotide: 
 20% non wild-type 
Geva et al., 
2000
N-terminus and 
TM domains; 
-factor
14-104 24,000 Number of single 
point mutants was 
not specified 
among 13 selected 
mutants of interest 
Error-prone PCR: 
3 mM MgCl2, 0.6 mM 
MnCl2
1 mM forcing NTP, 0.2 
mM others* 
Sommer  
et al., 2000 
IL2; V2 
vasopressin
31 30,000 1 out of 11 Spiked oligonucleotide: 
10% non wild-type 
Erlenbach  
et al., 2001 
Individual TM 
domains;
-factor
20-25 6,000 to 
40,000 per 
domain
498 out of 576 Spiked oligonucleotide: 
20% non wild-type 
Martin et al., 
2002
full length; 
CXCR4
352
(human)
>10,000 4 out of 26 Error-prone PCR: 
not specified, 
manganese
and dITP added 
Zhang et al., 
2002
TMV-TMVII; 
M3
four
fragment
s of 
16-19
20,000 12 out of around 
22 ( 15% of 150 
clones)
Error-prone PCR: 
9.5 mM MgCl2, 0.5 
mM MnCl2 
3.4 mM forcing NTP, 
0.2 mM others 
Schmidt et al., 
2003
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Whole receptor 
except for IL3, 
M3
87
86
135
107
49
900,000 21.7% of all 
primary yeast 
transformants
harbored M3 
receptor plasmids 
containing single 
nucleotide changes 
Error-prone PCR: 
7 mM MgCl2, 0.5 mM 
MnCl2
1 mM dCTP and dTTP, 
0.2 mM dATP and 
dGTP
Li et al., 2007 
IL3; -factor 21 20,000 72 out of 83 Spiked oligonucleotide: 
20% non wild-type 
Celic et al., 
2003
full length; 
CCR5
352 >10,000 1 out of 18 Error-prone PCR: 
manganese added 
Arias et al., 
2003
N-terminus to 
TMIII and TMV 
to C-terminus; 
A2B
120 and 
128
4,000 6 out of 14 Error-prone PCR: 
4.7 mM MgCl2; 0.5 mM 
MnCl2
3.4 mM forcing NTP, 
0.2 mM others 
Beukers et al., 
2004
TMII to 
C-terminus, in 
IL3 deficient 
(A274-K469)
mutant; M3 
277 200,000 3 out of 8 Error-prone PCR: 
7 mM MgCl2; 0.5 mM 
MnCl2
1 mM dCTP, 1mM 
dTTP, 0.2 mM dATP, 
0.2 mM dGTP 
Li et al., 2005 
N-terminus to 
TMIII,
TMIII-EL2,
TMIV-TMVII; 
-factor
76, 112 
and 146  
35,000 18 out of 20 
compensate 
F204S**
24 out of 34 
compensate 
Y266C**
Error-prone PCR: 
10-fold lower 
concentration of dATP 
or dGTP 
Lin et al., 2005 
EL2; C5a 24 40,000 0 out of 29 Spiked oligonucleotide: 
20% non wild-type 
Klco et al., 2005 
EL1 and EL3; 
C5a
16
28
350,000
and
425,000
1 out of 29 
0 out of 23 
Spiked oligonucleotide: 
20% non wild-type 
Klco et al., 2006 
*: Complementary to the error-prone PCR method, the mutated products obtained were subjected to oligonucleotide-directed 
mutagenesis through the use of a pool of degenerate oligonucleotides containing 0.7% of an altered nucleotide for each 
nucleotide position (Kunkel et al., 1987).  
**: Mutants were selected for their ability to compensate either the loss of function introduced by a F204S (ligand binding) or
Y266C (activation) mutation. 
EL: extracellular loop, IL: intracellular loop, NTP: nucleoside triphosphate, TM: transmembrane domain 
The number of mutants generated ranged from 4,000 to 2,000,000. These numbers have 
proven sufficient to generate informative mutants as identified through the screening assay. In 
several reports, site-directed mutagenesis was used to confirm the role of individual amino 
acids emerging from a random mutagenesis protocol (Sommers et al. 2000, Erlenbach et al., 
2001b; Celic et al., 2003; Klco et al., 2005). In most cases, the random mutagenesis studies 
yielded single point mutants of which the role could be directly interpreted (Sommers and 
Dumont, 1997; Baranski et al., 1999; Geva et al., 2000; Sommers et al., 2000; Erlenbach et al., 
2001b; Martin et al., 2002; Zhang et al., 2002; Arias et al., 2003; Celic et al., 2003; Schmidt et 
al., 2003; Beukers et al., 2004; Li et al., 2005; Lin et al., 2005; Scarselli et al., 2007). 
Some might doubt whether the heterologous expression of mammalian receptors in yeast can 
be predictive for the effects obtained when the receptors are expressed in their natural, 
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mammalian context. To address this issue several groups have compared both expression 
systems and obtained similar results (Zhang et al., 2002; Arias et al., 2003; Schmidt et al., 
2003; Beukers et al., 2004; Klco et al., 2005; Li et al., 2005). 
Conclusion 
G protein-coupled receptors are the major targets of today's medicines. Mutagenesis 
techniques are frequently and successfully applied to study their interaction with ligands, their 
mechanism of activation and their interaction with G proteins. Random mutagenesis is a very 
powerful tool to gain more insight in these receptor functions. Yeast cells are a very 
convenient host to express these mutated receptors. Moreover, the lack of endogenous 
activators makes yeast cells very suitable hosts to study e.g. orphan receptors. In addition, 
these cells have been engineered to communicate with human GPCRs resulting in the 
activation of a reporter gene, while at the same time the expression of their endogenous 
GPCRs has been knocked-out. This combination of random mutagenesis and expression in 
yeast has proven successful in the identification of ligands for orphan receptors and in high 
throughput screening, and has provided insight in G-protein coupling and receptor activation. 
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ummar  
The human adenosine A2B receptor belongs to class A G protein-coupled receptors (GPCRs). 
In our previous work, constitutively active mutant (CAM) human adenosine A2B receptors 
were identified from a random mutation bank based on their ability to grow in histidine-
deficient medium. In the current study, three known A2B receptor antagonists, ZM241385, 
DPCPX and MRS1706 were tested on wild-type and 9 CAM A2B receptors with different 
levels of constitutive activity in a yeast growth assay. All three compounds turned out to be 
inverse agonists for the adenosine A2B receptor as they were able to fully reverse the basal 
activity of 4 low level constitutively active A2B receptor mutants and to partially reverse the 
basal activity of 3 medium level constitutively active A2B receptor mutants. We also 
discovered 2 highly constitutively active or locked mutants whose basal activity could not be 
reversed by any of the three compounds. A two-state receptor model was employed to explain 
the experimental observations. Varying L, the ratio of active versus inactive receptors in this 
model yielded simulated dose-response curves that mimicked the experimental ones. This 
study is the first description of inverse agonists for the human adenosine A2B receptor. 
Moreover, the use of receptor mutants with varying levels of constitutive activity enabled us 
to determine the intrinsic efficacy of these inverse agonists. 
ntroduction 
G-protein-coupled receptors (GPCRs) constitute a large superfamily of transmembrane 
proteins which represent the target for nearly half of the marketed drugs (Drews, 2000; 
Hopkins and Groom, 2002). One of the GPCR family members, the adenosine receptor, is a 
group of widely distributed receptors which is composed of four receptor subtypes: A1, A2A,
A2B and A3. Of these, the adenosine A2B receptor has been implied in many physiological 
functions (Ralevic and Burnstock, 1998; Feoktistov et al., 1998; Holgate, 2005; Yaar et al., 
2005) and adenosine A2B receptor antagonists may be used in the treatment of asthma, type-II 
diabetes, Alzheimer’s disease and cystic fibrosis (Feoktistov et al. 1998; Volpini et al. 2003). 
The adenosine A2B receptor is also referred to as the low affinity receptor due to its very 
modest affinity for the endogenous ligand adenosine. Despite elaborate synthesis efforts, a 
long-established reference compound, NECA still has the highest affinity, 360 nM, for the 
human adenosine A2B receptor expressed in HEK-293 cells, but it lacks selectivity (De Zwart 
et al., 1998; Fredholm et al., 2001). Recently a new series of non-ribose agonists for 
adenosine receptors was described (Chang et al., 2005) including several highly potent 
agonists for the adenosine A2B receptor (Beukers et al., 2004a). LUF5835 e.g. was a full 
agonist with an EC50 value of 10 nM. Still none of these agonists was truly selective for the 
A2B receptor.  
Inverse agonists of A2B receptor 
43
In contrast, several selective antagonists have been identified for the adenosine A2B receptor. 
For example, the xanthine amide derivatives MRS1668, MRS1706 and MRS1754 are 
relatively new selective antagonists for the adenosine A2B receptor with Ki values in the 
nanomolar range (Kim et al., 2000). Except for these new antagonists, prototypic adenosine 
receptor antagonists such as ZM241385, DPCPX, XAC and CGS15943 have a good to 
reasonable affinity for the adenosine A2B receptor but are not selective versus other subtypes 
of adenosine receptors (Klotz et al., 1998; Ongini et al., 1999; Alexander et al., 1996). 
The phenomenon of constitutive receptor activity i.e. receptor signaling in the absence of 
agonists allows the discrimination between neutral antagonists and inverse agonists. Although 
the therapeutic implications remain as yet unclear, many clinically used drugs turn out to be 
inverse agonists rather than neutral antagonists (Costa and Cotecchia, 2005; Bond and 
IJzerman, 2006). Whether the currently known antagonists of the adenosine A2B receptor 
possess inverse agonistic properties is unknown as the wild-type (wt) adenosine A2B receptor 
lacks constitutive activity (Beukers et al., 2004b). 
In our previous work, we identified constitutively active mutant (CAM) adenosine A2B
receptors from a random mutation bank using a robust yeast selection assay (Beukers et al. 
2004b; Beukers and IJzerman, 2005). These yeast cells were genetically engineered to not 
only communicate with human GPCRs, but also identify (constitutively) active receptors 
(Pausch, 1997; Dowell and Brown, 2002). To this end the signal transduction pathway of 
yeast was coupled to the production of the essential amino acid, histidine. Yeast cells 
expressing gain-of-function or constitutively active adenosine A2B receptors were identified 
through their ability to grow in histidine-deficient medium. 
Since CAM receptors provide a useful tool to discriminate inverse agonists from neutral 
antagonists, CAM adenosine A2B receptors identified in our previous study were used in our 
current study to characterize three A2B receptor antagonists: ZM241385, DPCPX and 
MRS1706. All three compounds proved to be inverse agonists for the adenosine A2B receptor. 
The present study is the first to describe inverse agonists for the human adenosine A2B
receptor. Moreover, the use of CAM receptors with varying levels of constitutive activity 
enabled us to determine the different intrinsic efficacies of these compounds. Finally, 
mathematical simulation of our experimental data confirmed the intricate connection between 
the ligands’ intrinsic efficacy and the receptor’s constitutive activity. 
aterials and methods 
aterials
NECA (5'-N-ethylcarboxamidoadenosine) was purchased from Sigma Aldrich, Steinhem, 
Germany. ZM241385 (4-(2-[7-amino-2-(2-furyl[1,2,4]-triazolo[2,3-a[1,3,5]triazin-5-yl-
aminoethyl)phenol)) was a gift from Dr. S.M. Poucher, AstraZeneca Pharmaceuticals, 
Macclesfield, UK. DPCPX (8-Cyclopentyl-1, 3-dipropylxanthine) was purchased from RBI 
(Natick, MA, USA). MRS1706 (N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-
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dipropyl-1H-purin-8-yl)phenoxy] acetamide ) was obtained from Tocris Cookson Inc, Bristol, 
UK. 3-AT (3-amino-[1,2,4]-triazole) was purchased from Sigma Aldrich, St Louis, USA. 
A genetically modified yeast Saccharomyces cerevisiae strain with the following genotype: 
MATahis3 leu2 trp1 ura3 can1 gpa1 ::G i3 far1 ::ura3 sst2 ::ura3 Fus1::FUS1-HIS3
LEU2::FUS1-lacZ ste2 ::G418R was a gift from Dr. S. J. Dowell, GSK (Stevenage, UK). 
Constitutively active adenosine A2B receptor mutants (CAM) were obtained through random 
mutagenesis as previously described (Beukers et al., 2004b). These mutants were identified 
with a screening assay based on yeast growth. 
ethods
east growth assay 
Nine constitutively active adenosine A2B receptor mutants were selected from a random 
mutation bank based on their ability to grow on solid or in liquid medium in the absence of 
agonists. Single colonies of these nine CAM receptors were used to guarantee a consistent 
phenotype.
To perform growth assays on solid agar medium, yeast cells from an overnight culture were 
diluted to around 400,000 cells/ml (OD600  0.02) and droplets of 1.5 l were spotted on 
growth assay plates containing minimal agar medium, 20 mg/l adenine, 20 mg/l tryptophan, 
with or without either ZM241385 (1 nM to 0.1 mM), DPCPX (1nM to 0.1 mM) or MRS1706 
(0.1 nM to 10 M). Receptor-independent growth was suppressed through the addition of 7 
mM 3-AT. After incubation at 30 C for 48 hours, the plates were scanned and receptor-
mediated yeast growth was quantified with Quantity One imaging software from Bio-Rad 
(Hercules, CA). The growth rate of yeast was calculated as the density of each spot with a 
correction for local background on the plate. 
For growth assays in liquid medium, an overnight yeast culture was adjusted to OD600  0.2 
and 50 l was seeded into each well of a 96-wells plate. Every well contained 200 l minimal 
medium, 20 mg/l adenine, 20 mg/l tryptophan, 7 mM 3AT with or without the indicated 
concentrations of ZM241385, DPCPX or MRS1706. The cells were kept at 30 C for 35 
hours and yeast growth in 96-wells plates was automatically recorded using a Genios plate 
reader (Tecan Inc.). OD600 of every well was used to determine yeast growth. Variations in 
the background OD values were insignificant hence no background correction was carried out 
in the liquid medium growth assay experiments. 
Each experiment was repeated 3 to 5 times. The IC50 values and Emax values were calculated 
with Prism version 4.0 (GraphPad Software Inc., San Diego, CA).
Schild analysis 
NECA concentration-growth curves of the wild-type adenosine A2B receptor were obtained in 
the absence and presence of ZM241385, DPCPX or MRS1706. Dose ratios (DR) were 
calculated from the molar NECA concentrations producing a half-maximal response (EC50) in 
the presence of one of these three compounds divided by the EC50 obtained in the absence of 
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these compounds. The DRs were subjected to Schild analysis to determine whether the 
compounds acted as competitive antagonists (Arunlakshana and Schild, 1959):  
Log(DR-1)  nLog[B] + logKB
In this equation, [B] refers to the molar concentration of ZM241385, DPCPX or MRS1706 
and KB is the equilibrium dissociation constant of the complex of the receptor with one of the 
compounds. A plot of log (DR-1) values (y-axis) versus logarithm molar concentrations of 
these compounds (x-axis) yielded a straight line of which the intercept reflects the pKB or pA2
value of the compound and the slope (n) reveals whether the compound is a competitive 
antagonist (n 1) or not (n1).
Radioligand inding assay 
Yeasts (1*109 cells) were harvested after overnight culture and resuspended in ligand binding buffer 
(50 mM Tris–HCl, 10 mM MgCl2, 1mM EDTA and 0.01% CHAPS, PH8.26). Fifty microliter yeast 
cells (3 mg protein/ml) were incubated with 1.2 nM [3H] MRS1754 and 1mM NECA to determine 
non-specific binding in a total volume of 200 µl. Yeasts were incubated at 25 C for 2 hours and 
harvested by millipore or harvester. After rinsing the GFC filters 3 times with ice cold binding buffer, 
radioactivity was measured as counts per minute using a Perkin–Elmer 1450 Microbeta liquid 
scintillation and luminescence counter. All samples were run at least three times in duplicate. 
arameter fitting using rism 
The two-state receptor model was originally applied to describe the function of ion-channels 
and adapted to explain the activation of receptors (Leff, 1995). In this study, it is used to 
interpret and simulate our experimental data. The two-state receptor model is described by 
three parameters: L, the isomerization constant which is the ratio of the receptor in the active 
Ra state versus the inactive Ri state; , the intrinsic efficacy which refers to the affinity of a 
ligand for the active state of the receptor (Ra) over the inactive state of the receptor (Ri); KA,
the equilibrium dissociation constant of a ligand-receptor complex. 
According to the two-state receptor model, the proportion of receptors in the active state can 
be calculated as: 
[ ] /
[ ] / (1 ) 1
A
A
L A K L
A K L L





  
 equation 1 (Kenakin, 2003) 
 In the absence of ligand ([A]  0) the proportion of receptors in the active state, the 
constitutively active receptors, can be stated as: 
0 ( 1)L L
     equation 2 
From these equations the L value, the ratio of activated receptors versus inactivated receptors, 
can be calculated: 
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0 0(1 )L 
 
    equation 3 
The value 
0 (the proportion of receptors in the active state in the absence of ligand) of each 
CAM receptor was determined by quantification of spontaneous yeast growth in histidine-
deficient medium in the presence of 7 mM 3AT. Yeast growth is positively correlated to the 
proportion of receptors in the active state, thus yeast growth can be used to calculate the 

values of the receptors. To determine the 
 values of the different CAM receptors we first 
defined the two extreme values detected in this study. The lower limit of 
0 was set at 0.001 
(reflecting 0.1% of receptors in the active state) for the growth obtained upon expression of 
the wt receptor. The upper limit of 
0 was set at 0.999 (which means 99.9% of receptors are 
active) for the growth obtained upon expression of either one of the two mutant receptors, 
A18T/A23V/C83Y/A106V/R112S or Q214L/I230N/V240M/V250M/N254Y/T257S/
K269stop. These mutants exhibited the highest level of constitutive activity among all the 
mutants and could not be further activated by addition of agonists such as NECA (data not 
shown), which suggested that they have reached maximal levels of receptor activation. Thus, 
the L values of the wt and these two mutants were fixed at 0.001 and 999, respectively (see 
equation 3). 
The 
 values of mutants in the presence and absence of concentrations of ZM241385, DPCPX 
or MRS1706 were scaled according to two defined extreme values: 0.001 and 0.999. Then 
Graphpad Prism was used to perform curve fitting according to equation 1 and to determine 
the optimal values for L,  and KA. In the two-state receptor model, the  value is a 
characteristic of the compound and we assume that a compound has the same KA value for all 
mutant A2B receptors. Therefore, the L values of the different mutants were determined with 
the constraint that the  value and KA value for each compound were shared among the 
different mutants.  
Since the two highly CAM receptors A18T/A23V/C83Y/A106V/R112S and Q214L/I230N/ 
V240M/V250M/N254Y/T257S/K269stop could not be inhibited by any of the compounds 
tested, the growth of these two mutants in the presence and absence of inverse agonist could 
not be used for curve fitting in GraphPad Prism. 
Simulation of growth curves using at a  
The pharmacological two-state receptor model was implemented in the software package 
MatLab version 7.0 (The Mathwork, Inc, Natick, USA) and a graphic interface was composed 
to facilitate parameter input and to simulate curves. Concentration-proportion (	) curves were 
simulated and visualized with a fixed  and KA value and variable L values to mimic the 
experimental curves. 
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Results
dentification of constituti ely acti e mutants 
To select constitutively active mutant A2B receptors, we employed a yeast assay based on 
growth which was previously described (Beukers et al., 2004b). In brief, human adenosine 
A2B receptors couple to the endogenous signaling pathway of yeast (Brown et al., 2000) and 
activate the synthesis of histidine, which allows the yeast cells to grow in histidine-deficient 
medium. Hence, the growth of these yeast cells and the presence of active adenosine A2B
receptors are positively correlated and increased receptor activity results in increased yeast 
growth.
From our random mutation bank nine previously published A2B receptor mutants with 
different levels of constitutive activity were selected (Beukers et al., 2004b) and used as 
screening tools to discover inverse agonists. Among them, the highest levels of constitutive 
activity were obtained with two multiple mutant receptors, A18T/A23V/C83Y/A106V/R112S
and the truncated mutant Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop, missing 
the C-terminal and transmembrane helix 7. Mutants N36S/T42A, N36S/T42A/T66A and 
T42A/V54A showed intermediate levels of agonist-independent growth. Finally, three point 
mutants T42A, F84L, F84S and the double mutant F84L/S95G exhibited relatively low levels
Table 1. Constitutive activity of wild-type and mutant human adenosine A2B receptors. 
Yeast cells expressing the wild-type or one of the 9 mutant adenosine A2B receptors were screened on 
selection plates containing minimal agar medium plus tryptophan, adenine and 7 mM 3AT, the latter to 
suppress receptor-independent growth. -  indicates that yeast cells did not grow on the selection plate due 
to the lack of constitutive receptor activity; +  indicates that yeast cells did grow on the selection plates 
but only a weak constitutive activity was detectable; ++  indicates that the mutants exhibited constitutive 
activity 2 to 4 fold higher than + ; +++  indicates that the constitutive activity of the mutants was at least 
5 fold greater than + . 
WT/Mutants Constitutive activity 
Wild-type - 
T42A + 
F84L + 
F84S + 
F84L/S95G + 
N36S/T42A ++ 
N36S/T42A/T66A ++ 
T42A/V54A ++ 
A18T/A23V/C83Y/A106V/R112S +++ 
Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop +++ 
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of constitutive activity (Table 1).  
To verify whether the constitutive activity of the mutants was a result of the mutation or 
caused by increased receptor expression levels, radioligand binding studies were carried out. 
As can be seen in figure 1, all mutant receptors did recognize the radioligand [3H]MRS1754
and showed specific binding suggesting that the mutations did not affect ligand binding 
properties. In addition, the highest level of specific binding was obtained with the wild-type 
receptor suggesting that the constitutive activity was not a result from increased receptor 
expression levels.
Figure. 1 Total binding and specific binding of wt and mutant A2B receptors. 
Antagonism of 241385  PCP  and R 1706 at the wild-type adenosine A2B receptor  
The agonistic effect of NECA on the wild-type adenosine A2B receptor was antagonized by  
Table 2. Comparison of the pA2 values of ZM241385, DPCPX and MRS1706 as determined through 
antagonism of NECA-induced activation of adenosine A2B receptors in this study versus literature data 
obtained in different tissues and cells.  
Compound Tissue or cells pA2  from literature pA2 this study 
ZM241385 Rat mesenteric arterya 7.20  0.12 
CHO cellsb 7.32 (7.17-7.48) 
7.32  0.29 
DPCPX HEK293c 7.01
CHO.A2B4 celld 7.16
Guinea-pig cerebral cortexe 6.91
Guinea-pig tracheal epithelial cellsf 6.51  0.29                    
           
6.41  0.16   
MRS1706 n. d. 7.38  0.18 
a. Prentice et al., 1997, b. Ongini et al., 1999, c. Cooper et al., 1997, d. Alexander et al., 1996, e. Poucher et 
al., 1995, f. Pelletier et al., 2000. n. d.  not determined 
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ZM241385, DPCPX, and MRS1706 in a concentration-dependent manner (Figure 2A, C, and 
E), which resulted in a rightward shift of the concentration-response curve without a change 
of Emax. Schild analysis of this antagonism (n 3) yielded pA2 values of 7.32  0.29 for 
ZM241385, 6.41  0.16 for DPCPX and 7.38  0.18 for MRS1706. The slope of the Schild 
plot was 0.99  0.03 for ZM241385, 1.04  0.14 for DPCPX and 1.26  0.07 for MRS1706 
indicating the competitive interaction of these compounds with the receptor (Figure. 2B, D, 
and F). Table 2 displays a comparison of the pA2 values of ZM241385, DPCPX and 
MRS1706 obtained in this study with literature values. 
                               A                                                                              B 
                               C                                                                              D 
                               E                                                                               F 
Figure. 2 Concentration-response curves of NECA in the absence or presence of 10 M, 1 M and 0.1 M
ZM241385 (A), 100 M, 20 M and 2 M DPCPX (C), and 5 M, 0.5M and 0.1 M MRS1706 (E). 
Schild plot analyses for the determination of pA2 values of ZM241385, DPCPX, and MRS1706 at the 
adenosine A2B receptor are shown in B), D) and F).  
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n erse agonistic properties of 241385  PCP  and R 1706 
Three types of response of the constitutively active mutants were observed when yeast cells 
expressing CAM A2B receptors were cultured in the presence of ZM241385, DPCPX or 
MRS1706.
Both the mutants with low and intermediate levels of constitutive activity were inactivated by 
ZM241385, DPCPX, and MRS1706. Hence these compounds acted as inverse agonists on the  
                                                               A 
                                                              B 
                                                            C 
Figure. 3 Concentration-response curves of ZM241385, DPCPX, and MRS1706-induced inhibition of yeast 
growth. Yeast cells expressing 9 CAM adenosine A2B receptors with different levels of constitutive activity 
were tested in histidine-deficient solid medium containing 7 mM 3AT and concentrations of ZM241385 
(A), DPCPX (B) or MRS1706 (C) as indicated. Growth of the yeast cells was scanned and quantified with 
Quantity One imaging software. One representative experiment performed in duplicate is shown of at least 
three independent experiments. 
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constitutively active human adenosine A2B mutants, albeit with varying intrinsic activities and 
potencies as described in detail below (Table 3, Figure 3). 
Table 3. Comparison of the constitutive activity (CA), potency (IC50 value) and intrinsic activity (%  
inhibition) of ZM241385, DPCPX and MRS1706 towards CAM adenosine A2B receptors with low and 
termediate levels of constitutive activity. 
Results are expressed as mean  S.E.M. from at least 3 independent experiments. a IC50 value could not be 
determined due to small experimental window. 
The basal growth of yeast cells expressing T42A, F84L, F84S or F84L/S95G mutant 
receptors was dose-dependently reduced by ZM241385, DPCPX and MRS1706 from 91% to 
99%. In other words, the basal growth of yeast cells expressing these 4 low CAM receptors 
were almost completely inhibited in the presence of 10 M of any of these inverse agonists. 
The mutants with intermediate levels of constitutive activity, N36S/T42A, N36S/T42A/T66A 
and T42A/V54A were inhibited by all three inverse agonists albeit with lower intrinsic 
activities, ranging from 28% to 79%. None of the tested inverse agonists could, however, 
completely inhibit the growth of yeast cells expressing any of these 3 medium level CAM 
receptors.  
The multiple mutant A18T/A23V/C83Y/A106V/R112S and the truncated mutant 
Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop did not respond to ZM241385, 
DPCPX or MRS1706 at any of the concentrations tested. A representative curve of 
ZM241385 is shown in Figure 4. Apparently, these 2 CAM A2B receptors are endowed with 
robust activity and are locked in an active state.
Point mutants F84L and F84S behaved similar to each other with respect to both the potency 
and intrinsic efficacy of the inverse agonists, indicating that a mutation from phenylalanine to 
leucine or serine has the same effect. These two single mutants have very low constitutive 
activity and were completely inhibited by all three inverse agonists. An additional S95G 
mutation seemed to have no effect on either the constitutive activity or the inverse agonistic 
effect.
ZM241385 DPCPX MRS 
Mutants CA IC50 (nM) Imax (%) IC50 (nM) Imax (%) IC50 (nM) Imax (%) 
F84L + 135 88 95 7 1440 1394 92 3 43 21 91 12 
F84S + 107 37 99 2 1907 675 97 3 54 12 94 6 
F84L/S95G + 102 60 97 4 1430 314 99 2 40 32 94 8 
T42A + 71 34 96 5 1549 981 96 2 98 62 93 5 
T42A/V54A ++ 210 86 79 7 798 406 40 12 166 138 54 5 
N36S/T42A ++ 186 147 74 7 1550 1222 58 3 133 66 57 11 
N36S/T42A/T66A ++ 522 239 63 4 6247 2460 39 11 a 28 16
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Figure. 4 Effect of ZM241385 on the constitutive activity of the highly constitutively active 
A18T/A23V/C83Y/A106V/R112S (
) and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop ()
adenosine A2B receptors. No significant inhibition of yeast growth was observed after treatment with 
ZM241385.  
Like the point mutants F84L and F84S, the T42A mutant exhibited relatively low constitutive 
activity that was completely inhibited by all three inverse agonists. Comparison of the T42A 
point mutant with the T42A/V54A and the N36S/T42A double mutants showed that the IC50
values of the three inverse agonists were at most 3-fold altered when an additional V54A or 
N36S mutation was present. However, whereas the constitutive activity of the T42A mutant 
could be completely inhibited by all three inverse agonists, an additional V54A or N36S 
mutation resulted in a higher level of constitutive activity and could be only partially 
inhibited. Whereas the N36S mutation did not cause significant changes with respect to the 
potency of the three compounds, an additional T66A mutation along with the T42A/N36S 
double mutation increased the IC50 values of ZM241385 and DPCPX from 186 nM to 522 nM 
and from 1550 nM to 6247 nM, respectively. Due to the small window, the IC50 value of 
MRS1706 for the T42A/N36S/T66A triple mutant could not be determined. In addition, the 
level of constitutive activity of this N36S/T42A/T66A triple mutant is increased compared to 
the N36S/T42A double mutant. The most interesting observation concerning the CAM 
receptors containing a T42A mutation was that the additional mutations increased not only the 
constitutive activity of the receptor, but also made the receptor less sensitive towards the 
inverse agonists.
For ZM241385 and MRS1706, not only the intrinsic activity profoundly decreased on the 
mutants with increasing levels of constitutive activity, but their potency also slightly 
decreased. For instance, the IC50 values of ZM241385 for the medium level CAM 
N36S/T42A and T42A/V54A were approximately 2-fold higher than the IC50 values for this 
compound on the low level CAM receptors. In addition, the IC50 value of ZM241385 
increased another 2.5- to 3-fold for N36S/T42A/T66A which had slightly higher constitutive 
activity than the other two medium level CAM receptors. Similarly, the IC50 values of 
MRS1706 for medium level CAM receptors were also slightly higher than for low level CAM 
receptors, varying from 1.5-fold to 4-fold. However, the potency of DPCPX for mutants with 
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increased level of constitutive activity did not increase except for N36S/T42A/T66A triple 
mutant.
The rank order of potencies of the inverse agonists showed that with the exception of the 
T42A/V54A double mutant, the IC50 values of DPCPX were 8- to 22-fold higher than the 
values for ZM241385. The IC50 values of MRS1706 in turn were 11- to 36-fold lower than 
the values for DPCPX which is in accordance with the weaker antagonism of DPCPX at the 
wt adenosine A2B receptor (see Tables 2 and 3). 
Estimation of parameters of the two-state receptor model 
More than ten years ago the two-state receptor model was introduced to successfully explain 
some observations of GPCRs in cell lines and in recombinant receptor-expression systems 
(Leff, 1995); for example a partial agonist in one experimental system could behave as a full 
agonist in another. In this study, we applied this model to characterize both the constitutive 
activity of CAM adenosine A2B receptors and the intrinsic efficacy of the tested compounds. 
Three important parameters: L (the ratio of active receptors Ra versus inactive receptors Ri), 
(intrinsic efficacy, which reflects the ratio of ligand affinity for Ra over Ri) and KA
(equilibrium dissociation constant of the ligand-receptor complex (ARi)) were obtained from 
the scaled data of 3 to 5 independent experiments with GraphPad Prism. When >1, the 
ligand will enrich the Ra state and is classified as an agonist; conversely, if  1, the ligand 
will enrich the Ri state and is classified as an inverse agonist. Thus we applied the constraint 
of shared value for all data set  on these two parameters in curve fitting. Fitted  values were 
0.14  0.03, 0.35  0.03 and 0.31  0.02 for ZM241385, DPCPX and MRS1706, respectively. 
Among these 3 inverse agonists, ZM241385 had the lowest intrinsic efficacy value whereas 
MRS1706 and DPCPX had comparable intrinsic efficacies. This rank order of fitted  values 
was consistent with the maximal inhibition rate (Imax) of the inverse agonists on mutants with 
medium levels of constitutive activity (Table 3). 
Next to the intrinsic efficacies also the KA values were fitted and were 89  17, 449  146 and 
30  8 for ZM241385, DPCPX and MRS1706, respectively. According to the two-state 
receptor model, the dissociation constant KA is proportional to the EC50 (EC50
KA(1+L)/[(1/)+L]) (Kenakin, 2003). The general rank order of fitted KA values was DPCPX 
> ZM241385 > MRS1706, which was in agreement with the IC50 data (see Table 3). We felt 
confident to assume similar KA values for both wild type and mutant receptors, since IC50
values for a given compound did not vary to a great extent (Table 3).
The L values, representing the ratio of active versus inactive receptors, of low level and 
intermediate level CAM adenosine A2B receptors were determined with respect to the 
A18T/A23V/C83Y/A106V/R112S mutant and the truncated receptor as described in the 
Materials and Methods section. The fitted L values differentiated into 2 groups (Table 4):
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Table 4. Fitted parameters L for mutants with low level or medium level constitutive activity. 
mutants ZM241385 DPCPX MRS1706 
F84L 0.11 0.02 0.12 0.02 0.14 0.02 
F84S 0.22 0.03 0.16 0.02 0.22 0.02 
F84L/S95G 0.22 0.02 0.17 0.02 0.20 0.02 
T42A 0.20 0.16 0.16 0.02 0.18 0.02 
T42A/V54A 1.38 0.10 1.6 0.10 1.38 0.08 
N36S/T42A 1.49 0.10 1.47 0.10 1.52 0.08 
N36S/T42A/T66A 1.9 0.17 1.69 0.10 1.90 0.11 
Low level CAM receptors have L values around or slightly smaller than 0.2; intermediate 
level CAM receptors have L values ranging from 1.38 for the T42A/V54A mutant to 1.90 for 
the N36S/T42A/T66A mutant. These levels were 7- to 15-fold higher than the average L 
value of the low level CAM receptors. 
In order to discuss our experimental data further, we implemented the two-state receptor 
model in the software program MatLab and composed a graphic interface to facilitate 
parameter input and curve simulation. We varied L values but fixed  and KA at 0.2 and 5* 
10-8 M, respectively to see whether we could mimic our experimental data. When L values of 
0.2, 2 and 200 were used, the overall shape of the simulated curves mimicked the curves that 
we obtained with receptors with varying levels of constitutive activity (Figure. 5). The 
constitutive activity of CAM receptors with low L values (L  0.2) was completely inhibited 
by the inverse agonist; CAM receptors with medium L values (L  2) were partially inhibited 
(around 50%); and CAM receptors with high L values (L  200) could not be inhibited by 
inverse agonists with an  value of 0.2. Careful analysis of the simulated curves at L  0.2 
reveals that a slight amount of residual activity is expected to remain upon application of 
saturating levels of inverse agonists with an intrinsic efficacy of 0.2. Apparently, this residual 
growth of the yeast cells is beyond the detection limit. 
Besides these three types of simulated curves that we have also observed in our experiments, 
there was another type of curve that was not represented among our series of CAM receptors. 
When L is 20, the receptor could be inhibited for 15% by an inverse agonist with an  value 
of 0.2. We did not observe this level of inhibition in our experiments, because none of our 
CAM adenosine A2B receptors displayed an L value of around 20.
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                                 A                                                                              B 
Figure. 5 Simulated curves versus experimentally determined curves. A) Simulated dose-proportion (
)
curves. The parameters were: L  0.2 (mixed line), 2 (continuous line), 20 (dotted line) and 200 (dashed 
line);   0.2; KA  50 nM. B) Experimentally determined dose-proportion (
) curves from growth assays 
of mutants F84L (), N36S/T42A () and Q214L/I230N/V240M/V250M/N254Y/T257S/K269stop ()
on agar plates containing a range of concentrations of the inverse agonist MRS1706. On the X-axis the 
logarithm of the concentration of the ligand is shown. The Y-axis in A) describes the portion of receptors in 
the active state while the Y-axis in B) reflects the portion of receptors in the active state as calculated by 
the ratio of the growth of yeast cells expressing various CAM receptors versus the highest amount of 
growth obtained in yeast cells expressing a locked receptor. 
iscussion 
Evidence of constitutively active GPCRs has accumulated over the past 10 years, which 
enabled the distinction between neutral antagonists and inverse agonists for several GPCRs 
(Costa and Cotecchia, 2005). However, there is no report on inverse agonism for the wt 
human adenosine A2B receptor due to its lack of constitutive activity. One might speculate 
that a high basal activity would disturb the physiological function of the adenosine A2B
receptor due to its ubiquitous expression (Volpini 2003). The low constitutive activity of the 
wt adenosine A2B receptor, however, does not allow discrimination between antagonists and 
inverse agonists for this receptor subtype. 
In our previous work a random mutation bank was constructed and a collection of adenosine 
A2B receptor mutants with varying levels of constitutive activity was identified with a yeast 
growth assay (Beukers et al., 2004b). Yeast cells enabled us to identify CAM receptors 
among the randomly mutated receptors and these CAM receptors make it possible to study 
inverse agonism on the adenosine A2B receptor. In this study, 9 mutant receptors with 
different levels of constitutive activity were used to examine inverse agonistic properties of 3 
structurally different compounds, ZM241385, DPCPX and MRS1706. All three compounds 
have been described before in the literature as antagonists for the wild-type adenosine A2B
receptor (Alexander et al., 1996; Cooper et al., 1997; Pelletier et al., 2000; Poucher et al., 
1995; Prentice et al., 1997; Ongini et al., 1999).
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Before characterizing these three compounds on CAM A2B receptors, we tested them on the 
wild-type human adenosine A2B receptor expressed in yeast to check whether our yeast assay 
is comparable to assays with mammalian cells. The three compounds were tested as 
antagonists by their ability to shift NECA-induced dose-growth curves and the data were 
compared with literature values. In our yeast assay, ZM241385 was able to antagonize 
NECA-induced yeast growth with a pA2 value of 7.32 0.29 and DPCPX a pA2 value of 
6.41 0.16. As demonstrated in Table 2, the former was similar to the pA2 value of 7.20 which 
was observed for antagonist ZM241385 to antagonize the A2B receptor-mediated relaxant 
effect of NECA in the rat mesenteric artery (Prentice et al., 1997). The latter was close to the 
pA2 value of 6.51 reported in guinea-pig tracheal epithelial cells for the ability of DPCPX to 
antagonize NECA-evoked cyclic AMP generation (Pelletier et al., 2000). No pA2 value has 
been reported for MRS1706, but the pKi value found in radioligand binding studies (8.86) 
confirms our findings that MRS1706 is a potent antagonist (Kim et al., 2000). As shown in 
Table 2, comparison of these literature data to our own results indicated that the potencies 
obtained in the yeast system were in good agreement with mammalian data. In both cell 
systems the rank of order of potency of MRS1706, ZM241385 and DPCPX on the wild-type 
adenosine receptor is MRS1706  ZM241385 > DPCPX. 
Subsequent experiments on CAM adenosine A2B receptors expressed in yeast provided firm 
evidence that these three compounds should be classified as inverse agonists rather than 
antagonists because they inhibited the growth of CAM receptors. Interestingly, all three 
structurally diverse inverse agonists tested in this study behaved in a similar manner, that is 
they all showed full inverse agonism on low level CAM receptors, partial inverse agonism on 
medium level CAM mutants and no significant inverse agonism on high level CAM mutants 
although they bound these CAM receptors as well as other CAM receptors in radioligand 
binding assays (data not shown).
To interpret the different intrinsic activities of the inverse agonists on the CAM receptors at 
the molecular level, the two-state receptor model was used. In this simplified model, two 
states are identified: an inactive state (usually designated as the R state) and an active state 
(usually designated as the R* state). The equilibrium between receptors in the R versus R* 
state may be altered by ligands (Lefkowitz et al., 1993; Leff, 1995; Kenakin, 1996). Agonists 
stabilize R* while the inverse agonists stabilize the R state, and neutral antagonists have no 
preference for either state. This simplified pharmacological model does not take into 
consideration the multiple conformations of receptors in each state, receptor reserves or 
receptor to G protein-coupling, but it sufficed to explain our experimental observations. 
Simulation of our experimental data revealed that the ability of inverse agonists to inhibit 
constitutively active receptors depends on the intrinsic efficacy () of the compounds as well 
as on the level of constitutive activity of the CAM receptor. Thus, low (L  0.2) and medium 
level CAM receptors (L  2) could be fully and partially inhibited by inverse agonists with 
 0.2, respectively. Stronger inverse agonists, with smaller  values, should in theory be able 
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to fully inhibit not only these medium level CAM receptors but also the two locked  CAM 
receptors. 
Two precedents for such locked-on  receptors have been described in literature. For the 
adenosine A1 receptor, we identified a locked mutant receptor containing a G14T mutation. 
Indeed this mutation led not only to constitutive activity but also to a locked  phenotype in 
the sense that the basal activity of this receptor could not be modulated by either agonists or 
inverse agonists in both a GTPS and a cAMP assay (de Ligt et al., 2005). In another report, 
accumulation of [3H]IP in cells expressing Y368N mutant 5HT2C receptors revealed that this 
mutant was also locked  because none of the tested inverse agonists could inhibit the 
signaling of this receptor whereas these compounds were able to inhibit the constitutive 
activity of the wild-type receptor and of another mutant receptor (Prioleau et al., 2002).
For inverse agonists, the smaller the  values are, the stronger inverse agonism they will 
exhibit. The  value is a property that is intrinsic to a given compound and therefore 
independent of other factors in a test system. In contrast, the intrinsic activity may vary for 
example when a mutation alters the interaction between receptor and G protein. Such a direct 
effect of a mutation on the intrinsic activity was described by Ganguli et al. on CAM secretin 
receptors (Ganguli et al., 1998). Three CAM secretin receptors with comparable levels of 
constitutive activity were created. Whereas the natural hormone secretin was able to activate 
the two single point mutants H156R and T322P, secretin turned out to be an inverse agonist 
on the double mutant receptor containing both mutations. In this case, the double mutant 
affected the intrinsic activity due to a reduction of the basal coupling of the receptor with Gs
proteins.
In our study, on the other hand, the various CAM receptors display 3 different levels of 
constitutive activity (reflected in parameter L). The variation in intrinsic activity could be 
explained by these different L values as demonstrated by the simulations with variable L 
values whereas the intrinsic efficacy () and KA values of the ligands were fixed. Based on 
the experimental data, the rank order of intrinsic efficacy of ZM241385, DPCPX and 
MRS1706 is ZM241385>MRS1706DPCPX. In other words, despite its higher potency, 
MRS1706 is a weaker inverse agonist than ZM241385. 
In conclusion, we were able to characterize in a yeast growth assay ZM241385, DPCPX and 
MRS1706 as inverse agonists on the human adenosine A2B receptor. The investigations 
allowed us to quantify the effects of inverse agonists on receptors with different levels of 
constitutive activity, which to our knowledge is the first study of such nature. We learned that 
mutated adenosine A2B receptors with different levels of constitutive activity responded 
differently to three inverse agonists. Two high level CAM receptors were locked in an active 
state and were insensitive to the inverse agonists. The three intermediate level CAM receptors 
were partially inhibited, whereas the four low level CAM receptors were almost completely 
inhibited. These differences can be explained with different isomerization constant (L) values 
according to the two-state receptor model.  
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ummar  
Traditionally it is believed that the inhibitory effect of an inverse agonist increases with an 
increase in constitutive activity of its receptor. However this is not always the case. 
Previously we found that some inverse agonists do not show any inhibitory effect on two 
mutant adenosine A2B receptors with very high constitutive activity. In the present study, 
three groups of mutant human adenosine A2B receptors displaying different phenotypes were 
studied. N43F and I93N mutant receptors lacked detectable constitutive activity and were 
insensitive to agonists; mutant N43S behaved as a locked  receptor with strong constitutive 
activity and no longer responded to any ligand; the mutant A51V receptor possessing 
intermediate constitutive activity was sensitive to both agonists and inverse agonists. The 
two-state receptor model was used to analyze and simulate the behavior of locked receptors 
and to determine optimal conditions for the screening of inverse agonists. The response of an 
inverse agonist was shown to depend on both the intrinsic efficacy of the inverse agonist and 
the constitutive activity of a receptor it interacts with. The optimal window for measurements 
is achieved when the value of the isomerization constant (L) between the active (R*) and 
inactive (R) states of the receptor equals the reciprocal square root of the intrinsic efficacy ()
of the inverse agonist. When L is smaller than this value, the window will increase with an 
increase of the constitutive activity of the receptor; when L is bigger, the window will 
decrease with an increase of the constitutive activity.  
ntroduction 
Constitutive activity, the spontaneous basal signalling activity of GPCRs in the absence of 
agonists (Leff, 1995; Lefkowitz et al., 1993; Milligan and Bond, 1997) has been identified for 
a considerable number of GPCRs, not only for mutant but also for wild-type receptors (de 
Ligt et al., 2000). The first two receptors for which constitutive activity was described are the 
 opioid receptor (Koski et al., 1982) and 2-adrenoceptor (Cerione et al., 1984). Currently, 
constitutive activity has been identified for more than 60 wild-type receptors such as the 
biogenic amine, nucleoside, lipid, amino acid, peptide and protein receptors (for a review, see 
Seifert and Wenzel-Seifert, 2002). Constitutively active mutant receptors are considered to 
mimic an active conformation of the receptor probably through the release of an 
intermolecular restraint that retains the wild-type receptor in an inactive conformation (Parnot 
et al., 2002). 
Constitutive activity can be specifically suppressed by inverse agonists. Discrimination 
between antagonists and inverse agonists was first described in detail by Costa and Herz 
(1989). They identified two types of antagonists for the  opioid receptor: one exhibited no 
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intrinsic activity while the other displayed negative intrinsic activity measured as the ability to 
inhibit the GTPase activity of G proteins. This negative intrinsic activity is usually referred to 
as inverse agonism. So far, numerous inverse agonistic phenomena have since been described 
in various recombinant cell systems, in vivo systems and in animal models.  
Quite a few constitutively active mutant receptors are disease-related. Cases in point are 
retinitis pigmentosa and night blindness that are caused by constitutively active mutations of 
rhodopsin (Rao et al., 1994). Similarly, mutations in the V2 vasopressin receptor result in 
diabetes insipidus (Morello et al., 2000) and mutant Ca2+ sensing receptors are responsible for 
certain forms of hypocalcaemia and hypercalciuria (Chattopadhyay et al., 1996). It was also 
reported that several mutations in the LH receptor cause male precocious puberty (Shenker et 
al., 1993). Inverse agonists have special therapeutic benefits for the treatment of constitutive 
activity-related diseases because these compounds may bring down the constitutive activity. 
In fact, many of the antagonists’ that are clinically used are inverse agonists (for a review, 
see Bond and IJzerman, 2006; Milligan, 2003).  
Traditionally, it is believed that an inhibitory effect of an inverse agonist will increase with an 
increase in constitutive activity of the receptor it interacts with as reviewed by Seifert and 
Wenzel-Seifert (2002). However, this is not always valid. For example the G14T mutant 
adenosine A1 receptor has been reported to be a locked-on  receptor. Neither agonists nor 
inverse agonists were capable of modulating its basal activity in either a GTPS or a cAMP 
assay. Still the G14T mutant receptor was able to bind both the radiolabeled agonist 
[3H]CCPA and the inverse agonist [3H]DPCPX (de Ligt et al., 2005). In another study, 
substitution of a tyrosine in the highly conserved NP Y motif of the 5HT2C receptor with 
any of the naturally occurring amino acids revealed a locked-on Y7.53N mutant. Although 
this mutant had a similar affinity as the wild-type receptor for all inverse agonists tested and 
even an increased affinity for all the agonists tested, the high basal signaling of this receptor 
was neither increased by agonists nor decreased by inverse agonists (Prioleau et al., 2002). 
Recently we reported on two highly constitutively active mutant receptors, the 
A18T/A23V/C83Y/A106V/R112S  and   the   Q214L/I230N/V240M/V250M/N254Y/T257S/
K269stop adenosine A2B receptor. Both mutant receptors could not be inactivated by the 
inverse agonists ZM241385, DPCPX or MRS1706 (Li et al., 2007). These examples suggest 
that such very constitutively active receptors may no longer respond to inverse agonists 
questioning the general theory that the inhibitory effect of an inverse agonist will increase 
with an increase in constitutive activity.  
In the present study we aimed at a thorough understanding of the relationship between 
negative intrinsic efficacy and the level of constitutive activity for which the two-state 
receptor model provided the theoretical framework. It allowed us to explain how receptors 
can be locked in an active conformation and become irresponsive to agonists and inverse 
agonists. In addition, we were able to define conditions for optimal assay sensitivity using the 
same theoretical concept. 
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aterials and methods 
east  plasmid and A2B receptor antibody 
A genetically modified yeast Saccharomyces cerevisiae strain with the following genotype: 
MATahis3 leu2 trp1 ura3 can1 gpa1 ::G i3 far1 ::ura3 sst2 ::ura3 Fus1::FUS1-HIS3
LEU2::FUS1-lacZ ste2 ::G418R and expressing vector pDT-PGK was a gift from Dr. S. J. 
Dowell. Constitutively active adenosine A2B receptor mutants were either identified upon 
screening of a randomly mutated receptor library (Beukers et al., 2004) or constructed 
through site-directed mutagenesis. The A2B receptor antibody was kindly provided by Dr. I. 
Feoktistov. 
ite-directed mutation 
Site-directed mutation was introduced by PCR with mutation-inducing primers: 5’-
ACGCCCACCTTCTACTTCCTG3’ for the N43F mutant and 5’-
AAGGCTGAAGTTGGAGCTCTG3’ for the I93N mutant. Mutant genes were inserted into 
pDT-PGK vector at EcoRI/HindIII sites and were confirmed by DNA sequencing. 
east membrane preparation and immunoblot 
Transformed yeast cells were harvested in mid-exponential phase. Yeast cells were collected 
and washed with cold water and resuspend in ice cold lysis buffer (50 mM Tris-HCl PH7.5, 1 
mM EDTA and 0.1 mM PMSF). Yeast cells were broken by vigorous vortexing with glass 
beads. Unbroken cells were precipitated and removed after 5,000 g centrifugation for 10 min 
at 4 C. Subsequently, the supernatant was centrifuged at 40,000 g for 40 min at 4 C. The 
pellets were resuspended with cold collection buffer (50 mM Tris-HCl PH7.5, 1mM EDTA) 
and used to measure protein concentrations. 
Yeast membranes containing 0.5 mg protein/ml were denatured (3 - 5 min, 100 C), separated 
on SDS-PAGE and blotted on Hybond-ECL membrane (GE Healthcare). Hybond-ECL 
membrane was blocked with PBS containing 5% milk powder for 30 min, and then incubated 
with 1: 1,125 diluted A2B receptor antibody for 1 hr. After thorough removal of unbound 
antibody by rinsing the membrane with PBST (0.05% Tween-20, PBS pH 7.6), the membrane 
was incubated with 1: 2,000 diluted HRP-conjugated anti-rabbit IgG (Jackson Immuno 
Reseach) for 1 hr. Hybond-ECL membrane was washed again and enhanced 
chemiluminescence was used to visualize the A2B receptor. 
east screening assay 
Yeast screening assays were performed as described before (Beukers et al., 2004). In brief, 
yeast cells from an overnight culture were diluted to around 400,000 cells/ml (OD600  0.02). 
In solid medium assays, droplets of 1.5 l were spotted on histidine-deficient agar medium 
containing various concentrations of test compounds. In liquid medium assays, 50 l was 
seeded into each well of a 96-wells plate. Receptor-independent yeast growth was suppressed 
through the addition of 7 mM 3-AT. After incubation at 30 C for 48 hours for solid medium 
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assays and 35 hours for liquid medium assays, the growth of yeast was recorded and 
quantified with Quantity One imaging software from Bio-Rad (Hercules, CA). Each 
experiment was repeated 3 times. Prism software (GraphPad Software Inc., San Diego, CA) 
was used for curve fitting and to calculate the potency and efficacy of the compounds.  
Pharmacological modeling (two-state receptor model   
The two-state receptor model is described by three parameters: L, the isomerization constant 
which is the ratio of the receptor in the active Ra state versus the inactive Ri state; , the 
intrinsic efficacy which refers to the affinity of a ligand for the active state of the receptor (Ra)
over the inactive state of the receptor (Ri); KA, the equilibrium dissociation constant of a 
ligand-receptor complex. According to this model, the proportion of receptors in the active 
state is: 
[ ] /
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  equation 1 (Kenakin, 2003) 
In the absence of ligand ([A]  0), the proportion of receptors in the active state is: 
0 ( 1)L L
                          equation 2 
When the saturation concentration of the ligand is reached ([A]  ), the proportion of 
receptors in the active state becomes: 

 L/(1+L)    equation 3 
Thus, the theoretical activity window between unliganded and ligand-occupied receptor is: 

0-
   L/(L+1)- L/(1+L)   equation 4 
To obtain a graphical display of the theoretical window ( 
0-
 ), equation 4 was implemented 
in the MatLab software package version 8.0 (The Mathwork, Inc, Natick, USA). A bell-
shaped curve was obtained by plotting the theoretical window ( 
0-
 ) against logarithmic L 
values (L was varied from 0.01 to 100 with an interval of 0.01) with fixed  values, on which 
the experimental data were superimposed. Similarly, the effect of  on the bell-shaped curve 
was investigated and displayed as a 3-D mesh with the MatLab software. 
Results
election of mutant A2B receptors 
To test the interaction of inverse agonists with human adenosine A2B receptors, we used our 
previously described yeast assay (Li et al., 2007). The relationship between the level of 
constitutive activity of a receptor and the sensitivity to measure the relative intrinsic efficacy 
of a ligand was determined with mutant receptors displaying different levels of constitutive 
activity. We selected mutant receptors with mutations at amino acids positions N43 (2.40), 
A51 (2.48) and I93 (3.40), i.e. located distant to the ligand binding site to avoid disturbance of 
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the interaction between ligands and the receptor (see snake plot’ in the supplementary data 
for the location of these positions). We feel confident that these amino acids do not affect 
ligand binding, as is evident from mutagenesis studies on adenosine receptors (Kim et al., 
2003) and from results of two-entropies analysis (Ye et al., 2006). Detailed information can 
be found in the supplementary material. 
All in all we examined four mutants, two point mutants N43F and I93N created through site-
directed mutagenesis, and another two point mutants A51V and N43S selected from a random 
mutation bank (Beukers et al., 2004).
These four mutant receptors represent three different phenotypes: 1) receptors without 
detectable constitutive activity that are insensitive to agonists (N43F and I93N), 2) a strongly 
constitutively active receptor that no longer respond to ligands (N43S) and 3) a receptor with 
some constitutive activity, sensitive to both agonists and inverse agonists (A51V). Our 
findings with these three categories will be described below. 
Receptors without detectable constituti e acti ity and insensiti e to agonists 
Neither the wild-type nor the I93N or N43F mutant receptors were able to induce yeast 
growth in the absence of an agonist. Upon addition of NECA, a prototypic A2B receptor 
agonist, the wild-type receptor induced maximum yeast growth with an EC50 value for NECA 
of 110  26 nM. However, in the presence of NECA, little growth was observed for yeast 
cells expressing the N43F mutant receptor while no growth was seen with yeast cells 
expressing the I93N mutant receptor (Figure 1A). To examine whether the N43F and I93N 
mutant receptors were expressed in the yeast cells, yeast membranes were prepared and 
analyzed with a western blot (Figure 1B).
                                   A                                                                          B 
Figure. 1 A) Growth of yeast cells expressing the wild-type adenosine A2B receptor or the N43F or I93N 
mutant receptor. Growth was measured in the absence or presence of increasing concentrations of NECA. 
The experiment was repeated 3 times, of which the means  SEM are shown. B) Western blot analysis of 
control, empty vector (lane 1), or wild-type (lane 2), N43F (lane 3) and I93N (lane 4) A2B receptors 
expressed in the yeast membrane. Two bands with an apparent molecular mass around 29 kD and 52 kD 
(indicated by arrows) were detected as A2B receptor specific bands. 
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On the membranes expressing the wild-type receptor, the anti-A2B receptor antibody labeled a 
band with an apparent molecular mass around 29 kD which is close to the molecular weight 
of the A2B receptor. In addition, bands with apparent molecular masses bigger than 50 kD 
were labeled. These higher-mass bands may be the result of receptor oligomerization and/or 
posttranslational modifications. This western blot result is similar to that obtained on 
mammalian cells (Feoktistov et al., 2003). The blot showed that the N43F mutant receptor 
was expressed at similar levels as the wild-type receptor while the I93N mutant receptor 
showed around 50% decreased expression compared to the wild-type receptor. 
Since the expression level of the two mutant receptors could not account for the insensitivity 
to the agonist, we analyzed this behavior with a pharmacological model. Matlab was used to 
mimic the activation of receptors with little constitutive activity (L values ranging from 0.01 
to 0.0001) by an agonist with an  value of 100 and KA Figure 2, a smaller L value 
corresponds to a less constitutively active receptor that is also less responsive to the agonist. 
When its L value is very small (L  0.0001), a receptor can hardly be activated by the same 
agonist. In functional assays, such a receptor will be unresponsive to an agonist and 
characterized as being locked in an inactive conformation. 
Figure. 2 Simulation of receptor activation with different ratios of active versus inactive receptors as 
represented by different L values. Receptor activation by an agonist with an intrinsic efficacy ( value) of 
100 and an affinity (KA) of 100 nM is shown. Continuous line L 0.01; dashed line L 0.001; dotted line 
L 0.0001.  
trongly constituti ely acti e receptors insensiti e to both agonists and in erse agonists  
The constitutively active mutant N43S receptor was retrieved from a random mutation bank 
(Beukers et al., 2004). It was characterized by a high level of constitutive activity and could 
not be further activated by 10 µM of the agonist NECA (Figure 3). It also did not respond to 
the inverse agonist ZM241385 (10 µM) which exhibited the greatest relative intrinsic efficacy 
among the three tested inverse agonists DPCPX, MRS1706 and ZM241385 as shown in our 
previous study (Li et al., 2007).
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Figure. 3 Growth of yeast cells expressing the wild-type adenosine A2B receptor or the N43S mutant 
receptor. Growth was measured in the absence (control) or presence of 10 M NECA or 10 M ZM241385. 
Each experiment was repeated 3 times, of which the means  SEM are shown. *** p  0.001, student’s 
unpaired t test. 
Matlab was used to mimic the activation and inhibition of receptors with a high level of 
constitutive activity (L  1000). The  values were set from 100 for an agonist to 0.1 and 0.01 
for inverse agonists. As shown in figure 4, it is hard to detect agonism and inverse agonism of 
a ligand on receptors with such a big L value. In other words, this receptor is locked in an 
active state and can not be further activated or inhibited.
Figure. 4 Simulation of a concentration-response curve for a receptor with a ratio of active versus inactive 
receptors (L value) of 1000 and an inverse agonist with intrinsic efficacies ( values) varying from 100 
(straight line), 0.1 (dashed line) or 0.01 (dotted line). 
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odestly constituti ely acti e receptors sensiti e to both agonists and in erse agonists 
From our random screening assay we identified a mutant A51V receptor which exhibited an 
intermediate level of constitutive activity. It appeared sensitive to both agonists and inverse 
agonists. Thus in a single experiment the efficacy of the agonist NECA as well as the efficacy 
of the inverse agonist ZM241385 could be determined (Figure 5). The EC50 value was 96  25 
nM for NECA and 203  37 nM for ZM241385. 
Figure. 5 Activation and inhibition of the growth of yeast cells expressing the A51V mutant A2B receptor 
by the agonist NECA or the inverse agonist ZM241385, respectively. The experiment was repeated 3 times, 
of which the means  SEM are shown. 
Prediction of the experimental window with pharmacological modeling of the two-state receptor 
model 
The two-state receptor model was used to determine the optimal experimental window to 
measure the intrinsic efficacy of compounds. Theoretically, when all the receptors are in an 
inactive state, the proportion of activated receptors (
) is 0 and no test system would be able 
to detect any signal. Conversely, when all the receptors are in an active state, 
 equals 1 and 
the test system will detect a maximal signal. This simplified model is based on two 
assumptions. First, only the R and R* states of the receptor and the interaction between the 
receptor and ligand are considered while receptor/G protein interactions are not. Second, the 
reported signal is assumed to be positively correlated with either agonist-induced or 
constitutive receptor activation in a given system. Based on these assumptions, the readout 
signal will reflect the ability of ligands to activate or inactivate the receptor. In addition, the 
theoretical window of a ligand in a functional assay can be calculated by the difference 
between the proportion of activated receptors in the absence and presence of the ligand. For 
agonists the proportion of active receptors in the absence of ligand (
0) is subtracted from the 
proportion of active receptors in the presence of ligand (
). Conversely, to determine the 
experimental window for inverse agonists, the proportion of receptors in the presence of 
excess amount ligand (
) is subtracted from the proportion of active receptors in the absence 
of ligand (
0). The absolute value of the response ( 
0-
 ) is thus between 0 and 1. The 
experimental window, (
-
0) for agonists and (
0-
) for inverse agonists, is expressed as a 
percentage of the theoretically maximal response. 
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The absolute value of equation 4 in the two-state receptor model was implemented in the 
software package MatLab. Figure 6 displays the theoretical window (
0-
), that is obtained 
for a hypothetical inverse agonist ( value equals 0.2) on a series of hypothetical receptors (L 
values vary from 0.01 to 100). The largest experimental window is obtained on a hypothetical 
receptor with an L value of 2.3. On such a receptor the maximal hypothetical window is 38% 
of the maximal response that the system can produce.  
The ability to determine the intrinsic efficacy of ligands is also affected by the reproducibility 
and sensitivity of the assay. For example, when the standard deviation equals 10% of the 
maximum response, no significant response can be detected for an inverse agonist with an 
value of 0.2 on receptors with L values below 0.15 (10-0.83) or above 34 (101.53) (see Figure 6).
At receptors with this level of constitutive activity the effect of the ligand will not be 
significantly different from the standard deviation of the signal caused by the constitutive 
activity. In a more reproducible assay with a standard deviation of 5% of the maximum 
response, the range of receptors for which a response of this inverse agonist can be detected 
will increase to receptors with L values between 0.07 (10-1.17) and 74 (101.87) (Figure 6). 
Figure. 6 The bell-shaped curve represents the plot of the theoretical window (
0-
) versus the logarithm of 
L (the ratio of active versus inactive receptors) using series of L values (from 0.01 to 100 with an interval 
of 0.01) and a single  value equal to 0.2. The horizontal lines represent the detection limit with standard 
deviations of 5% and 10% of the maximal response for the lower and upper line, respectively. 
The level of constitutive activity is lin ed to the ma imum response in a non-linear manner  
Our results suggest that the level of constitutive activity of a receptor affects the ability to 
determine the intrinsic activity of a ligand. To test this hypothesis, the theoretical curve and 
available experimental data are shown in one figure (Figure 7). The experimental data stem 
from a previous study where we reported on 7 mutant human adenosine A2B receptors. F84L, 
F84S, F84L/S95G, T42A are mutants with low levels of constitutive activity and T42A/V54A, 
N36S/T42A, N36S/T42A/T66A are mutants with intermediate levels of constitutive activity 
(Li et al., 2007). The inverse agonist ZM241385 had the highest intrinsic efficacy of the three 
inverse agonist tested with an  value of 0.14. In this study, we normalized the experimental 
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window of ZM241385 on these mutants with respect to the maximal response in the yeast 
assay, and obtained the following percentages of maximum responses: 10%, 16.5%, 17.5%, 
14.6%, 47.4%, 45% and 39.6% for F84L, F84S, F84L/S95G, T42A, T42A/V54A, 
N36S/T42A and N36S/T42A/T66A, respectively. The L values of these mutants were 0.12, 
0.20, 0.20, 0.18, 1.45, 1.49 and 1.83, respectively. These experimental data were 
superimposed on the bell-shaped curve representing the theoretical maximum window 
(caused by an inverse agonist with an  value equal to 0.14) obtained with L values ranging 
from 0.01 to 100 (Figure 7). The plot shows that the experimentally determined data were 
located on or very close to the left-hand side of the theoretical curve. In our studies, receptors 
with high levels of constitutive activity (higher constitutive activity than N36S/T42A/T66A 
mutant, but less constitutively active than locked-on mutant) have not been identified so far. 
As a consequence we have no experimental data available to explore the right-hand side of the 
curve in figure 7. The L value of the highly constitutively active mutants which were non-
responsive to ligands could not be determined experimentally because of the very high L 
values. This is due to the fact that a very small experimental standard deviation leads to huge 
standard deviations in L values when almost all the receptors are constitutively active and 
maximum activation is achieved. Thus, we could not calculate the L value of the N43S 
mutant receptor and superimpose its data on the bell-shaped curve. Although the L value of 
the N43S mutant receptor can not be quantified, the mutant receptor does show a decreased 
response at such high L values. 
Figure.7 The bell-shaped curve represents the plot of the experimental window (
0-
) versus the logarithm 
of L (the ratio of active versus inactive receptors) using series of L values (from 0.01 to 100 with an 
interval of 0.01) and a single  value equal to 0.14. The data points represent the previously reported 
experimental data of ZM241385 tested on 7 mutant adenosine A2B receptors (Li et al., 2007). From left to 
right, the mutants were F84L, T42A, F84S, F84L/S95G, T42A/V54A, N36S/T42A and N36S/T42A/T66A. 
The L values of these mutants were 0.12, 0.18, 0.20, 0.20, 1.45, 1.49 and 1.83, respectively. The calculated 
experimental windows were 10%, 14.6%, 16.5%, 17.5%, 47.4%, 45% and 39.6%, respectively. 
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oth the intrinsic efficacy  and the isomeri ation constant  determine the e perimental 
window
Both the intrinsic efficacy  and the isomerization constant L determine the experimental 
window (equation 4). The relationship between the logarithm of L (x-axis), the logarithm of 
                                                                   A 
                            B                                                                    C 
Figure. 8 A) Three-dimensional mesh of the percentage of maximum theoretical window for hypothetic 
inverse agonists with continuous intrinsic efficacyvalues between 0.001 to 1 on hypothetic receptors 
with continuous ratios of active versus inactive receptors (L values) between 0.001 to 1000. In figure 8B, 
concentration-response curves are shown for receptors with L values of 0.01, 1, 10 and 100 for a strong 
inverse agonist with an  value of 0.001 (closed circles in figure 8A). Similarly, in figure 8C, 
concentration-response curves are shown for a weak inverse agonist with an  value of 0.1 (open circles in 
figure 8A).    
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(z-axis) and the percentage of the maximum theoretical window (y-axis) can be visualized in 
a 3-D mesh (see Figure 8A). A series of bell-shaped curves represent the percentage of the 
maximum theoretical window that can be achieved when log  and log L are varied. This 
mesh shows that for a ligand with an valuebetween 0.001 and 1 an optimal theoretical 
window can be achieved for receptors with a log L value close to 1. 
Within the framework of the two-state receptor model, the theoretical window ( 
0-
 ) is 
calculated as L/(L+1)- L/(1+L) . An optimal theoretical window will be obtained when the 
relationship between the level of constitutive activity (L) of a receptor and the value of the 
ligand obeys the following equation 
                                                                    equation 5 
The 3-D mesh is composed of a series of bell-shaped curve according to the different intrinsic 
efficacies of a ligand. The maximum is achieved when L equals the reciprocal square root of 
. When L is bigger than the reciprocal square root of , the window will decrease with an 
increase of L. Conversely, when L is smaller than the reciprocal square root of , the window 
will increase with an increase of L. 
We chose two positions in the mesh to simulate dose-response curves and analyzed the 
theoretical windows. Although the theoretical window is independent of KA, KA is necessary 
to simulate concentration-effect curves because it determines the relative EC50 value of a 
concentration-effect curve. In the simulation, we used a fixed KA value of 100 nM. In figure 
8B and 8C we simulated the situation where  is fixed and L is variable. If the ligand is a 
very strong inverse agonist (	, a bigger window is observed on receptors with higher 
levels of constitutive activity provided that the ligand is soluble enough to allow testing at 
mM concentrations (Figure 8B). If the ligand is a very weak inverse agonist	, the 
window will first increase and then decrease with increasing levels of constitutive activity of 
the receptor (Figure 8C).Fixing  while varying L resulted in concentration-effect curves 
similar to the ones shown in figure 2 and figure 4.  
iscussion 
In our previous study, we found two remarkable mutant human adenosine A2B receptors 
which are highly constitutively active and did not respond to the tested inverse agonists (Li et 
al., 2007). This finding suggested that the inhibitory effect of an inverse agonist could 
decrease with an increase in constitutive activity of the receptors and contrasts with the 
positive relationship between the inhibitory effect and constitutive activity that is often 
suggested.
In the current study, we aimed at providing a theoretical framework to unravel the 
relationship between the inhibitory effect of an inverse agonist and the constitutive activity of 
a receptor. We considered our experimental findings within the boundaries of the two-state 
receptor model. In this context, all the conformations a receptor might adopt and all the 
subsequent effector systems activated by such conformations (Kenakin, 2005) can be 
1L

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classified into two states: 1) an active state, resulting in a measurable readout signal and 2) an 
inactive state, which cannot induce a readout signal. In our yeast assay, a single downstream 
signaling event was measured, i.e. the growth of yeast cells, which is positively correlated to 
the activation of the receptors. In this situation the two-state receptor model can be usefully 
applied as we have shown in our previous work (Li et al., 2007). Similar to our previous work, 
the reported intrinsic efficacies are relative intrinsic efficacies as they are system-dependent 
(Li et al., 2007). In addition, we assume that the downstream signaling effects in our yeast 
system are identical among the mutants ratifying the use of the simplified two-state receptor 
model. If downstream signaling events need to be accounted for, the two-state model should 
be extended with an intervening forcing function (supplementary data to Li et al., 2007).  
The two-state model assumes that the receptor states exist in equilibrium between R* (active) 
and R (inactive), in which R* represents the receptor populations that lead to yeast growth. 
The isomerization constant (L) determines the ratio between the two receptor populations. 
The L value is a measure for the percentage of receptors that are present in the active 
conformation in the absence of ligand and therefore L reflects the level of constitutive activity 
of a receptor. Bigger L values correspond to more active receptors in a ligand-free system.  
L also determines whether the receptor can be easily activated or not. A receptor with a 
preference for the inactive state will require an agonist with a large intrinsic efficacy to 
activate it. This situation is depicted in figure 2, in which an agonist can behave as a partial 
agonist on a receptor with a small L value (L  0.001). When the L value is even smaller (L  
0.0001), the effect of the agonist will be beyond the detection limit.  
Several observations in the literature may be explained by such small L values. For instance, 
the V60L mutant human melanocortin receptor showed impaired ability to respond to -MSH 
although expression levels and ligand binding were indistinguishable from that of the wild-
type receptor (Schioth et al., 1999). Similarly, the I51A mutant cholecystokinin (CCK) 
receptor showed decreased efficacies upon CCK stimulation while binding features were very 
similar to those of the wild-type CCK1 receptor (Escrieut et al., 2002). A third example is the 
R68L mutation in the first intracellular loop of the CCK-B receptor. This mutant completely 
lost its ability to respond to both CCK and gastrin as determined in cAMP experiments, 
although it was expressed at a comparable level as the wild-type receptor without impaired 
binding affinity for gastrin (Wu et al., 1999). These mutant receptors, as well as the N43F and 
I93N human adenosine A2B receptor in this study, have an impaired response to their agonist 
and this may be due to rather small L values.    
Whereas receptors with small L values respond poorly to agonists, highly constitutively active 
receptors seem to be insensitive to inhibition by inverse agonists (Figure 4). To inhibit 
receptors with an L value of 1000, inverse agonists with a large intrinsic efficacy (  0.01 in 
this example) are required to obtain at least some inhibitory effect. Inverse agonists with a 
smaller intrinsic efficacy ( 0.1) hardly show any effect. In other words, such a receptor 
appears to be locked in an active state unless highly efficacious inverse agonists are applied.  
Measuring negative intrinsic efficacy 
75
Some receptors indeed possess such high levels of constitutive activity rendering them 
unresponsive to any known inverse agonist. A couple of examples of such receptors have 
been mentioned and referred to in the introduction: the G14T mutant adenosine A1 receptor, 
the Y7.53N mutant 5HT2C receptor and two human adenosine A2B mutants, the 
A18T/A23V/C83Y/A106V/R112S and the   Q214L/I230N/V240M/V250M/N254Y/T257S/ 
K269stop mutant. In the current study, the human adenosine A2B N43S mutant receptor was 
identified as a receptor that is too constitutively active to be silenced by known inverse 
agonists.
As a consequence of the above, one should be cautious using receptors with a high 
constitutive activity to screen for inverse agonists, because only high-efficacy inverse agonists 
can be identified while weaker inverse agonists will be overlooked. These weaker ligands 
might however be good lead compounds for drug development and may also provide useful 
information for structure-activity relationships.  
To detect inverse agonists with low efficacy or to rank compounds based on their intrinsic 
efficacy, receptors with intermediate levels of constitutive activity provide a better test system 
than receptors with either a rather high constitutive activity or negligible constitutive activity. 
This is true for wild-type receptors displaying constitutive activity as well as for mutant 
receptors provided that the mutation does not affect ligand binding, G protein-coupling and 
receptor expression levels. As explained in the results section, the greatest sensitivity will be 
obtained with a receptor for which the L value is equal to the reciprocal square root of the 
value. When L is smaller than this value, an increase of L will increase the window. On the 
contrary, when L is bigger than this value, the window will decrease with an increase of L.
As we mentioned above, the assumption that the inhibitory effect of an inverse agonist will 
increase with an increase in constitutive activity of the receptors is valid only for highly 
efficacious inverse agonists. Such inverse agonists have small  values, thus the reciprocal 
square root value of is very big. In that case a maximum experimental window can only be 
achieved when L is very big or, in other words, when the receptor is very constitutively active. 
However, receptors with such high constitutive activity are not common; usually the L values 
are smaller than the values required to achieve the maximum windows. In that case, the 
window increases with increasing constitutive activity (Figure 8B).  
On the other hand, for weaker inverse agonists with larger  values, the reciprocal square root 
value of is relatively small and receptors may have L values exceeding the optimal value for 
achieving the maximum window. Thus, for weak inverse agonists, there are two possibilities:
when L values of the receptors are smaller than the reciprocal square root value of the 
window is increased with an increase of L; when L values are bigger than that, the window is 
decreased with an increase of L (Figure 8C), such that the window disappears with the highest 
L values, effectively yielding a locked’ receptor. 
In conclusion, we explored in this study the relationship between the inhibitory effect of 
inverse agonists and the level of constitutive activity of receptors. High constitutive activity 
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may yield lock  receptors that do not respond to inverse agonists, as a consequence of the 
delicate balance between receptor isomerization constant and ligand intrinsic efficacy. 
Receptors with intermediate levels of constitutive activity however allow detection of both 
agonists and inverse agonists as the three groups of mutant A2B receptors with different 
phenotypes show. Such receptors are in fact good screening tools since they provide an 
optimal window to sense the intrinsic efficacy of ligands. 
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upplementar  data  
1. na e plot of human adenosine A2B receptor
Snake plot of human adenosine A2B receptor with studied positions N43 (2.40), A51 (2.48) 
and I93 (3.40) in bold circles. N43 (2.40) is located in the 1st intracellular loop, close to helix 
2, A51 (2.48) and I93 (3.40) are in helix 2 and helix 3, respectively. 
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2. Two-entropies analysis 
The mutated residues are located distant from the ligand binding site as shown in the two-
entropy analysis. This is a newly developed bioinformatics method and was shown to 
successfully discriminate positions involved in the ligand binding sites from the other 
positions (Ye et al., 2006). In short, the principle of the two-entropy analysis to find amino 
acids involved in ligand binding is based on the assumption that such amino acids must be 
divergent among subfamilies recognizing different endogenous ligands and be similar or even 
identical within a subfamily recognizing the same endogenous ligand. Scores are given to 
individual positions, the smaller a value is, the more conserved the position is, and vice versa. 
According to this principle, the amino acids involved in ligand binding should appear in the 
upper left corner (as shown in the ellipse) of the two-entropy plot.
Two of the mutated positions in the A2B receptor, A51 (2.48) and I93 (3.40), were found in 
the center of the plot which suggested that they are not likely to be involved in ligand binding. 
These two positions are highlighted in the two-entropy plot. The other position, N43 (2.40), is 
located at the interface of helix 2 and intracellular loop 1. The intra- and extracellular loops of 
the receptors were not evaluated in the two-entropy analysis, but in general the intracellular 
loops are not considered to be involved in direct ligand binding. The reader is referred to Ye 
et al., Proteins 63 (2006) 1018-1030 for more information. 
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ummar  
The human adenosine A2B receptor belongs to class A GPCRs and is involved in important 
physiological functions. In our previous study, we applied random mutagenesis followed by 
functional screening to identify gain-of-function and/or constitutively active mutant receptors. 
To our surprise, none of the identified mutant receptors contained mutations in the conserved 
NPxxY motif or, in an extended version, the NxxxNPxxY motif. In this project we applied 
site-directed mutagenesis to investigate the role of the NxxxNPxxY motif and the potential salt 
bridge between TM1 (E14) and TM7 (H280) in receptor activation. In total 12 mutant receptors 
were constructed and tested with 5 agonists: NECA, CPA, CGS21680, IBMECA and LUF5833. 
The results confirmed our previous random mutagenesis experiments because none of the 
site-directed mutants displayed either gain-of-function or constitutive activity. With the 
exception of the N294I (increased expression levels), N286A (decreased expression levels) and 
H280E (abolished expression) mutant receptors, all constructed mutants were expressed at 
levels comparable to the wild-type receptor. Except for N294I which behaved similar to the 
wild-type receptor, the agonist potency and/or efficacy for the other mutant receptors were 
reduced to varying degrees. Despite normal expression levels, mutants E14H, I61A, I61D, 
I61K and Y290F did not respond to any of the tested agonists. Apparently, both the potential 
salt bridge and the NxxxNPxxY motif play an important role in the process of receptor
activation. Interestingly, analysis of two homology models of the adenosine A2B receptor based 
on the crystal structures of the human 2 adrenergic receptor and bovine rhodopsin, respectively, 
revealed subtle differences among these receptors. These differences may explain why the role 
of the NxxxNPxxY motif differs among Class A GPCRs. 
ntroduction 
The adenosine receptor is a member of the rhodopsin-like family of G protein-coupled 
receptors (GPCRs). In human, there are 4 subtypes of adenosine receptors: A1, A2A, A2B, and 
A3. Among them, the A2B subtype is implied in atherosclerosis of smooth muscle cells, in 
mast cell activation in asthma, resulting in bronchoconstriction, in intestinal (dys)function, and 
in dilation of certain vascular beds (Feoktistov et al., 1998; Ralevic and Burnstock, 1998;
Holgate, 2005; Yaar et al., 2005). 
Despite extensive efforts, structural information on GPCRs is still scarce. To date, two crystal 
structures are available, that of the inactive state of bovine rhodopsin (Palczewski et al., 2000) 
and, very recently, of the human 2 adrenergic receptor (Cherezov et al., 2007; Rasmussen et 
al., 2007; Rosenbaum et al., 2007). Until now the structure of bovine rhodopsin has been used 
as a template to build homology models for GPCRs (Bissantz et al., 2003; Fano et al., 2006; 
Hobrath and Wang, 2006; Nowak et al., 2006). The availability of the 2-adrenergic receptor 
structure enabled us to build and compare two homology models of the human adenosine A2B
receptors. 
Rhodopsin-like GPCRs (class A GPCRs) share a large number of conserved sequence 
patterns. For example, the most conserved residues in each transmembrane (TM) helix are: 
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N1.50, D2.50, R3.50, W4.50, P5.50, P6.50, and P7.50, following the numbering scheme 
introduced by Ballesteros and Weinstein (1995). These patterns are easily identified and used 
for multiple sequence alignment of rhodopsin-like GPCRs to allow sequence comparison and 
model building (Mirzadegan et al., 2003).  
Highly conserved patterns imply an important structural and/or functional role. Several 
conserved patterns have been identified among class A GPCRs: a disulfide bridge formed by 
the two Cys residues located in extracellular loop 2 (IL2) and at the beginning of TM3 (Klco 
et al., 2005); salt bridges between TM3 and TM6 or TM1 and TM7 (Kim et al., 1997; 
Ballesteros et al., 2001); the DRY/ERY motif at the end of TM3 (Alewijnse et al., 2000); 
CWxP in TM 6 (Shi et al., 2002; Ruprecht et al., 2004); and an extended motif consisting of 
the NPxxY motif in TM 7 with the F in TM8 5 or 6 amino acids downstream of the NPxxY 
motif (Govaerts et al., 2001; Urizar et al., 2005; Mirzadegan, et al., 2003) This NPxxY motif 
is highly conserved and is part of the NxxxNPxxY motif.  
In our previous study (Beukers et al., 2004a), we applied random mutagenesis followed by 
functional screening to identify gain-of-function and/or constitutive active receptors. To our 
surprise, none of the identified mutant receptors contained mutations either in the conserved 
NPxxY motif or in the NxxxNPxxY motif. The random mutagenesis method can be limited in 
that not all potential amino acid substitutions are obtained. This is because chances are small 
that a simultaneous substitution of more than one nucleotide occurs within a single codon. In 
the present study we therefore investigated the activation of the human adenosine A2B
receptor through site-directed rather than random mutagenesis, while still using our robust and 
straightforward yeast screening assay. 
The site-directed mutations were made based on the following criteria 1) sequence 
comparison among adenosine receptors and receptors with known structures 2) general GPCR 
receptor activation domains and 3) comparison of receptor homology models built on two 
different templates.  
aterial and methods 
east  plasmid and A2B receptor antibody 
A genetically modified yeast Saccharomyces cerevisiae strain with the following genotype: 
MATahis3 leu2 trp1 ura3 can1 gpa1 ::G i3 far1 ::ura3 sst2 ::ura3 Fus1::FUS1-HIS3
LEU2::FUS1-lacZ ste2 ::G418R and expressing vector pDT-PGK was a gift from Dr. S. J. 
Dowell. Adenosine A2B receptor mutants were constructed through site-directed mutagenesis. 
The A2B receptor antibody was kindly provided by Dr. I. Feoktistov. 
ite-directed mutagenesis 
Site-directed mutation was introduced by PCR with mutation-inducing primers: 5’- TGAC 
AACTGACTGGGCATGTGACA3’ for the N282Q mutant, 5’- TGACAACTGATCTGG 
CATGTGA3’ for N282R mutant, 5’-AGACAATGGGAGCGACAACTGAAT3’ for N286A 
mutant, 5’-AGACAATGGGCTGGACAACTGAAT3’ for N286Q mutant, 5’- AGACAA 
TGGGTCTGACAACTGAAT3’ for N286R mutant, 5’- CCGGTAAGCAAAGACAATG
GG3’ for Y290F mutant, 5’ CGGTAAGCATTGACAATGGGA3’ for Y290N mutant and 5’- 
GAAGTCTCGGATCCGGTAAGC3’ for N294I mutant; 5’-CATGGTCTCCGCTC
TTCGCCGCCCCCTTTGCCATC3’ for I61A; 5’-CATGGTCTCCGCTCTTCGCCGAC 
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CCCTTTGCCATC3’ for I61D; 5’-CATGGTCTCCGCTCTTCGCCAAACCCTTTGCC 
ATC3’ I61K;   5’CATGAATTCATGCTGCTGGAGACACAGGACGCGCTGTACGTGGC 
GCTGCACCTGGTCATCG 3’ for E14H and 5'-CATGGTCTCCTTCTTCTGTCAGAG
GCCAATTCAGTTG3' for H280E.  
Restriction sites in the primers are indicated in italics. Mutant genes were inserted into 
pDT-PGK vector at EcoRI/HindIII sites and were confirmed by DNA sequencing. The 
plasmids containing any of the above mentioned mutant genes were transferred into yeast 
Saccharomyces cerevisiae and selected on plates with minimal media without uracil, which 
enabled us to isolate the transformants containing the mutation.
Figure 1. Snake plot of the human adenosine A2B receptor with studied positions E14 (1.39), I61 (2.58), I93 
(3.40), N282 (7.45), N286 (7.49), Y290 (7.53) and N294 (7.57) in bold circles. E14 (1.39), I61 (2.58) and 
I93 (3.40) are located in the first, second, and third helices respectively. N282 (7.45), N286 (7.49), Y290 
(7.53) and N294 (7.57) are located in helix seven. 
east cells immunoblotting 
Transformed yeast cells were cultured overnight at 30 C and around 4*105 yeast cells were 
harvested in mid-exponential phase. These cells were broken by vigorous vortexing with glass 
beads 2 times of 1 min after washing with water and 20% TCA (20% w/v trichloro acetic 
acid). Broken yeast cells were collected and denatured (3 - 5 min, 100 C), separated on 
SDS-PAGE and blotted on Hybond-ECL membrane (GE Healthcare). Hybond-ECL 
membrane was blocked with PBS containing 5% milk powder for 30 min, and then incubated 
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with 1: 1,125 diluted A2B receptor antibody for 1 hr. After thorough removal of unbound 
antibody by rinsing the membrane with PBST (0.05% Tween-20, PBS PH 7.6), the membrane 
was incubated with 1: 2,000 diluted HRP-conjugated anti-rabbit IgG (Jackson Immuno 
Reseach) for 1 hr. Hybond-ECL membrane was washed again and the specific signal of A2B
receptors was probed according to the ECL Western blotting analysis system (GE 
Healthcare). 
east screening assay 
Yeast screening assays were performed as described before (Beukers et al., 2004a). In brief, 
yeast cells from an overnight culture were diluted to around 400,000 cells/ml (OD600  0.02), 
50 l was seeded into each well of a 96-wells plate. Receptor-independent yeast growth was 
suppressed through the addition of 7 mM 3-AT. After incubation at 30 C for 35 hours the 
yeast growth revealed by optical density (OD) was recorded. Each experiment was repeated at 
least 3 times. Prism software (GraphPad Software Inc., San Diego, CA) was used to calculate 
the potency and efficacy of the compounds.  
A2B model 
All the primary sequences were obtained from NCBI. The crystal structure of bovine 
rhodopsin was obtained from the Protein Data Bank (http://www.rcsb.org/pdb) (Berman HM, 
2000) and the primary sequence was extracted from the crystal structure. The primary 
sequence of the human 2 adrenergic receptor was extracted from the crystal structure. The 
primary sequences of the human adenosine A1 (NP 001041695.1), A2A (NP 000666.2), A2B
(NP 000667.1), A3 (NP 065734.5) receptors were obtained from NCBI. Sequence alignment 
of human adenosine A1, A2A, A2B, A3, human 2 adrenergic receptor and bovine rhodopsin 
was performed using CLUSTALW (Chenna et al., 2003). The following helical segments of 
rhodopsin-like GPCRs were properly aligned: Asn (1.50); Asp (2.50); Asp/Glu (3.49)-Arg 
(3.50)-Tyr (3.51); Trp (4.50); Tyr (5.50); Tyr (6.48)-Leu (6.49)-Pro (6.50); and Asn(7.49)-Pro 
(7.50)-(Xaa)2-Tyr(7.53). We applied the Ballosteros numbering scheme (Ballesteros and 
Weinstein, 1995), labeling the most conserved position in each helix with 50 and numbering 
the remaining residues according to their distance and direction with respect to the conserved 
residues.
The structural homology models were created using InsightII (San Diego, CA, USA).  
oc ing
Docking simulations were performed with AutoDock (http://autodock.scripps.edu/) Grid 
maps of 20x20x20 angstrom representing the protein were calculated with AutoGrid. Such 
maps were centered on the oxygen atom of the -hydroxy group of residue T89. Docking 
simulations were carried out using the Lamarckian genetic algorithm, with an initial 
population of 100 individuals, a maximum number of 10,000,000 energy evaluations and a 
maximum number of 50,000 generations (http://autodock.scripps.edu/faqs-help/tutorial/
using-autodock-withautodocktools/UsingAutoDockWithADTv2e.pdf). Resulting orientations 
lying within 1.5 angstrom in the RMSD were clustered together. Finally the configuration 
with the most favorable free energy of binding was further optimized by 1500 energy 
minimization steps with InsightII.
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Results
ultiple se uence alignment  
Figure 2. Multiple amino acid sequence alignment of the human adenosine A1, A2A, A2B, A3, human 2
adrenergic receptors and bovine rhodopsin. Conserved residues are marked in black. Similar residues are 
marked in grey. 
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CLUSTALW was applied to create a sequence alignment of the human adenosine A1, A2A,
A2B, A3, human 2 adrenergic receptor and bovine rhodopsin. In the alignment, the most 
conserved residues were properly aligned as shown in figure 2. 
Overall, the sequences of the human adenosine A2B and bovine rhodopsin are 12% identical, 
whereas the A2B and 2 adrenergic receptor are 17% identical. The sequence identity between 
the A2B receptor and other adenosine subfamily receptors is greater than 25%; among these 
the A2A receptor has the highest identity 41% (Table 1). 
Table 1. Identity among bovine rhodopsin, 2 adrenergic receptor and the 4 subtypes of human 
adenosine receptors. 
Identity (%) rhodopsin 2 A1 A2A A2B
2 11.0     
A1 9.3 15.7    
A2A 11.9 17.9 32.9   
A2B 11.9 17.4 31.1 40.8  
A3 9.5 15.5 32.2 26.5 25.6 
Adenosine A2B receptor model 
As shown in figure 3A, the loop that connects helix 7 and 8 is different between the two 
templates of bovine rhodopsin and the 2-adrenergic receptor. There are six residues between 
the conserved NPxxY motifs and F in bovine rhodopsin while there are only five in the 2
adrenergic receptor (Figure 3A).  
Starting with the 3-D structures of bovine rhodopsin (Berman et al., 2000) and the 
2-adrenergic receptor (Cherezov et al., 2007) as templates, Insight II (San Diego, CA, USA) 
was applied to build homology models for the 3-D structure of the human adenosine A2B 
receptor. There are several differences between the A2B models based on these two templates. 
Firstly, a few differences were found in helix 7 and the link between helix 7 and helix 8 
(Figure 3B). At the end of helix 7 in the 2 adrenergic receptor model, S329 and P330 
together lead to a sharp turn. These residues are absent in the A2B receptor and as a result such
a sharp turn is absent and instead a set of 3 amino acids constitutes a bigger turn (Figure 3Ba). 
Thus we introduced a gap in the 2 adrenergic receptor-based A2B receptor model to 
compensate for this structural difference. Residue Y(Y7.53) in the NPxxY motif forms a pi-pi 
stacking interaction with residue F in helix 8 in both models, but different rotamers are used 
by these two interacting aromatic residues (Figure 3Bb). The first N (N7.45) in the 
NxxxNPxxY motif points to the core of the receptor according to the bovine rhodopsin-based 
model while the same residue is pointing outwards according to the 2 adrenergic 
receptor-based model (Figure 3Bc). Secondly, according to the 2-adrenergic receptor model, 
the area of helix 1 close to the extracellular side of the receptor is further away from the 
centre of the receptor compared to bovine rhodopsin (Cherezov et al., 2007), shifting E14 to 
aplane more distant to residue H280. As a consequence, the formation of a salt bridge 
between these two residues which seems to occur according to the homology model based on 
the rhodopsin structure (Figure 3Cd) would no longer be feasible in the 2 adrenergic 
receptor-based model (Figure 3Ce). Thirdly, the length of the helices is slightly different: helix 
4 (119-143) is 3 amino acids longer than that according to the bovine rhodopsin model and 
helix 6 is 4 amino acids shorter (228-259). 
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Figure 3. A) Multiple sequence alignment of helix 7 and 8 for the human adenosine A1, A2A, A2B, A3,
human 2 adrenergic receptor and bovine rhodopsin. Conserved residues marked in black. In bovine 
rhodopsin six residues separate F from the conserved NPxxY motif, in the 2 adrenergic receptor five 
residues do so, see red box. B) Structural overlay of helix 7 and helix 8 of bovine rhodopsin (blue) and the 
2 adrenergic receptor (green). a) the 2 adrenergic receptor uses one residue less to finish the turn between 
helix 7 and helix 8 compared to bovine rhodopsin; b) The pi-pi stack is conserved in both bovine rhodopsin 
and the 2 adrenergic receptor but different rotamers are adapted; c) difference in position 7.44 between 
bovine rhodopsin and 2 adrenergic receptor. C) different interactions between E14, H280 and I61 in A2B
homology models based on bovine rhodopsin (d) and 2 adrenergic receptor (e). d) In the model based on 
the bovine rhodopsin template, E14 and H280 are close enough to form a salt bridge, I61 is the vicinity. e) 
In the model based on the 2 adrenergic receptor template, E14 and H280 are not close enough to form a 
salt bridge. 
Shedding light on the activation of the A2B receptor 
89
Role of 282  286  290 and 294 in ligand binding 
The software package Autodock was used to investigate the interaction between the 
prototypic adenosine receptor agonist NECA and the NxxxNPxxY motif of the adenosine A2B
receptor model built based on the bovine rhodopsin crystal structure (1GZM) (see Figure 4). 
The residue in closest proximity to NECA is N282 in the neighbourhood of the ribose moiety 
of NECA. However, this N282 (7.45) is rather conserved among all class A GPCRs (60.1% N, 
18% S, 9% H). Thus N282 is not expected to contribute to ligand-specific interactions. The 
other mutated residues of this motif, N286, Y290 and N294 are far away from NECA and 
unlikely to be directly involved in ligand binding (Figure 4). 
Figure 4. Docking of NECA in a ribbon representation of the 3-D human adenosine A2B receptor model 
based on the bovine rhodopsin template with N282, N286, Y290 and N294 highlighted. 
Role of xxx Pxx  motif in receptor acti ation 
The NxxxNPxxY motif in TM7 has been reported to be involved in the agonist-induced and 
constitutive activation of many GPCRs (Prioleau et al., 2002; Govaerts et al., 2001; Urizar et 
al., 2005). As mentioned before, our random mutagenesis screen did not reveal any mutations 
in this motif (Beukers et al., 2004a). To investigate whether this motif is important for 
receptor activation of the adenosine A2B receptor, we created the following mutants: N282Q, 
N282R, N286A, N286Q, N286R, Y290F, and Y290N. Activation of these mutants by 5 
agonists, NECA, CPA, CGS21680, IBMECA and LUF5833, was determined. Among them, 
NECA is a non-selective agonist for adenosine receptors (de Zwart et al., 1998), whereas CPA, 
CGS21680 and IBMECA are selective agonists for adenosine A1, A2A and A3 receptors, 
respectively (Klotz et al., 1998). LUF5833 is a non-selective, non-ribose agonist with high 
affinity for the adenosine A2B receptor, although it had highest affinity for the adenosine A1
receptor (Beukers et al., 2004b). These agonists fully elicit the growth of yeast cells 
transfected with the wild-type human adenosine A2B receptor, with an EC50 value of 104 nM, 
3 µM, 20 µM, 6 µM and 4 nM, for NECA, CPA, CGS21680, IBMECA and LUF5833, 
respectively (Figure 5). The potency of the agonists for the wild-type and mutant adenosine 
A2B receptors is presented in Table 2, their efficacy in Table 3. 
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Figure 5. Concentration-effect curves for the five agonists: NECA, CPA, CGS21680, IBMECA and 
LUF5833 on the wild-type receptor. 
None of the mutants showed any spontaneous activity. Replacement of N282 with other 
hydrophilic residues, Q and R, led to impaired receptor activation. The EC50 values of the 
ribose agonist NECA increased 22-fold and 12-fold for the N282Q and N282R mutant 
receptors, respectively. Slightly less pronounced effects were seen with the other ribose 
agonists CPA, CGS21680 and IBMECA; interestingly the potency of the non-ribose agonist 
LUF5833 seemed least affected by N282Q. 
Table 2. EC50 values of the ribose agonists NECA, CPA, CGS21680 and IBMECA and the non-ribose 
agonist LUF5833 determined on the wild-type and on mutant adenosine A2B receptors. The EC50 values on 
the wild-type receptor as shown in the table were used to calculate the fold difference of the mutant 
receptor versus the wild-type receptor.  
Fold to WT NECA CPA CGS21680 IBMECA LUF5833 
WT 1 1 1 1 1
N282Q 22 21 26 18 3
N282R 12 9 5 4 6
N286A 66 14 - 4 -
N286Q 81 27 - - -
N286R 3 2 1 1 2
Y290F 12 7 1 3 4
Y290N - - - - - 
N294I 1 1 1 1 1
E14H - - - - - 
H280E - - - - - 
E14H/H280E - - - - - 
I61A - nd nd nd - 
I61D - nd nd nd - 
I61K - nd nd nd - 
WT 
EC50
104  20 nM 3  1 µM 20 
(11-28) µM 
6
(4-8) µM 
4  3 nM 
nd: not determined 
-: no activation 
The N286R receptor behaved similar to the wild-type (wt) receptor with respect to agonist 
activation. The greatest effect was seen with NECA which had an almost 3-fold reduced 
potency despite the fact that the receptor expression level of the N286R receptor was 
increased 20% compared to wild-type receptor (Figure 6). Apparently, the introduction of the 
positively charged arginine at N286 is well tolerated. 
-11 -1 - - - - - - -
1
1
C
N C
C
C S2
lo a onist
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Table 3. The Emax values of the ribose agonists NECA, CPA, CGS21680 and IBMECA and the non-ribose 
agonist LUF5833 determined on the wild-type and on mutant adenosine A2B receptors. The Emax values 
were calculated with respect to the Emax value for the respective compound on the wild-type receptor. The 
Emax values of the compounds for the wild-type receptor were set at 100%. 
% to WT NECA CPA CGS21680 IBMECA LUF5833 
WT 100 100 100 100 100 
N282Q 96 89 67 94 85 
N282R 106 111 81 112 93 
N286A 99 39 9 18 14 
N286Q 19 10 - - - 
N286R 95 105 87 99 68 
Y290F 97 95 74 70 62 
Y290N - - - - - 
N294I 94 109 99 101 93 
E14H - - - - - 
H280E - - - - - 
E14H/H280E - - - - - 
I61A - nd nd nd - 
I61D - nd nd nd - 
I61K - nd nd nd - 
nd: not determined 
-: no activation 
Instead, introduction of an alanine or glutamine residue at position 286 (N286A and N286Q) 
drastically reduced the ability of the agonists to activate the receptor. For example, the 
potency of NECA was decreased 81-fold on the N286Q and 66-fold on the N286A mutant. 
Moreover, although NECA was still able to fully activate the N286A receptor it was no longer 
able to fully activate the N286Q mutant. CGS21680, CPA, IBMECA and LUF5833 did not 
activate these mutant receptors to any considerable extent. The responsiveness of the N286A 
mutant receptor could be at least partially ascribed to reduced receptor expression levels. The 
N286Q mutation on the other hand rendered the receptor less responsive without affecting 
receptor expression levels (Figure 6). 
Figure 6. Western blot analysis of A2B receptors expressed in yeast cells. Lane 1, yeasts carrying empty 
vector; lane 2 yeast cells expressing wild-type receptor; lane 3-10, mutants N282Q, N282R, N286A, 
N286Q, N286R, Y290F, Y290N and N294I. Two bands with an apparent molecular mass around 29 kD 
and bigger than 50 kD (indicated by arrows) were detected as A2B receptor specific bands.
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Mutation of tyrosine 290 to a hydrophilic asparagine residue (Y290N) revealed a locked off  
mutant, which could no longer be activated by any of the agonists tested. A more conserved 
replacement of tyrosine 290 with phenylalanine, Y290F, could be activated albeit with 
reduced potency of especially NECA (12-fold) and CPA (7-fold). Both Y290 mutants were 
expressed at levels similar to the wild-type receptor (Figure 6). 
The N294I receptor behaved more or less similar to the wild-type receptor for all agonists 
tested, which suggested that the presence of a hydrophobic (I) or hydrophilic (N) amino acid 
at this position does not affect receptor activation. Interestingly, the expression level of the 
N294I mutant receptor is much higher than the wild-type receptor, which suggests that this 
amino acid is involved in receptor expression and or stabilization (Figure 6). 
Mutations in the NxxxNPxxxY motif affect the efficacy as well as the potency of the ligands. 
On the wild-type receptor all agonists behave as full agonists (Figure 5). They acted as full 
agonists on the N294I mutant receptor as well, while partial agonism was revealed upon 
characterization of these compounds on several mutant receptors. While its potency was 
reduced most significantly, NECA exhibited the greatest efficacy among the agonists tested. 
Except for the N286Q mutant, all the responsive mutants were fully activated by NECA. 
Besides the N286Q mutant, CPA showed dramatically reduced maximal responses on the 
N286A mutant, while it was able to fully activate the other responsive mutants. The other 
ligands, CGS21680, IBMECA and LUF5833 could not activate the N286Q mutant, slightly 
activated the N286A mutant and partially activated the Y290F mutant. Based on these 
findings, the following rank order for intrinsic activity was obtained: 
NECA>CPA>IBMECA  CGS21680 LUF5833. 
Role of salt bridge in receptor acti ation 
According to the models based on the crystal structure of bovine rhodopsin, adenosine 
receptors share a salt bridge between a glutamate, E14, in TM1 (1.39) and a histidine, H280, 
in TM7 (7.43). This potential salt bridge is a common feature in adenosine receptors but is not 
present in rhodopsin and the 2 adrenergic receptor. Thus we investigated what would happen 
when these two amino acids are swapped. In the same model, I61 is located in close proximity 
to the potential salt bridge. If the potential salt bridge is critical for receptor activation, then 
one would expect an I61 mutation to affect receptor activation. Based on these assumptions, 
the following series of point mutants were constructed to investigate the potential salt bridge 
region, I61A, I61D, I61K, E14H, H280E and the double mutant E14H/ H280E. 
Point mutant H280E resulted in a locked off  receptor, which could not be activated by any 
of the tested agonists. Inversion of the potential salt bridge by swapping both residues yielded 
the double mutant E14H/H280E, which did not respond to any of the tested agonists either. 
Thus simply swapping these two residues could not restore the wild-type receptor phenotype. 
Characterization of both point mutations individually revealed that the H280E mutant was not 
properly expressed as was the E14H/H280E double mutant receptor, which finding might 
explain that both receptor mutants were locked off . The E14H mutant, on the other hand, 
showed enhanced expression levels, about 150% compared to the wild-type receptor (Figure 
7). However this mutant was also not able to respond to any of the agonists, indicating that 
this residue is essential for agonist-induced receptor activation. 
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Figure 7. Western blot of mutant A2B receptors. A) Lane 1 yeast carrying the empty vector, lane 2-4, yeast 
cells expressing mutant receptors E14H, H280E, E14H/H280E, lane 5 yeast cells expressing wild-type 
receptor. B) Lane 1 yeast carrying the empty vector; lane 2-4 yeast cells expressing mutant receptors I61A, 
I61D, I61K, lane 5 yeast cells expressing wild-type receptor.  
Two bands with an apparent molecular mass around 29 kD and > 50 kD (indicated by arrows) were 
detected as A2B receptor specific bands. None of these bands were observed for the H280E single mutant 
and E14H/H280E double mutant receptor. 
Interestingly, the I61 mutants exhibited different expression levels: I61A showed a 50% 
enhanced level of expression relative to the wild-type receptor while replacement of 
isoleucine to the charged amino acids aspartate and lysine reduced the receptor expression to 
59% and 45%, respectively (Figure 7). All these three mutants no longer responded to either 
the ribose agonist NECA or the non-ribose agonist LUF5833, indicating that the I61 mutation 
not only affects receptor expression levels but also receptor function. 
iscussion 
mportant motifs in GPCRs 
 motif 
The NPxxY motif in TM7 is located close to the cytosolic interface, and is regarded as an 
important motif in class A GPCRs. Based on previous reports in literature this motif was 
expected to be of critical structural and/or functional importance and therefore subjected to 
mutagenesis. Mutations in this motif have been reported to affect receptor expression (Urizar 
et al., 2005; Lu et al., 2001), ligand binding (Gales et al., 2000; Lu et al., 2001), signaling 
(Urizar, 2005; Lu et al., 2001; Ferrand et al., 2006) and internalization (Kalatskaya et al., 
2004) in the various GPCRs that were studied. 
In this study, we constructed 7 point mutants with a mutation in the NxxxNPxxY motif, 
N282Q, N282R, N286A, N286Q, N286R, Y290F, and Y290N, determined their expression 
levels and their response to five different agonists of different selectivity and chemical nature.  
Among these mutants, only the N286A mutant receptor was expressed at a greatly reduced 
level compared to the wild-type receptor, suggesting a role for N286 (7.49) in the human 
adenosine A2B receptor in expression and/or receptor stabilization. There are reports on 
distinct effects of different receptors carrying a N7.49 mutation. Angelova et al. mutated the 
corresponding amino acid N597 in the rat LH receptor yielding the N597A, N597D and 
N597K mutants. Both receptor expression levels and receptor activation of all three mutants 
were compromised (Angelova et al., 2000). In the CCR5 receptor, the N293A mutant 
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exhibited poor expression as well (Dragic et al., 2000). These findings are in good agreement 
with our assumption that N of the NPxxY motif plays a critical role in receptor expression, in 
that mutating this residue results in lower receptor levels. However, there are also reports 
revealing that a mutation at this position did not significantly affect the receptor expression 
level, for example, the N391A cholecystokinin B receptor (CCKBR) (Gal s et al., 2000) and 
the N376D human serotonin 5-HT2B receptor (Manivet et al., 2002). Evidently, the important 
amino acids determining receptor expression and/or receptor stabilization are 
receptor-dependent.  
To provide information on the role of N of the NPxxY motif in receptor activation, 3 
replacements were investigated. All three mutants behaved differently to each other. While 
N286R behaved rather similar to the wild-type receptor, both the N286A and N286Q mutant 
showed dramatically reduced activation. N286Q could not be activated by CGS21680, 
IBMECA or LUF5833 whereas the N286A mutant was only slightly activated which might 
suggest that these agonists have a smaller intrinsic efficacy than the other agonists. 
Substitution of this residue N7.49 in other GPCRs resulted in various phenotypes of mutant 
receptors. The N619R human LH receptor showed impaired efficacy towards the endogenous 
hormone hCG (Zhang et al., 2005). The equivalent mutation in the rat LH receptor, N597R, 
yielded a loss-of-function mutant while the N597Q mutant was constitutively active 
(Angelova et al., 2000). The N391A CCK-B receptor could not stimulate PLC and MAPK 
pathways in transiently transfected COS cells (Gal s et al., 2000). The N376D 5-HT2B
receptor had a decreased affinity for the endogenous ligand 5-HT and could not be fully 
activated with respect to IP3 production (Manivet et al., 2002). In another report, the N308D 
5-HT4 receptor displayed increased, around 2-fold, constitutive activity compared to the 
wild-type receptor (Joubert et al., 2002). Mutation of N316D in the thyrotropin-releasing 
hormone receptor resulted in a 6-fold higher affinity for methyl-thyrotropin compared to the 
wild-type receptor without affecting the maximal activity. The N316A mutant 
thyrotropin-releasing receptor showed decreased maximum activity as well as reduced affinity 
for thyrotropin-releasing hormone (Perlman et al., 1997). 
To provide information on Y in the NPxxY motif, Y290 was substituted with phenylalanine 
and asparagine. Despite normal expression levels, the Y290N mutant did not respond to the 
agonists tested. Y290F was responsive, but LUF5833, CGS21680 and IBMECA had a 
reduced efficacy and the potency of NECA and CPA was significantly impaired. Both the 
rhodopsin and the 2 adrenergic receptor structure show that the Y and F in the conserved 
NPxxYx(5,6)F motif form a pi-pi interaction. Several reports reveal the importance of this 
tyrosine residue in receptor activation, as receptor function is impaired by its mutation. For 
example, the Y297A CCR5 receptor was found to be functionally impaired in its ability to 
inhibit forskolin-stimulated cAMP formation in transiently transfected HEK293 cells 
(Aramori et al., 1997). Similarly, the rat Y305A neurokinin-1 receptor showed impaired 
signaling (B hm et al., 1997). A 160-fold decreased efficacy of acetylcholine was found at the 
Y418A M1 muscarinic acetylcholine receptor (Lu et al., 2001). A possible explanation for this 
loss in signaling might be that substitution of tyrosine with alanine affected the coupling to 
the G protein as shown for the Y293A platelet-activating factor receptor mutant (Le Gouill et 
al., 1997). 
Compared to the tyrosine to alanine substitution, more conserved substitutions appear to have 
less striking effects on the function of the receptor, as was found for the rat Y305F 
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neurokinin-1 receptor receptor (B hm et al., 1997), the Y305F bradykinin B2 receptor 
(Kalatskaya et al., 2004) and the Y293F platelet-activating receptor (Le Gouill et al., 1997). 
However, in several cases, these conserved’ substitutions of Y7.53 did significantly affect 
receptor function. For example, the Y282F adenosine A3 receptor showed a significant 
decrease of maximal response and its expression level was 60% compared to the wild-type 
receptor (Chen et al., 2001). The Y325F mutant V2 vasopressin receptor induced cAMP 
accumulation with reduced efficiency (Bouley et al., 2003). The Y7.53F 5-HT2C receptor was 
able to bind 5-HT with high affinity but could not be activated by it (Prioleau et al., 2002). On 
the other hand, the Y7.53N mutant 5-HT2C receptor exhibited very high constitutive activity 
which could be neither increased by agonists nor decreased by inverse agonists (Prioleau et al., 
2002).
Since Y7.53 is located at the cytosolic interface, it is expected to affect signaling and 
internalization. However, this residue was also reported to affect ligand binding which might 
be explained either by a direct ligand interaction or indirect conformational changes. Both the 
Y299A cannabinoid CB2 receptor and the human Y304A SST5 receptor completely lost their 
ability of agonist binding (Feng and Song, 2001; Hukovic et al., 1998). In addition, the Y282F
adenosine A3 receptor had also a significantly decreased affinity for agonists, next to its 
reduced maximal response (Chen et al., 2001). Increases in agonist binding affinity, 10-fold, 
have also been reported, e.g., for the Y543H M3 muscarinic acetylcholine receptor (Schmidt 
et al., 2003). Decreased receptor expression levels were also obtained for the Y7.53K, 
Y7.53D, and Y7.53E 5-HT2C receptors. 
Despite their normal expression levels, mutants N282Q and N282R significantly reduced the 
potency of all agonists tested whereas N282R also reduced the efficacy of IBMECA and 
LUF5833. This result is different from the N7.45 mutations in the LH receptor. The N593Q 
mutant was expressed at levels comparable to the wild-type receptor, but the responsiveness to
hCG was lost while the N593R mutant showed slight constitutive activity and behaved similar 
to the wild-type receptor upon stimulation with hCG (Angelova et al., 2000). Mutation of 
N7.45 in the human AT1 receptor, N294A, showed severely attenuated function although 
ligand binding was unaffected, while N294M behaved similar to the wild-type receptor 
(Hunyady et al., 1998; P rodin et al., 2002). In the human D5 dopamine receptor, the N351D 
mutant resulted in an approximately 10-fold decrease in dopamine binding affinity (Cravchik 
and Gejman, 1999). In contrast, mutation of N410A in the M1 muscarinic acetylcholine 
receptor caused a slightly increased affinity while the Emax of acetylcholine was decreased (Lu
et al., 2001).
Taken together, these data suggest that the roles of the conserved residues N7.45, N7.49 and 
Y7.53 in the NxxxNPxxY motif are receptor-specific. An example is given below to compare 
the difference induced by the same substitutions in the rat LH receptor, the human 5-HT2C
receptor and the human adenosine A2B receptor (Table 4). 
Residue N294 (7.57) located 4 residues downstream of the NPxxY motif is characteristic for 
the adenosine A2B receptor, because all other adenosine receptors share an isoleucine at this 
position. Evaluation of the point mutant N294I revealed that this residue is involved in 
receptor expression, i.e. the N294I mutant A2B receptor was expressed at 3-fold higher levels 
than the wild-type receptor. The mutation did not affect the activation of the receptor, which 
suggests that this mutation stabilizes receptor integrity. To our knowledge this residue has not 
been subjected to mutation in other receptors.  
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Table 4. Effect of NxxxNPxxY mutations in the current study compared to literature data on the LH 
receptor (Angelova et al., 2000) and 5-HT2C receptor (Prioleau et al., 2002). 
Mutation A2B receptor  LH receptor 5-HT2C
N7.45Q Less sensitive to NECA Dramatically reduced 
response to hCG  
N7.45R Less sensitive to NECA Constitutively active  
N7.49A Reduced potency of NECA Reduced maximal response 
to hCG 
N7.49R Similar to wild-type, slightly 
reduced potency of NECA 
Impaired efficacy to hCG  
N7.49Q Loss of function Constitutively active  
Y7.53F No response to agonists 
tested
 Loss of function 
Y7.53N Loss of function Constitutively 
active 
Salt ridge 
Salt bridges have been suggested to form an intramolecular constraint to keep receptors in an 
inactive conformation or alternatively to be involved in ligand binding. For example, E113 in 
TM3 and K296 in TM7 form a salt bridge in rhodopsin and mutation of these two residues 
results in constitutive activation of the protein (Robinson, 1992). In the 1b adrenergic 
receptor D125 and K331 are assumed to form a salt bridge. The single point mutants D125K 
and K331D gained constitutive activity and the D125K/K331D double mutant regained the 
wild-type phenotype suggesting that the salt bridge was recovered and emphasizing the strong 
interaction between D125 and K331 (Porter et al., 1996; Porter and Perez, 1999). However, 
similar experiments with the 5-HT2A receptor (Kristiansen et al., 2000) demonstrated that 
mutation of aspartate in TM3 decreased the constitutive activity of the 5-HT2A receptor, 
opposite to the effect obtained with the of 1b adrenergic receptor. 
The adenosine receptors share a glutamic acid in TM1 (1.39) and a histidine in TM7 (7.43) 
which are highly conserved among all subtypes and seem to be close enough to form a salt 
bridge. These two residues were reported to be involved in ligand binding. The E16A A1
human adenosine receptor resulted in dramatically reduced affinity of the agonist CCPA 
(Barbhaiya et al., 1996). Mutation of H278 to L in bovine A1 receptors almost abolished both 
agonist and antagonist binding (Olah et al., 1992). In the A2A human adenosine receptor, two 
mutants E13Q and H278Y were investigated. Both displayed significantly reduced affinity for 
adenosine-derived agonists, and H278Y also had reduced affinity (20-fold) for the antagonist 
theophylline (Gao et al., 2000). In another study, substitution of H278 with alanine abolished 
the binding of radiolabeled CGS 21680 and XAC (Kim et al., 1995). The H272E mutant 
human adenosine A3 receptor displayed a different profile of reduced affinity for most of the 
uncharged agonists and antagonists tested (Jacobson et al., 2001). Taken together, these data 
indicate that the presence of both E1.39 and H7.43 in adenosine receptors facilitates ligand 
binding, especially for agonists. 
The presence of charged residues in the otherwise hydrophobic transmembrane region 
suggests that these residues play important roles. Mutation of ten out of the fourteen charged 
residues in the transmembrane region of the human prostacyclin receptor to alanine resulted in 
defective binding and/or activation, suggesting that these charged residues are indeed 
important in maintaining the binding pocket and ensuring normal activation (Stitham et al., 
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2007). In our study, the two residues forming the potential salt bridge also affected receptor 
activation. H280E eliminated receptor activation, while the reason why the E14H mutant 
receptor is non-responsive to any of the agonists tested requires further investigation. 
Residue I61 (2.58) was investigated in this study because it was predicted to be in the vicinity 
of the potential salt bridge formed by E1.39 and H7.42 according to the rhodopsin-based 
computer homology model. This residue is not conserved in class A GPCRs but is conserved 
among the A1, A2A and A2B receptors, whereas the A3 receptor contains a methionine at this 
position. Assuming that the salt bridge is crucial for agonist-induced activation one would 
expect that mutation of the nearby I61 residue is poorly tolerated. Indeed mutation of this 
residue to alanine, aspartate or lysine results in a receptor that can no longer respond to 
agonists although the receptor is well expressed.  
Taken together, the potential salt bridge is apparently very sensitive to single amino acid 
substitutions in this area as displayed for the E1.39, I2.58 and H7.43 mutations. The 
conserved residues in the NxxxNPxxY motif also seem to be very sensitive to mutation 
considering the behavior of the point mutants and our previous random mutagenesis results 
that did not identify any gain-of-function mutant by mutations in this region (Beukers et al., 
2004a).
omology models 
Typically, homology models are based on the alignment of entire helical regions between 
rhodopsin and receptors with unknown structure. Loop areas are normally ignored or modeled 
based on databases of loop conformations. These models have been used to design 
experiments as well as to explain experimental data. We used the structure of bovine 
rhodopsin as a template to build a homology model of the human adenosine A2B receptor to 
guide the selection of amino acids for site-directed mutagenesis. The recent disclosure of the 
3-D structure of the human 2 adrenergic receptor enabled us to make a homology model 
based on this template too. 
A structural overlay was made to investigate the differences between the two models with 
respect to the regions of interest in this study. The following differences were identified, i) the 
angle between helix 7 and 8, ii) the number of residues to link helix 7 and 8, iii) the location 
and side chain orientation of residues in the NxxxNPxxY motif, and iv) the nature of the salt 
bridge between helix 1 and helix 7. These findings suggest that care should be taken to 
interpret experimental data based on a single model. 
Cherezov already pointed to the shortcoming of homology models generated from a single 
structural template, as the structural divergence between two receptors would be quite 
difficult to predict accurately using only one receptor as a template (Cherezov et al., 2007). 
His conclusion was drawn from a similarity comparison between the 2 adrenergic receptor 
crystal structure and homology models of the 2 adrenergic receptor based on the structure of 
bovine rhodopsin and which were substantiated with biochemical data (Bissantz et al., 2003; 
Furse and Lybrand, 2003; Gouldson et al., 2004). Since the latter models used bovine 
rhodopsin as a template, they are more similar to the rhodopsin rather than the real 2
adrenergic receptor structure. 
Although all class A receptors share a similar backbone consisting of 7 transmembrane 
domains linked by extracellular and intracellular loops, each receptor has its own 
characteristics. Slight differences in the structure may result in significant differences in 
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intramolecular interactions. For example, in rhodopsin, E6.30 forms an ionic bond with R3.50 
of the conserved D(E)RY motif (Palczewski et al., 2000). This interaction is postulated to be 
important for maintaining rhodopsin in the inactive state, but the charged groups of the two 
residues R3.50 and E6.30 are too far apart to form an ionic bond in the structure of the 2
adrenergic receptor-T4 lysozyme fusion protein (Cherezov et al., 2007). In the present study, 
mutations in the human adenosine A2B receptor NxxxNPxxY motif were made equivalent to 
LH receptor and 5-HT2C receptor mutations, however with strikingly different results. 
Apparently, the NxxxNPxxY network in the A2B receptor functions in a different manner 
compared to the network in the LH and the 5-HT2C receptors (Table 4). The potential salt 
bridge is also atypical with respect to other adenosine receptors since the E1.39H mutant is 
irresponsive to agonists whereas the H7.42E mutant is not expressed at all. These results 
suggest that the human adenosine A2B receptor NxxxNPxxY network and the potential salt 
bridge are optimized for receptor function of this receptor subtype and every receptor may be 
slightly different in this respect. 
Conclusion 
Although GPCRs share several conserved motifs, the functional role of these motifs seem to 
differ among individual receptors. Site-directed mutagenesis of the NxxxNPxxY motif of the 
adenosine A2B receptor indicated that this motif is involved in the receptor activation due to 
the fact that most mutations in this study led to impaired receptor activation. Similarly, the 
role of the characteristic adenosine receptor salt bridge between E1.39 and H7.42 differs 
among the various subtypes of adenosine receptors. Mutagenesis experiments on the 
adenosine A2B receptor show that the H7.42E receptor is no longer expressed suggesting a 
role for this residue in receptor stability and/or expression of this adenosine receptor subtype. 
The recently revealed structure of the 2-adrenergic receptor sheds light on these findings as 
slight structural changes have been identified between the crystal structures of this receptor 
and bovine rhodopsin which may result in significant differences in intramolecular 
interactions.  
When homology receptor models are constructed, we must therefore bear in mind that each 
receptor has its own characteristics and that the use of a structurally unrelated receptor as a 
template will yield inaccurate receptor models. The challenge will be to identify the optimal 
receptor structure for each homology model. 
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ummar  
G protein-coupled receptors (GPCRs) are the target for many of the body’s endogenous 
hormones and neurotransmitters, and thus play a major role in physiology. Not surprisingly, 
somatic mutations in GPCRs may disturb normal physiology, and indeed several of these 
have been implied in disease. Drugs acting on GPCRs have been developed for wild-type, not 
mutated, GPCRs only. So far, the majority of clinically used ligands for GPCRs are 
orthosteric ligands, i.e. they occupy the binding site that is also home for the endogenous 
ligands. They are able to improve a disease state by induction or suppression of the activation 
of receptors. It is questionable, however, whether the use of currently available orthosteric 
ligands can restore the mutant to the wild-type phenotype. An ideal drug for mutant receptors 
should be able to fully restore the mutant receptor function back to the wild-type function, 
bringing the disease phenotype back to a normal physiological state.  
Compared to orthosteric ligands, allosteric ligands display a more complicated interaction 
with a receptor/endogenous ligand pair. They are able to cooperatively modify receptor 
binding and function unlike the orthosteric ligands that only compete with endogenous 
ligands. Hence a proper allosteric ligand, i.e. a ligand with appropriate binding cooperativity 
and functional cooperativity, may be able to reverse the mutant receptor phenotype into the 
wild-type phenotype. 
In this Chapter we address, lay the theoretical framework for, and present examples of the 
potential therapeutic benefits of allosteric over orthosteric ligands in mutation-related diseases. 
ntroduction 
G protein-coupled receptors (GPCRs) constitute a large family of transmembrane proteins, 
mediating the communication between the outside and inside of cells. GPCRs are expressed 
in organisms varying from yeasts to plants and animals and function as sensitive sensors to 
detect a wide array of so called first messengers including light (photons), cations, small 
molecules such as amines, sugars, lipids and peptides up to large proteins. GPCRs take up 
more than 1% of the human genome and are the molecular targets for approximately 30% of 
currently marketed drugs (Miller et al, 2004). 
Quite a few diseases are caused by somatic mutations in GPCRs. These mutations may 
influence expression levels of receptors, their localization, their interaction with endogenous 
ligands and, very prominently, their basal activity (Table 1). Therefore we will focus on 
disease-related mutations that affect this basal or constitutive activity of the receptor. Well 
known receptor mutations that cause increased constitutive activity are the ones in rhodopsin 
that are responsible for night blindness (Rao et al, 1994). Other examples of constitutively 
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active mutations leading to disease include autosomal dominant hypocalcemia induced by 
constitutively active Ca2+ receptor (Zhao et al, 1999).  
Table 1 Overview of naturally occurring mutant GPCRs with increased or decreased constitutive activity 
GPCR Constitutive 
activity change  
Effect on effector system 
activity 
Clinical  phenotype/disease References 
rhodopsin increase enhanced basal activity 
of cGMP-degrading 
PDE 
night blindness 
retinitis pigmentosa 
Rao et al., 1994 
Ca2+ receptor increase enhanced basal activity 
of PLC 
autosomal dominant 
hypocalcemia 
Zhao et al., 1999 
MC2R increase enhanced basal activity 
of AC 
in ACTH-independent 
Cushing’s syndrome 
Swords et al., 
2002
MC4R decrease decreased basal activity 
of AC 
obesity Vaisse et al., 
2000
FSHR increase enhanced basal activity 
of AC 
male fertility Gromoll et al., 
1996
TSHR increase enhanced basal activity 
of AC 
hyperfunctioning thyroid 
adenoma;  familial 
hyperthyroidism 
Parma et al., 
1993
LHR increase enhanced basal activity 
of AC 
male-limited precocious 
puberty 
Wu et al., 1998 
TRHR decrease impaired IP  production isolated central
hypothyroidism 
Collu at al., 1997 
PTH-PTHrPR increase enhanced basal activity 
of AC,  but  impaired 
agonist stimulation of 
AC
Jansen-type metaphyseal 
chondrodysplasia 
Schipani et al., 
1995
V2R increase decreased basal activity 
of AC 
nephrogenic diabetes 
insipidus
Sadeghi et al., 
1997
In addition, several receptor families seem to be prone to disease-causing mutations. A fine 
example is the melanocortin receptor family where gain-of-function mutations in the 
melanocortin 2 receptor (MC2R) were found to be involved in ACTH-independent Cushing’s 
syndrome (Swords F, 2002), whereas loss-of-function mutations in the MC4R resulting in 
obesity (Vaisse et al, 2000). 
Mutations affecting constitutive activity and thereby causing disease are also frequently 
reported for GPCRs recognizing endocrine hormones. Gain-of-function mutations of the 
follicle-stimulating hormone receptor (FSHR) caused male fertility after hypophysectomy 
(Gromoll et al, 1996), whereas mutations of the PTH receptor resulted in short-limb dwarfism 
and skeletal deformities (Schipani et al, 1995). In addition, quite a few mutations of the 
thyrotropin receptor (TSHR) leading to constitutive activation of the cAMP signaling 
pathway have been implied in hyperfunctioning thyroid adenoma or familial hyperthyroidism 
(Parma et al, 1993). Finally, male precocious puberty is caused by constitutively activating 
mutations of the LH receptor (Laue et al, 1994; Shenker et al, 1993). 
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Next to increase or decrease constitutively active mutations mentioned in table 1, there are 
also mutant receptors with disease-related gain-of-function or loss-of-function. For example, a 
mutant thyrotropin-releasing hormone (TRH) receptor was found unable to bind TRH and 
could not be activated, which caused a rare disorder called isolated central hypothyroidism 
(Collu, 1997). In addition, loss-of-function mutations of the FSHR result in pure ovarian 
dysgenesis (Simoni, 1997), of the gonadotropin-releasing hormone (GnRH) receptor in 
hypogonadism (de Roux et al, 1997; Karges et al, 2003), and of the LH receptor in Leydig 
cell hypoplasia (Wu et al, 1998). Other loss-of-function mutants responsible for disease 
include mutations of the type 2 vasopressin receptor (V2R) causing nephrogenic diabetes 
insipidus (Sadeghi et al, 1997) and loss-of-function mutations of the thromboxane A2 (TXA2) 
receptor which are associated with bleeding disorder (Hirata et al, 1994). 
To treat such receptor-induced diseases we face a conceptual problem: currently available 
drugs have been developed for wild-type, healthy’ receptors. Such drugs almost invariably 
interact with the orthosteric binding site on a GPCR where the endogenous ligand binds too. 
Figure 1. Inverse agonism on a constitutively active receptor. 
A constitutively active mutant receptor (L  0.5; with L as the isomerization constant determining the 
equilibrium between the active state R* and inactive state R in the absence of ligands) was treated with an 
inverse agonist (KA  100 nM,   0.1). Upon increasing the concentrations of the inverse agonist from 100 
nM, to 1M, 10 M and 100 M, the dose-response curve of the endogenous ligand (KA  100 nM,   10) 
is shifted right-wards. See the appendix for all equations that we derived from pharmacological modeling. 
These drugs however are unable to adjust the basal activity without affecting the EC50 value 
of the endogenous ligand. For example, using an inverse agonist to treat a constitutively 
active mutant GPCR can dramatically affect the sensitivity of the receptor to the endogenous 
ligand due to the competition for the same binding site (Figure 1).  
There are arguments suggesting allosteric ligands may provide therapeutic advantages over 
orthosteric ligands under certain circumstances (Hall, 2000; May et al, 2007). Allosteric 
modulators are defined as ligands that bind to an allosteric site on a GPCR thereby 
modulating the binding and/or signaling properties generated via interactions with the 
orthosteric site (May et al, 2007). The difference between an allosteric ligand and an 
orthosteric ligand lies in the fact that the former can exert its function through both its own 
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interaction with the receptor and by influencing the effects of an orthosteric ligand. Hence 
allosteric ligands modulate the receptors’ behavior in a more intricate way. In fact, this 
realization has led to a renewed emphasis on GPCRs as drug targets with many allosteric 
modulators in clinical trials now, and at least one, an allosteric modulator of the Ca2+-sensing
receptor, having reached the market. 
 This chapter focuses on the potential therapeutic benefit of allosteric ligands in treating 
mutation-related diseases that affect constitutive activity. 
ow can orthosteric ligands affect the beha iour of a mutant receptor to its endogenous ligand 
As stated above, orthosteric ligands are commonly used to address disease-related GPCR 
mutations. The effects orthosteric ligands can have on endogenous ligands to counteract the 
diseased phenotype are shown below. For a detailed mathematical framework and the 
equations used for the pharmacological modeling in the Figures we refer to the appendix to 
this Chapter. These effects encompass normalization of the basal activity, of the potency and 
of the maximal response. A one-site competition model is proposed to explicitly include the 
effects of two competitive ligands. This model uses the two-state model of receptor activation 
as its basis, improving a drug competition model proposed in 1983 (Gero, 1983) in that both 
association and the intrinsic efficacy of the ligands are taken into consideration. According to 
the one-site competition model, the effect of an orthosteric ligand is defined by its parameters 
, N and [B] (See supplementary data). Three situations can be identified, in which ligand B 
is either an agonist, a neutral antagonist or an inverse agonist. 
The ability of an agonist B to enhance the stimulation of the endogenous ligand A is displayed 
in Figure 2A, B. Exposure of the receptor to the agonist produces an initially active  receptor 
in a new system, in which the initial  activity of the receptor is governed by the intrinsic 
efficacy of the agonist. We refer here to initial  activity as the term basal activity is used to 
describe the activity achieved in the absence of any ligand. The initial  activity on the other 
hand is the result of the presence of a concentration of ligand B. The initial  activity of the 
receptor is directly proportional to the value of , a greater  value will yield a bigger initial  
activity of the receptor. If the agonist B has an intrinsic efficacy smaller or equal to the 
intrinsic efficacy of the endogenous ligand A, the maximal receptor activation upon combined 
addition of the endogenous ligand and the agonist B will be the same.  
The effect of a variation of the  value of ligand B being an agonist is presented in Figure 2A. 
Increasing values of  (5, 10, 50 and 500, dashed lines) result in increased initial  activities 
for the receptor with an L value of 0.1. The concentration for agonist B is set at 100 nM.
The effect of a variation of the concentration of orthosteric ligand B being an agonist is 
presented in Figure 2B. A competitive interaction results in a theoretically limitless rightward 
shift of the sigmoidal curve for the endogenous ligand in the presence of increasing 
concentrations (10 nM, 100 nM, 1 µM, 10 µM and 100 µM, dashed lines) of the agonist B 
with a  value of 10. The effect of ligand B being an antagonist is presented in Figure 2C. A 
competitive interaction results in a theoretically limitless rightward shift of the concentration-
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activation curve for the endogenous ligand A in the presence of increasing concentrations (10 
nM, 100 nM, 1 µM, 10 µM and 100 µM, dashed lines) of the antagonist B. The intrinsic 
activity of ligand B being an antagonist equals 1. 
                                     A                                                                                 B 
               
                                                                            
                                        C                                                                           D 
                                                                       e) 
                                                                      E 
Figure 2. Competition between an orthosteric ligand (B) and an endogenous ligand (A) and its effects on 
receptor activation. The parameters for the endogenous ligand (continuous lines) are consistent throughout 
figures 2A-2E:   50, K  107. The association constant of ligand B is set at 107. In addition the L value of 
the receptor is set at 0.1 in figures 2A-2C and to 1 in figure 2D-E. 
Disease-related CAM GPCRs and allosteric modulators 
109
The effect of a variation of the  value of ligand B being an inverse agonist is shown in Figure 
2D. With an increase in the intrinsic efficacies (0.5, 0.1, 0.01, 0.001, dashed lines) at a 
concentration of 1 µM of the inverse agonist B the initial  activity of the receptor is 
decreased while at the same time the sigmoidal curve is shifted to the right. 
The effect of the variation of the concentration of the applied inverse agonist B is shown in 
Figure 2E. With an increase of the concentration (100 nM, 1 µM, 10 µM and 100 µM) and an 
intrinsic efficacy of 0.5, again the initial  activity of the receptor is decreased and the 
endogenous ligand-induced sigmoidal curve is shifted to the right. 
In the mean time, the potency of the endogenous ligand will be impaired due to the 
competitive binding of agonist B to the orthosteric site. If B has an  value that is bigger than 
the  value of the endogenous ligand A, the initial  activation of the receptor will be even 
greater than the activation obtained in the presence of a saturating concentration of A. This is 
actually a rather interesting situation, because in this case an increasing concentration of 
ligand A will competitively bring down the initial  activity induced by ligand B until the 
maximal activation ligand A can achieve is reached. 
The second situation predicts the effects of the addition of a competitive antagonist B to the 
endogenous ligand A (see Figure 2C). Ligand B causes a rightward shift of the sigmoidal 
curve induced by ligand A without affecting either the basal activity of the receptor or the 
maximal receptor activation to ligand A. 
Finally, the effect of ligand B being an inverse agonist is presented in Figure 2D, 2E. Similar 
to what was observed for ligand B as a competitive antagonist, the concentration-effect curves 
for ligand A are rightwardly shifted in the presence of ligand B. This shift depends mainly on 
N and the concentration of ligand B. Similar to ligand B being an agonist, the inverse 
agonistic ligand B is able to modulate the initial  activity of the receptor but cannot affect 
the maximal receptor activation reached by the endogenous ligand A. The ability to reduce the 
initial  activity is governed by the intrinsic efficacy  of ligand B. The smaller  is, the less 
initial  activity of the receptor will be present. Thus the effect of the inverse agonist B on the 
endogenous ligand A is a combination of a decreased initial  activity and a decreased 
potency of ligand A.
The simulated curves in Figure 2 reveal that all three categories of orthosteric ligands impair 
the potency of the endogenous ligand and none of them can influence maximal receptor 
activation. Thus, by simply changing parameters , N and the concentration of orthosteric 
ligands it is not possible to modify all potential changes receptor mutations may cause for the 
receptor’s behaviour. Although agonists and inverse agonists can be used to treat changes in 
the basal activity induced by a receptor mutation, a significant price is paid because 
orthosteric ligands hinder the endogenous ligand from properly interacting with the receptor.  
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Comparison of allosteric ligands with orthosteric ligands  
A few examples that show how a saturating concentration of an allosteric ligand, or rather its 
parameters ,  and , affect the behavior of a receptor/endogenous ligand complex, are given 
in figure 3. An increased intrinsic efficacy, , results in an enhanced initial  activity of the 
receptor and an increased maximal receptor activation (Figure 3A). When  > 1, an 
increased  value will increase the potency of the endogenous ligand (Figure 3A) while   1 
would result in a decreased potency of the endogenous ligand. An increase in the activation  
                                                                       
                                     A                                                                                 B 
                                    C                                                                                  D 
Figure 3. Simulation of the allosteric effect caused by variation of the parameters of an allosteric modulator. 
The following parameters are consistent throughout K  100 nM, M  100 nM,   100, and [C]  100 nM). 
In addition the L value of the receptor is set at 0.1 in figures 3A, 3B, 3D and 1 in figure 3C. 
A) Variation of parameter  from 0.01, 0.1, 1, 10 to 100 leads to an increased initial  activity of the 
receptor and increased maximal receptor activation as well as an increased potency of the endogenous 
ligand (the other parameters are fixed:   1,   1). B) Variation of parameter  from 0.01, 0.1, 1, 10, 100 
leads to an increased maximal response while the potency of the endogenous ligand is increased (the other 
parameters are fixed:   1,   1). C) Variation of parameter  and  at the same time under the condition 
that their product equals 1. The pairs of  and  are set as   1,   1 (continuous line),   10,   0.1 
(dotted line) and   0.1,   10 (dashed line). D) Variation of parameter  from 0.01, 0.1, 1, 10 and 100 
leads to a leftward shift of the dose-response curves (the other parameters are fixed:   1,   1).  
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cooperativity value  results in an enhanced maximal receptor activation by the endogenous 
ligand (Figure 3B). In addition, changing  results in an alteration of the potency of the 
endogenous ligand. If  > 1, an increased  value results in an increased potency of the 
endogenous ligand (Figure 3B). If  and  vary at the same time under the condition that their 
product equals 1, then the maximal receptor activation by ligand A will not change (Figure 
3C). On the contrary, if   1, the potency of the endogenous ligand will decrease when the 
 value is increased. The binding cooperativity parameter  only affects the potency of the 
endogenous ligand. Increased  values lead to a leftward shift of the concentration-effect 
curves of the endogenous ligand (Figure 3D). 
Comparing the effects of orthosteric ligands with allosteric ligands: from theory to practice 
As discussed above, allosteric ligands have a larger number of intervening mechanisms at 
their disposal than orthosteric ligands (Table 2). The differences relate to the greater potential 
of allosteric, but not orthosteric, ligands to interfere with the potency and the maximal 
response achieved by the endogenous orthosteric ligand. Whereas the application of an 
orthosteric ligand will always reduce the potency of the endogenous ligand resulting in a 
rightward shift of its concentration-effect curve, the characteristics of a particular allosteric 
ligand may enable it to increase or decrease the potency of the endogenous ligand or leave it 
unaffected. In addition, the application of an orthosteric ligand will not affect the maximal 
response, whereas an allosteric ligand may increase or decrease the maximal response or, 
again, leave it unaffected. Thus, whereas orthosteric ligands can only modulate the initial 
activity and will always decrease the potency of the endogenous ligand, allosteric ligands can 
modulate all three parameters, initial activity, potency and maximal response at will based on 
its particular characteristics. A few examples describing the practical consequences of these 
added properties of allosteric ligands are addressed below. 
Table 2. Comparing potential interfering mechanisms of orthosteric ligands with those of allosteric ligands. 
The theoretical examples provided above are also reflected in several publications showing 
effects of allosteric ligands on the initial  receptor activity, on the maximal response and on 
the sensitivity to orthosteric ligands. Concerning constitutive activity, the allosteric modulator 
MPEP inhibited the constitutive activity of the human mGluR5 receptor while concentration-
dependently decreasing the agonist efficacy of L-glutamate without affecting its potency 
(Pagano et al, 2000). A second example in which the constitutive activity was decreased with 
an allosteric modulator is represented by BAY36-7620. This allosteric modulator of the 
mGluR1 receptor inhibited its constitutive activity and decreased the maximal effect as well 
as the potency of L-glutamate (Carroll et al, 2001). 
Effect on Orthosteric ligands Allosteric ligands 
initial activity increase, decrease or no effect increase, decrease or no effect 
potency  decrease increase, decrease or no effect 
maximal response no effect increase, decrease or no effect 
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Other examples where allosteric modulators affect the maximal effect of the orthosteric 
agonist include ORG27569, which allosterically increased the agonist affinity for the 
cannabinoid CB1 receptor while at the same time the Emax values for the agonists were 
significantly reduced (Price et al, 2005). Opposite effects on Emax values have been reported 
for benzodiazepines which were shown to increase the maximal response of partial agonists 
on the 1-adrenergic receptors with only a slight change of their potency (Waugh et al, 1999). 
Two more examples have been reported in the literature where an allosteric modulator had 
little or no effect on the potency of the endogenous orthosteric ligand whereas the efficacy 
was increased. On the adenosine A3 receptor a newly synthesized compound, N-(3,4-
Dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4amine, was shown to increase 
agonist efficacy without influencing agonist potency (Goblyos, et al, 2006). The second 
example is taken from the Ca2+ receptor where both NPS467 and NPS568 caused a leftward 
shift of the Ca2+ concentration-response curve without any effect on the maximal effect 
achieved by Ca2+ (Hammerland et al, 1998).  
The two next and last examples are cases where the efficacy of the agonist is increased but 
where opposite effects on agonist potency are achieved. DU124183 concentration-
dependently increased agonist efficacy on the adenosine A3 receptor but decreased agonist 
potency (Goblyos et al, 2006), whereas GS39783 increased both the potency and efficacy of 
GABA on its receptor (Urwyler et al, 2001).
Comparison of the properties of allosteric ligands ersus orthosteric ligands in treating 
pathophysiology caused by mutant receptors 
Since allosteric ligands do not compete for the binding site of endogenous ligands, and 
cooperatively affect a receptor’s behavior both through binding and through function, they 
have added features to also influence GPCRs that suffer from somatic mutations. Three 
examples where allosteric ligands may provide advantages over orthosteric ligands are 
presented below. 
ounteracting increased asal activity and increased ma imal response without affecting 
the potency of the endogenous orthosteric ligand 
A mutation in helix VI of the follicle-stimulating hormone receptor (D567N) was studied by 
Smits et al. (2003). This mutation leads to ovarian hyperstimulation syndrome. Functional 
characterization of this receptor revealed that the D567N mutation increased basal activity in 
transiently transfected COS-7 cells and caused an increased maximal response while the 
sensitivity to the endogenous ligand follicle-stimulating hormone (FSH) was unchanged. The 
constitutive activity and the greater maximal response of the receptor were not caused by 
increased receptor expression levels, as the amount of mutant receptor expression was 69% of 
that of the wild type receptor.  
To revert the mutated receptor back to the normal state, a decrease in initial  activity can be 
achieved by treating the mutant receptor with either an inverse agonist or an allosteric 
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modulator. However, as discussed before inverse agonists cannot reduce the receptor’s 
maximal response, and cause a decreased potency of follicle-stimulating hormone as shown in 
figure 4 (dotted line). To decrease the initial  activity as well as the maximal response while 
at the same time keeping the potency of the endogenous ligand intact, an allosteric modulator 
is required (Figure 4 dashed line). 
                                                                   A 
                                                         B 
Figure 4. Different effects on D567N mutant follicle-stimulating hormone receptor. 
A) cAMP production in both wild type and D567N mutant receptor upon stimulation with FSH 
(reproduced from Smits, 2003). B) Simulation of the treatment of the mutant receptor (L  0.11, continuous 
line) with an inverse agonist (  0.4, N  107, [B]  1 M; dotted line) and an allosteric modulator (  0.4, 
  1.8,   2, M  107, [C]  1 M; dashed line). The inverse agonist decreases the initial  activity of the 
receptor and impairs the potency of the endogenous ligand A. The maximal response cannot be reduced by 
the inverse agonist. The allosteric modulator decreases the initial  activity of the receptor as well as the 
maximal response to follicle-stimulating hormone and does not change the sensitivity of the receptor to 
follicle-stimulating hormone.  
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ounteracting increased asal activity and decreased ma imal response without affecting 
the potency of the endogenous orthosteric ligand 
A number of GPCR mutants that display a rather complicated effect have been described in 
the literature; while their basal activity is higher than the wild-type receptor, their maximal 
response to the endogenous ligand is decreased. Three cases were reported. Both the D564G 
and H578Y mutant human luteinizing hormone (LH) receptor were found in patients suffering 
from familial male-limited precocious puberty (Laue et al, 1995). These two mutant receptors 
were characterized by their high basal cAMP production which could be further stimulated by 
hCG. However, the maximal response to hCG of these mutant receptors was much lower than 
that of the wild-type receptor. Another example concerns mutant GPR54 receptors. Similar to 
mutant LH receptors, the L148S mutant GPR54 receptor also displayed higher basal activity 
combined with a reduced maximal response to the endogenous kisspeptin ligand (Seminara et 
al, 2003). The last example is the H223R mutant of the PTH-PTHrP receptor (Schipani et al, 
1995) (Figure 5A). Orthosteric ligands are not able to decrease the initial  activity of these 
mutants and increase the maximum effect at the same time. However if an allosteric ligand 
could be made with a   1 and the product of   > 1, then the initial  activity and the 
maximal effect can be modified in opposite ways (Figure 5B). 
                                     A                                                                  B 
Figure 5. Mutant receptors with increased basal activity and decreased maximal response. 
A) The H223R mutant PTH-PTHrP receptor (circles) has a higher basal activity level than the wild-type 
receptor (squares), but a reduced maximal response to ligands [Nle8,18, Tyr34] bovine PTH(1-34)amide 
(filled squares and circles) and [Tyr36] human PTHrP ( 1-36) amide (open squares and circles) (reproduced 
from Schipani, E, 1995). B) Simulation of the treatment of the mutant receptor (continuous line) with an 
allosteric modulator (dashed line) to bring it back to wild-type phenotype. The parameters were set at: L  
0.25,   3,   0.5,   1000,   0.05, K  5*109, M  107, the concentration of the allosteric ligand was 
100 nM. 
ounteracting reduced asal activity and decreased ma imal response without affecting the 
potency of the endogenous orthosteric ligand 
Loss of function mutations of the type 2 vasopressin receptor (V2R) result in recessive 
nephrogenic diabetes insipidus. One well-characterized mutant displaying this phenotype is 
the D85N receptor. This mutant has normal expression, maturation and transportation to the 
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cell membrane while the binding affinity and efficacy for the endogenous peptide arginine-
vasopressin are reduced (Sadeghi et al, 1997). The D85N mutant receptor also showed 
reduced basal activity compared to the wild-type receptor. (Orthosteric) agonists can 
compensate for the reduced initial  activity of the mutant receptor but cannot increase the 
maximal response to arginine-vasopressin. Such an agonist will also shift the concentration-
effect curve of the endogenous ligand to the right. The same holds for another V2R mutant, 
G201D. This mutant displays a decreased basal activity and a decreased response to the 
endogenous agonist. Due to the competitive nature of an agonist for the endogenous binding 
site, treatment with an agonist would decrease rather than increase the potency of arginine- 
vasopressin. However, by adjusting the cooperativity parameters  and , an allosteric ligand 
may increase the basal activity of the receptor as well as the potency of the endogenous ligand 
(Figure 6). 
                                 A                                                                       B 
Figure 6. Mutant receptors with decreased basal activity and decreased sensitivity to the endogenous 
agonist. A) D85N and G201D mutant human type 2 vasopressin receptors display lower basal activity 
levels and reduced sensitivity to arginine vasopressin compared to the wild-type receptor (reproduced from 
Sadeghi H, 1997). B) Simulation of the treatment of the mutant D85N receptor (continuous line) with an 
allosteric modulator to restore the wild-type phenotype (dashed line). The parameters are set as: L  0.11, 
 9,   3.5,   10,   50, K  3*109, M  107, the concentration of allosteric ligand is 100 nM. Upon 
application of 100 nM of an agonist (  3.5, N  107) the initial  activity is increased, the maximal 
response is unaltered and arginine-vasopressin shows a decreased potency on the mutant receptor (dotted 
line). 
Additional examples of mutant receptors displaying a decreased basal activity compared with 
a decreased maximal response include several loss-of-function mutant melanocortin-4 
receptors (MC4R) which cause obesity. Again, treatment of these mutant receptors with 
agonists cannot restore the wild-type phenotype because these mutants require an increased 
response as well as an increased sensitivity to -MSH (Vaisse et al, 2000; Biebermann et al, 
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2003; Farooqi et al, 2003). The same is true for the loss-of-function A204E mutant growth 
hormone secretagogue receptor (GHSR), which has a lower basal activity and a lower 
maximal response to ghrelin compared to the wild-type receptor (Pantel et al, 2006). 
ounteracting decreased ma imal response and restoring the potency of the endogenous 
orthosteric ligand 
The S390R mutant endothelin B receptor responsible for Hirschsprung’s disease displayed a 
reduced, around 90%, ET-1-induced intracellular Ca2+ transient compared to the wild-type 
receptor while at the same time the EC50 value of ET-1 was 30 fold increased (Tanaka et al, 
1998). Again, allosteric ligands would be needed to increase the maximal response. In 
addition, two mutant GnRH receptors were found in a family with idiopathic 
hypogonadotropic hypogonadism. One of the mutants leads to decreased affinity for GnRH 
while another did not modify the binding of the hormone but decreased the activation by 
GnRH (de Roux et al, 1997). Restoration of the wild-type phenotype of both mutants requires 
again allosteric ligands, one with the property to enhance the binding of the receptor and 
GnRH and another with the ability to enhance the stimulation by GnRH. This is yet another 
situation where allosteric ligands only can revert the aberration to normal physiology. In 
theory an allosteric ligand can treat’ mutant receptors with impaired signal transduction 
ability, since the functional cooperativity of allosteric ligands can modify the stimulation of a 
receptor by its endogenous ligand. Examples of such mutant receptors include the partial loss-
of-function mutant FSH receptor, which causes ovarian dysgenesis due to impairment of FSH 
function and reduced cAMP generation when expressed in COS-7 cells (Beau et al, 1998). In 
addition, a loss-of-function TRH receptor has been described which is resistant to the action 
of thyrotropin and results in hypothyroidism or euthyroidism with increased thyrotropin 
secretion (Sunthornthepvarakui, 1994). Finally, also a loss-of-function thromboxane A2 
(TXA2) receptor has been reported which resulted in a bleeding disorder due to a defective 
platelet response to TXA2 (Hirata et al, 1994). 
Additional theoretical ad antages of allosteric ligands o er orthosteric ligands 
In theory, allosteric sites should be more divergent than orthosteric sites as they are less 
subject to evolutionary pressure. Therefore, in principle greater selectivity may be achieved 
with allosteric ligands compared to orthosteric ligands (May et al, 2007). Not only do the 
allosteric ligands allow more selective binding to the receptors due to more divergent binding 
sites, the cooperativity between allosteric ligands and orthosteric sites further enhances the 
selectivity. An example is provided by the small molecule thiochrome. Thiochrome 
selectively increases the affinity of acetylcholine for the M4 muscarinic acetylcholine receptor 
(mAchR) over the other receptor subtypes although it does bind to allosteric sites on all five 
mAchRs (Lazareno et al, 2004). This example demonstrates selective cooperativity of an 
allosteric ligand which interacts with closely related receptors.  
A second advantage of allosteric modulators is that allosteric modulators can enhance or 
attenuate the effect of an orthosteric ligand without displaying an effect on its own. In other 
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words, the allosteric effect is dependent on or effectuated by the endogenous ligand. An 
overdose of an allosteric modulator will therefore cause less side effects than an overdose of 
an orthosteric ligand as the effective window of the allosteric modulator is bounded on one 
hand by the basal activity of the receptor and by the effect of the endogenous agonist on the 
other (Gao et al, 2006; Gilchrist et al, 2007).
Traditional orthosteric ligands have been shown to cause drug tolerance. That is, these ligands 
induce a dramatic increase or reduction of the receptor number due to their up- or 
downregulation by using inverse agonists or agonists, respectively (Dohlman et al, 1991; 
Collins et al, 1992; Milligan and Bond, 1997; MacEwan and Milligan, 1996, Smit et al, 1996). 
However, no effects of allosteric modulators on receptor expression levels have been reported 
so far. In fact, there is evidence that allosteric modulators do not change receptor expression 
levels. An example is the allosteric agonist ASLW which induced increased CXCR4 
chemokine receptor activation compared to the agonist SDF-1 but did not cause receptor 
internalization (Sachpatzidis et al, 2003). 
Collateral efficacy of allosteric ligands and its therapeutic benefit 
There is growing evidence that orthosteric ligands may cause collateral efficacy also referred 
to as ligand-directed signaling or differential receptor trafficking (for a review, see Kenakin, 
2005). These differences may be explained as ligands binding to receptors preferably stabilize 
certain conformations of a receptor, thereby triggering various receptor activation pathways. 
Since allosteric ligands also have a certain affinity to receptors it is reasonable to assume that 
they also exhibit collateral efficacy like orthosteric ligands. In other words, allosteric ligands 
can also stabilize certain receptor conformations resulting in a biased affinity of the 
orthosteric ligand thereby displaying preference for certain signaling pathways. A few reports 
revealed such a collateral efficacy of allosteric ligands. One of the examples is the allosteric 
modulator eburnamonine, which enhanced the potency of the muscarinic agonist arecoline 
while, in contrast, the compound decreased the potency of another agonist, pilocarpine 
(Jakub k et al, 1997). A second example is the gadolinium ion (Gd3+). This allosteric enhancer 
potentiates the glutamine-mediated Ca2+ mobilization through Gq/11 while it inhibits cAMP 
accumulation through Gs proteins (Abe et al, 2003; Tateyama and Kubo, 2006). A third, even 
more interesting example is aplaviroc, an anti-HIV drug. It allosterically modulates the 
chemokine CCR5 receptor by blocking the binding of 125I-MIP-1 (macrophage inflammatory 
protein-1) but not that of 125I-RANTES (regulated upon activation, normal T-cell expressed 
and secreted). Interestingly, aplaviroc selectively blocks the binding of MIP-1a and not of 
RANTES. As a result, aplaviroc may therefore elicit a unique viral resistance profile (Watson 
et al, 2005). 
The ability of allosteric ligands to display collateral efficacy may provide a therapeutic benefit. 
For example, an FSH receptor mutation in the transmembrane domain of this receptor results 
in recurrent spontaneous ovarian hyperstimulation syndrome. Functional assays revealed that 
this mutant receptor displays wild-type behaviour with respect to constitutive activity and the 
response to follicle stimulating hormone. However, the mutation rendered the receptor 
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sensitive to human chorionic gonadotropin (Vasseur et al, 2003). To treat this disease, an 
allosteric ligand might be able to discriminate between the unwanted activation by chorionic 
gonadotropin versus the desired stimulation by follicle stimulating hormone. 
Conclusions 
Allosteric ligands display certain unique features which may be used advantageously in the 
treatment of diseases caused by somatic mutations in GPCRs. Unlike orthosteric ligands these 
allosteric compounds are able to modulate independently the initial  activity and the 
maximal receptor response without affecting the potency of the endogenous ligands. In 
addition, they may provide added selectivity, including collateral selectivity, and may lack 
drug tolerance inducing activity. 
ppendi
According to the two-state receptor model (Leff, 1995; Kenakin, 2003), receptors coexist in 
an equilibrium between an active state and an inactive state. Three parameters determine the 
ratio between both states of a receptor in a given system where only 1 ligand (A) is present or 
absent. The isomerization constant (L) of a receptor determines the equilibrium between the 
active state (R*) and the inactive state (R) in the absence of ligands;  is the intrinsic efficacy 
of ligand A (where A represents the endogenous ligand), or in other words  is the ratio of the 
affinity of A for the active state receptor versus the inactive state receptor; K is the association 
constant of A. If only the ratio of active state receptors in the whole receptor pool (R*/RT) is 
taken as a measure for activation and downstream effects are neglected, this model can be 
used to simulate or predict the effect of an endogenous ligand on a receptor species. Such a 
simplified model can be successfully applied for instance to predict the intrinsic efficacy of 
inverse agonists on constitutively active mutant receptors expressed in yeast (Li, 2007). 
When an orthosteric ligand (B) is added to the system, which may be an agonist, antagonist or 
inverse agonist, and which competes for the orthosteric binding site without having a 
cooperative effect on ligand A, there will be two additional factors,  and the product of N[B], 
that may affect the equilibrium between the active and inactive receptors. In this model two 
intrinsic efficacies are defined: , the intrinsic efficacy of ligand A and , the intrinsic 
efficacy of ligand B. These intrinsic efficacies indicate whether the ligands A and B have a 
preference for R or for R*. The intrinsic efficacy may be larger than 1 (agonists) identifying a 
preference for R*, equal to 1 (antagonist) and no preference for R or R*, or between 0 and 1 
(inverse agonist) with a preference for R. Similar to parameter K identifying the association 
constant of ligand A, N is the association constant of ligand B. An allosteric modulator 
(ligand C) is able to modulate the binding and/or function of the receptor/endogenous ligand 
pair. To account for this cooperative effect parameters  and  were introduced (Hall, 2000). 
Parameter  denotes the binding cooperativity between ligand C and ligand A, recorded by a 
ratio of affinity of ligand C for ligand A/receptor complex AR and receptor R. Positive 
binding cooperativity ( > 1) indicates an increased level of binding of ligand A in the 
presence of ligand C and negative binding cooperativity (  1) suggests a decreased level of 
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binding. Parameter  represents the activation cooperativity between ligand C and ligand A, 
that is the ratio of affinity of ligand C for ligand A/active state receptor complex (AR*) and 
ligand A/inactive state receptor complex (AR). Similar to the binding cooperativity, also for 
the activation cooperativity we can identify a positive activation cooperativity ( > 1) 
indicating an increased level of activation in the presence of ligand C and a negative 
activation cooperativity (  1), indicating a decreased level of activation. In addition to 
parameters  and  describing the cooperativity effects of ligand C to ligand A, the intrinsic 
efficacy of ligand C is described by . When   1, ligand C does not affect the equilibrium 
between R and R*. When  > 1, however, ligand C shifts the equilibrium towards R* and 
when   1 ligand C shifts the equilibrium towards R. The association constant for ligand C is 
described by M. Thus four factors: , ,  and the product of M[C] of an allosteric ligand are 
able to modify the equilibrium states for an endogenous ligand/receptor pair. The reasoning in 
this appendix so far is based on the following pharmacological modeling. 
According to the two-state receptor model, the proportion of receptors in the active state is 
(Kenakin, 2003):
[ ] [ *] [ *]
[ ] [ ] [ *] [ ] [ *]
act
T
R R AR
R R R AR AR


  
  equation 1 
Equation 1 can be restated as 
[ ] [ ]
[ ] (1 )[ ] 1
act
T
R L A L
R L A L




  
   equation 2     
In the absence of ligand ([A]  0), the proportion of receptors in the active state represents the 
basal activity of the receptor 
[ ]
[ ] 1
act basal
T
R L
R L


    equation 3 
When a theoretically infinite concentration of ligand A is present ([A]), the proportion of 
receptors in the active state, or the maximal receptor activation of the receptor to ligand A is: 
max[ ]
[ ] 1
act
T
R L
R L




    equation 4 
When half of the maximal receptor activation is achieved, the proportion of receptors in the 
active state can be stated as  
1 / 2[ ] 1
[ ] (1 )
act
T
R L
R L



    equation 5 
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Two-state model can be extended to the one site competition model (for detail, see 
supplementary data). In this model, ligand B competes with endogenous ligand A to bind to 
both forms of receptors (R and R*). Similar to ligand A which can form AR and AR* with 
different forms of receptors, ligand B can form BR or BR*. According to this model, the 
following equation can be derived describing the proportion of receptors in the active state 
when two ligands (endogenous ligand A and an orthosteric ligand B) compete for the same 
binding site of a receptor:  
[ ] [ *] [ *] [ *]
[ ] [ ] [ *] [ ] [ *] [ ] [ *]
act
T
R R AR BR
R R R AR AR BR BR
 

    
 equation 6 
Equation 6 can be restated as 
[ ] (1 [ ] [ ])
[ ] 1 [ ](1 ) [ ](1 )
act
T
R L A N B
R L A L N B L
 
 
 

    
  equation 7 
It can be seen from this expression that in the absence of ligand A ([A]  0, [B] 0), the 
proportion of receptors in the active state or the initial activity (to discriminate from the basal 
activity of the receptor, the activity induced by other ligands in the absence of the endogenous 
ligand were referred to as initial activity in this study) of the receptor obeys the following 
equation:
[ ] (1 [ ])
[ ] 1 [ ](1 )
act
T
R L N B
R L N B L




  
    equation 8 
When a theoretically infinite concentration of ligand B is present ([B]), equation 8 can be 
simplified into 
[ ]
[ ] 1
act
T
R L
R L




     equation 9 
Equation 9 shows that the addition of an agonistic ligand B ( > 1) will enhance, whereas an 
inverse agonistic ligand B (0    1) will reduce the initial  activity of the receptor as 
shown in figures 2a and 2c. If   1, in other words when ligand B is a neutral antagonist, 
equation 8 is identical to equation 2, indicating that an antagonist cannot modify the initial  
activity of the receptor. 
When a theoretically infinite concentration of ligand A is present ([A]), the proportion of 
receptors in the active state, or the maximal receptor activation of the receptor by ligand A is: 
max[ ]
[ ] 1
act
T
R L
R L


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This equation is identical to equation 4, which reveals that the addition of an orthosteric 
ligand cannot modify the maximal receptor activation of the receptor by the endogenous 
ligand A. 
When half of the maximal receptor activation is achieved, the proportion of receptors in the 
active state can be stated as  
1 / 2[ ] 1 [ ](1 )
[ ] (1 )
act
T
R L N B L
R L


  


      equation 10    
Comparing equation 10 with equation 5 leads to the conclusion that the additional presence of 
an orthosteric ligand results in a rightward shift of the sigmoidal concentration-effect curve of 
the endogenous ligand.
Using the same approach as above, it is possible to predict the effect of the addition of an 
allosteric modulator C to the concentration-effect curve of the endogenous ligand A. We refer 
to the two-state allosteric model (Hall, 2000), which describes the allosteric interactions at 
receptors and especially accounts for the effect of the allosteric ligand itself on receptor 
activation. According to this model, the proportion of receptors in the active state is: 
[ ] [ *] [ *] [ *] [ * ]
[ ] [ ] [ *] [ ] [ *] [ ] [ *] [ ] [ * ]
act
T
R R AR CR AR C
R R R AR AR CR CR ARC AR C
  

      
  equation 11 
Equation 11 can be restated as 
[ ] (1 [ ] [ ](1 [ ])
[ ] 1 [ ](1 ) [ ](1 [ ](1 )
act
T
R L A M C A
R L M B L A L M C L
  
   
  

      
  equation 12   
In the absence of ligand A, the initial  activity of the receptor can be stated as 
[ ] (1 [ ])
[ ] 1 [ ](1 )
act basal
T
R L M C
R L M C L




  
      equation 13    
This equation is identical to equation 8 except that M and [C] are the parameters for an 
allosteric ligand while N and [B] are the parameters for an orthosteric ligand. This equation 
reveals that the initial  activity is governed by both the receptor (L) and the allosteric ligand 
( and product of M[C]). Analogous to the orthosteric ligand, an allosteric ligand is also able 
to modify the initial  activity of the receptor/endogenous ligand complex if   1, i.e. when 
the allosteric ligand has a preference for either the active or the inactive state of the receptor. 
In the presence of a saturating concentration of ligand C, equation 13 can be restated as 
[ ]
[ ] 1
act basal
T
R L
R L




     equation 14 
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When a theoretically infinite concentration of ligand C is present ([C]), the maximal 
activation of the receptor can be stated as 
max[ ] (1 [ ])
[ ] 1 [ ](1 )
act
T
R L M C
R L M C L
 
  


  
  equation 15 
This equation is more complicated than the equation for maximal receptor activation in the 
presence of an orthosteric ligand only (see equation 4). Equation 15 reveals that the maximum 
response of a receptor to its endogenous ligand is governed by the receptor (L), the 
endogenous ligand () and the allosteric ligand (, , , and product of M[C]). Thus an 
allosteric ligand is able to modify the maximum response of the receptor to its endogenous 
ligand.
When half of the maximal receptor activation is achieved, the proportion of receptors in the 
active state can be stated as  
1 / 2[ ] 1 [ ](1 )
[ ] (1 [ ](1 ))
act
T
R L M C L
R L M C L

  
  

  
  equation 16 
Comparing equation 16 with equation 10, we learn that binding cooperativity , functional 
cooperativity , as well as the intrinsic efficacy and the product of M[C] affect the sensitivity 
of the receptor to its endogenous ligand.  
It is interesting to note that in the presence of a saturating concentration of ligand C, equation 
16 can be restated as
1 / 2[ ] (1 )
[ ] (1 )
act
T
R L
R L

 



   equation 17 
This constant reveals the ceiling effect of an allosteric ligand because the right part of 
equation 17 is a constant and is thus independent from the concentration of ligand C.  
Effect of    on a receptor endogenous ligand pair 
By investigating the effect of ,  and  on a receptor/endogenous ligand pair, the  
initial  activity, Emax and EC50/IC50 deduced from the two-state receptor model and the two-
state allosteric receptor model can be compared.
Equation 3 defines the basal activity of a receptor in the absence of any ligand and equation 
14 describes the initial  activity of a receptor in a new equilibrium when an allosteric ligand 
is present in the absence of an endogenous ligand. If the two equations are identical, a 
condition is revealed whereby the allosteric ligand is not able to change the basal activity of a 
receptor. Thus, a new equation is obtained 
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1 1
L L
L L



 
     equation 18 
This equation only holds when   1. In this case, the allosteric ligand has no preference for 
either the active state or the inactive state of the receptor. In other words, the allosteric ligand 
cannot affect receptor activation or inactivation by itself. If the allosteric ligand increases the 
initial  activity of a receptor, that is, the allosteric ligand has an agonistic nature, a new 
expression is obtained 
1 1
L L
L L



 
This equation only holds when  > 1. On the contrary, if   1, the allosteric ligand reduces 
the initial  activity and this allosteric ligand has inverse agonist characteristics. Allosteric 
ligands with a preference for either the active or the inactive state of the receptor are able to 
modify the initial  activity of a receptor (Figure 3a). Since this property is only related to the 
intrinsic efficacy  of the ligand, the ability to modify the initial  activity of a receptor of the 
allosteric ligand is indistinguishable from an orthosteric ligand.  
Similarly, it is possible to examine the condition in which allosteric ligands do not affect the 
maximal activation induced by an endogenous ligand, that is 
(1 [ ])
1 1 [ ](1 )
L L M C
L L M C L
  
   


   
    equation 19 
Simplifying this equation yields   1, which reveals that only the intrinsic efficacy  and 
the activation cooperativity  of an allosteric ligand affect the maximal receptor activation 
induced by its endogenous ligand. If   1, a receptor’s maximal activation will decrease in 
the presence of allosteric ligands; if  > 1, a receptor’s maximal activation will increase 
when an allosteric ligand is present (Figure 3b). For a pure allosteric ligand which cannot 
activate or inactivate a receptor by itself (  1),  alone determines its effect on maximal 
receptor activation. In this case,  > 1 results in an increased maximal receptor activation and 
vice versa (Figure 3c). Since orthosteric ligands have no cooperative effect on the endogenous 
ligand, these ligands are unable to modify the maximal receptor activation. 
We also investigated under which circumstances an allosteric ligand does affect the potency 
of an endogenous ligand. When equation 5 (the proportion of receptors in the active state 
when half of the maximal receptor activation is achieved in the presence of ligand A) is 
identical to equation 16 (the proportion of receptors in the active state when half of the 
maximal receptor activation is achieved in the presence of both ligand A and ligand C), an 
allosteric ligand does not affect the potency of an endogenous ligand to a receptor, thus a new 
expression is obtained 
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1 1 [ ](1 )
(1 ) (1 [ ](1 ))
L L M C L
L L M C L

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   equation 20 
Manipulation of this equation yields 
(1 )(1 )
(1 )(1 )
L L
L L
 

 

 
      equation 21 
If the left part of equation 20 is smaller than the right part, or  being smaller than the right 
part of equation 21, the allosteric ligand is able to reduce the potency of the endogenous 
ligand, thus a rightward shift of the sigmoidal curve of the endogenous ligand will be 
observed and vice versa (Figure 3d). Equation 21 reveals that ,  and  of an allosteric 
modulator can affect the potency of an endogenous ligand on a receptor. Increasing  and 
both results in an increased potency of the endogenous ligand.
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General Conclusions 
By the research described in this thesis, new insights were gained concerning the 
identification of inverse agonists for the human adenosine A2B receptor and their intrinsic 
efficacy. The antagonists ZM241385, DPCPX and MRS1706 exhibited intrinsic efficacy 
values () of 0.14, 0.35 and 0.31, respectively, on 7 constitutively active mutant (CAM) 
human adenosine A2B receptors as determined with a yeast growth assay. These compounds 
were therefore classified as inverse agonists (  1) for the human adenosine A2B receptor.
Subsequently, a series of 9 CAM receptors with varying levels of constitutive activity were 
used to quantify the effects of the three inverse agonists. These experiments showed that 
mutated adenosine A2B receptors with various levels of constitutive activity responded 
differently to these three inverse agonists. Two high level CAM receptors were locked in an 
active state and were insensitive to the inverse agonists. The three intermediate level CAM 
receptors were partially inhibited, whereas the four low level CAM receptors were almost 
completely inhibited. 
Next, the two-state receptor model was used to theoretically explain these experimental 
observations. The response of an inverse agonist and the experimental window were shown to 
depend not only on the intrinsic efficacy of the inverse agonist, but also on the receptor 
isomerization constant (L) value which defines the level of constitutive activity of a receptor.  
A further study investigated the optimal conditions for the screening of inverse agonists. The 
data revealed that the optimal window for measurements is achieved when the value of the 
isomerization constant (L, being the ratio between the active (R*) and inactive (R) states of 
the receptor thereby determining the constitutive activity of the receptor) equals the reciprocal 
square root of the intrinsic efficacy () of the inverse agonist. When L is smaller than this 
value, the window will increase with an increase of the constitutive activity of the receptor. 
On the other hand, when L is bigger than the reciprocal square root of the intrinsic efficacy 
() of the inverse agonist, the window will decrease with an increase of the constitutive 
activity. In other words, receptors with intermediate levels of constitutive activity should be 
the most sensitive screening tools to detect inverse agonists.  
Concerning receptor activation, site-directed mutant A2B receptors were constructed to 
investigate the role of the NxxxNPxxY motif and the potential salt bridge between TM1 (E14) 
and TM7 (H280) in receptor activation. In total 12 mutant receptors were constructed and 
tested with 5 agonists: NECA, CPA, CGS21680, IBMECA and LUF5833. N282, N286 and 
Y290 of the NxxxNPxxY motif were subjected to mutation yielding seven point mutants 
N282Q, N282R, N286A, N286Q, N286R, Y290N and Y290F. Except for the N286A mutant 
receptor which was expressed at lower levels all constructed mutants were expressed at levels 
comparable to the wild-type receptor. With respect to the NxxxNPxxY motif, the N282R and 
N286R receptors behaved more or less similar to the wild-type receptor for all agonists tested. 
Interestingly, the introduction of a glutamine at position 282 was reasonably well tolerated 
(N282Q), but the introduction of an alanine or glutamine residue at position 286 (N286A and 
N286Q) drastically reduced the ability of the agonists to activate the receptor. Whereas the 
responsiveness of the N286A mutant receptor could at least partially be ascribed to reduced 
receptor expression levels, the N286Q was expressed at wild-type levels. Mutation of Y290 to 
N and F revealed that this residue is very sensitive to mutagenesis also. Whereas the 
conservative Y290F mutant still responded quite well to the agonists, the Y290N receptor 
could no longer be activated despite the fact that this receptor was expressed at normal levels. 
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To study the role of the potential salt bridge, three mutants were made. Mutation of H280E 
and E14H/H280E abolished receptor expression. Apparently the salt bridge in the adenosine 
A2B receptor can not be swapped as the H280E mutation interferes with receptor expression. 
Moreover, although the E14H mutant receptor was normally expressed no activation by any 
of the tested agonists could be identified. Interestingly, based on a rhodopsin-based homology 
model of the adenosine A2B receptor, the proximity of I61 to the salt bridge suggested a 
potential role for this amino acid. To evaluate the role of this residue I61A, I61D and I61K 
mutant receptors were made. None of these mutants responded to any of the tested agonists 
despite normal expression levels. 
Apparently, both the potential salt bridge and the NxxxNPxxY motif play an important role in 
the process of receptor activation explaining why most changes at this region impair receptor 
activation. This result is consistent with our previous findings that none of the gain-of-
function mutant receptors identified from the random mutation bank (Beukers et al., 2004) 
contained mutations in the conserved NPxxY motif or the NxxxNPxxY motif. Based on the 
experiments performed, we are not able to indicate whether effects on receptor activation are 
also reflected in ligand binding. The location of the mutated residues would suggest however 
that ligand binding would not be altered for the mutants that were properly expressed.
Based on the crystal structures of the human 2 adrenergic receptor and bovine rhodopsin, two 
homology models of the adenosine A2B receptor were made. Analysis of these two models 
revealed subtle differences in the length and angle of helixes, the turn between helix 7 and 
helix 8 and rotamers of interacting aromatic residues at the cytosolic side of helix 7 and in 
helix 8. These differences actually account for changes in the intramolecular interactions 
within the two models of the adenosine A2B receptor, despite the fact that GPCRs share a 
common overall structure. Thus we conclude that receptor activation is a receptor-specific 
phenomenon as shown by site directed mutagenesis experiments addressing the conserved 
NPxxY motif and the characteristic adenosine receptor salt bridge. 
A comparison of inverse agonists and allosteric modulators to treat disease-related receptor 
mutations caused by constitutive activity indicated that allosteric ligands display a more 
complicated interaction with a receptor/endogenous ligand pair and are able to cooperatively 
modify receptor binding and function. Unlike the orthosteric ligands that only compete with 
endogenous ligands, a proper allosteric ligand, i.e. a ligand with appropriate binding 
cooperativity and functional cooperativity, may be able to reverse the mutant receptor 
phenotype into the wild-type phenotype. Thus allosteric modulators but not inverse agonists 
are able to reverse constitutive activity without affecting the EC50 value of the endogenous 
agonist thereby providing in theory a more physiological treatment to diseases stemming from 
constitutively active GPCR mutations. 
Perspecti es 
irect read-out for human adenosine A2B receptors 
As a model, we use the adenosine A2B receptors (wild-type and mutants) expressed in yeast 
and measure cell growth as a read-out for GPCR activity. This system is ideally suited to 
select mutant receptors of interest from a large pool of mutant receptors. However, strictly 
speaking, yeast growth is not a direct reflection of GPCR activity. Activation of A2B receptors 
expressed on the yeast membrane results in the activation of the Fus1 promoter and induces 
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the synthesis of imidazole glycerolphosphate dehydratase, a key enzyme in the synthesis of 
histidine. Thus yeast growth in histidine-deficient medium is positively correlated rather than 
proportional to the activation of A2B receptors. Supplementary data may therefore be obtained 
by expression in a mammalian system, by investigating more proximal read-outs such as 
GTP-dependent adenylyl cyclase activity or, even better, guanine nucleotide exchange.
easure receptor acti ation in mammalian cells 
Compared to mammalian cells, yeast cells are more convenient in both random and site-
directed mutagenesis studies as these cells take up a single plasmid. The combination of such 
a mutagenesis approach and a robust screening assay make yeast cells a great tool to 
investigate receptor activation in an indirect way. However, some differences between yeast 
and mammalian cells, for example post-translational modifications, may need to be taken into 
consideration. It is known that yeast S. cerevisiae cells can only synthesize core or high 
mannose oligosaccharides and do not have the ability to synthesize mature or complex 
oligosaccharides (Miret et al., 2002). As a result rhodopsin expressed in yeast S. cerevisiae
has a glycosylation pattern different from natively purified bovine rhodopsin as revealed with 
SDS/PAGE and in an endoglycosidase H sensitivity assay (Mollaaghababa et al., 1996).
Another difference between yeast and mammalian cells is the lipid composition of the 
membrane which may affect the behavior of heterologously expressed receptors in yeasts. 
Lagane and his colleges demonstrated that the loss of agonist affinity of the human µ opioid 
receptor expressed in S. cerevisiae could be simply restored by replacing ergosterol from 
yeast with cholesterol which is normally found in mammalian rather than yeast plasma 
membranes (Lagane et al., 2000). 
Depending on the receptor of interest and the research questions at hand these differences 
between yeast and mammalian expression systems should be taken into consideration. In 
some cases it may be useful to supplement experiments in yeast with experiments in 
mammalian cells. Alternatively, a direct translation from in vitro cells to for example brain 
slices or in vivo research may be considered. An example where substantiation of yeast 
experiments with experiments in mammalian cells was useful has been described for the 
muscarinic M3 receptor. At first a random mutagenesis study of the rat M3 muscarinic 
acetylcholine receptor was performed in S. cerevisiae yielding 174 mutants with the desired 
phenotype were identified. To confirm this result, mutants were transfected in COS7 cells and 
159 out of 174 mutants showed consistent behavior in yeast and mammalian cells (Li et al., 
2007).
In our study of the adenosine A2B receptor, the phenotype with regard to the interaction with 
ligands of several mutants identified from the random mutagenesis screen in yeast were 
confirmed in mammalian cells. These findings suggest that the translation from yeast to 
mammalian cells for this receptor subtype seems to be straightforward. It would be interesting 
nevertheless to extend findings obtained in yeast to mammalian cells and preferably in vivo
test systems. Such extended investigations will enable the identification of ligand-selective 
down-stream signaling pathways and of interactions with other protein partners. 
Conser ed GPCR motifs 
There has been a sustained effort to elucidate the functional mechanisms of GPCRs, including
their ability to undergo conformational changes and activate G proteins (Schwartz et al., 
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2006). The functional role of the two Ns and Y in the conserved NxxxNPxxY motif of the 
human adenosine A2B receptor was investigated in our study (Chapter 5). There are other 
conserved GPCR motifs, for example, the E/DRY motif. This triplet of amino acids located at 
the boundary between transmembrane domain (TM) III and intracellular loop 2 of class A 
GPCRs, has been suggested to play a pivotal role in regulating GPCR conformational states 
(Rovati et al., 2006). Mutation studies of charged residues in the E/DRY motif of class A 
GPCRs revealed a role for this motif in G protein coupling, receptor expression, ligand 
binding, ligand-depend receptor activation and constitutive receptor activation (for reviews, 
see Rovati et al., 2006 and Flanagan 2005). In his review, Rovati pointed out that there is no 
rule for the function of this motif despite its high conservation. If every receptor has its own 
story, it would be interesting to investigate the role the E/DRY motif plays in the adenosine 
A2B receptor. 
The cytosolic part of helix 7 and helix 8 also deserves more detailed investigation. It is well 
known that - interactions exist between Y290 in helix 7 and F297 in helix 8. Mutations 
which disturb this interaction result in receptors with impaired signaling ability, as has been 
demonstrated for the CCR5 receptor, neurokinin-1 receptor and M1 muscarinic acetylcholine 
receptor (Aramori et al., 1997; B hm et al., 1997; Lu et al., 2001). In our study (see Chapter
5), two mutants were constructed; Y290F showed less activation than the wild-type receptor 
and Y290N could not be activated at all. To investigate whether - interactions exist 
between Y290 and F297, a swapped Y290F/F297Y mutant receptor should be constructed to 
see if the phenotype of the wild-type receptor is regained. An important control would be to 
make single point F297 mutations also to rule out any unforeseen effects like we encountered 
while investigating the salt bridge between E14 and H280. In that case mutation of H280 was 
detrimental to receptor expression. 
Helix 8 is an important helix although it has been studied much less extensively. It is located 
on the cytosolic side of the membrane, and it is suggested to be involved in cell membrane 
location, binding with cell skeleton, internalization and G protein coupling (Bermak et al., 
2001; Feng et al., 2003). It is interesting to note that adenosine receptors possess a cluster of 
aromatic amino acids at the end of helix 7 and helix 8. In the A2B receptor, Y290, F297 and 
F301 may interact in pairs. A hydrophobic residue (I) was found 4 amino acids downstream 
of this cluster. Such a pattern is not only conserved among adenosine receptors, but also 
present in many other receptors, for example rhodopsin and the 2 adrenergic receptor (figure 
1). If conservation is a measure for importance, then this aromatic cluster would be interesting 
to be investigated. Residue F (in grey box in figure 1) located in helix 8 is one of the residues 
thought to form - interactions with residues in helix 7. In addition, the residues 4 and 8 
amino acids downstream of this F residue are also hydrophobic (see black box in figure 1). 
Figure 1. Alignment of helix 8 of human adenosine A1, A2A, A2B, A3, human 2 adrenergic receptors and 
bovine rhodopsin. Conserved residues are marked in black. Residue F located in helix 8 is located in the 
grey box, whereas the black boxes highlight the hydrophobic residues present 4 and 8 amino acids 
downstream of this F residue.  
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Allosteric modulators ersus in erse agonists  
Constitutive activity, the spontaneous basal signalling activity of GPCRs in the absence of 
agonists, has been identified for a considerable number of GPCRs, mutant as well as wild-
type receptors (de Ligt et al., 2000). Quite a few constitutively active mutant receptors are 
disease-related. For example, night blindness, diabetes insipidus, and male precocious puberty 
are caused by constitutively active mutations of rhodopsin, the V2 vasopressin receptor and 
the LH receptor, respectively (Rao et al., 1994; Morello et al., 2000; Shenker et al., 1993). 
Inverse agonists have therapeutic benefits for the treatment of constitutive activity-related 
diseases because these compounds are able to reduce the constitutive activity of the receptors. 
However, as demonstrated in Chapter 6, inverse agonists will also reduce the sensitivity of 
the receptor to its endogenous ligand due to competition.  
Besides inverse agonists, allosteric modulators may be a great supplement to the available 
ligand repertoire due to their ability to selectively increase or decrease receptor activity 
without affecting the EC50 value of the endogenous ligand. In fact, the tightly controlled 
release and synthesis of endogenous ligands is retained while the allosteric modulator itself 
only potentiates or dampens this response rather than having an effect by itself. The potential 
to use allosteric modulators to treat particular diseases stemming from increased constitutive 
receptor activity warrants further exploration. 
In this thesis, a combined approach was described to investigate the constitutive activity of G 
protein coupled receptors (GPCRs) using human adenosine A2B receptors as a prototype and 
to evaluate disease-related constitutive GPCR activity as a target for treatment. A yeast 
expression system proved to be a very versatile experimental tool to easily follow receptor 
activation. Integration of the results of these studies with pharmacological and theoretical 
receptor models laid the foundation for a deeper and detailed understanding of a receptor’s 
constitutive activity. In future research, a combination of more physiological expression 
systems together with such receptor models should be investigated to validate the therapeutic 
application of inverse agonists and allosteric modulators, and to discriminate between these 
two ligand categories. 
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ummar  
In this thesis a combined approach is described to investigate the constitutive activity of 
G protein protein-coupled receptors (GPCRs) using human adenosine A2B receptors and to 
evaluate disease-related constitutive GPCR activity as a target for treatment. To this end a 
yeast expression system together with pharmacological and theoretical receptor models have 
been applied. 
In Chapter 2 the advantages of yeasts as tools to study GPCRs are reviewed. Adapted 
yeast cells able to communicate with mammalian GPCRs have become available and provide 
a very convenient system to express mutated receptors. A major advantage of yeast cells over 
mammalian cells extends from easy culturing conditions to the characteristic of yeast cells to 
allow entry of only a single plasmid. This latter property in combination with the robust 
screening assay based on yeast growth makes them an ideal test system to study randomly as 
well as site-directed mutated receptors. In chapters 3 to 5 this yeast growth assay is the main 
experimental tool to evaluate the functional properties of random and site-directed mutant 
receptors. 
In chapters 3 and 4 the yeast system is exploited to study inverse agonism of the human 
adenosine A2B receptor. At first, constitutively active mutant (CAM) human adenosine A2B
receptors have been used to discriminate inverse agonists of the adenosine A2B receptor from 
A2B receptor antagonists. As a result, three inverse agonists ZM241385, DPCPX and 
MRS1706 were identified and their rank order of efficacy determined. Moreover, an 
interesting system-dependent phenomenon was noticed, that is the intrinsic activities of the 
inverse agonists were affected by the level of constitutive activity. It was demonstrated that 
inverse agonists show the greatest intrinsic activity on receptors displaying a medium level of 
constitutive activity.
To further investigate the relationship between the effectiveness of an inverse agonist 
and the level of constitutive activity of the receptor, the two-state receptor model was 
introduced in both Chapter 3 and Chapter 4. According to this two-state model, both the 
receptor isomerization constant (L) and the intrinsic efficacy () of the inverse agonist 
determines the sensitivity to detect the intrinsic activity of an inverse agonist which is 
reflected by the observed experimental window. The biggest experimental window can be 
achieved on receptors with an L value equaling the reciprocal square root of . Our 
experiments show that mutant A2B receptors with an intermediate level of constitutive activity 
possess the greatest experimental window, whereas mutants with a low level of constitutive 
activity showed small experimental windows and highly constitutively active mutants did not 
respond to our tested inverse agonists. Based on these findings we conclude that receptors 
with intermediate levels of constitutive activity should be the most sensitive screening tools 
for detecting inverse agonists. 
In Chapter 5 the activation of the human adenosine A2B receptor was investigated. To 
investigate the role of the NxxxNPxxY motif and the potential salt bridge between TM1 (E14) 
and TM7 (H280) in receptor activation, site-directed mutagenesis was applied to yield 15 
mutant A2B receptors. The mutations were selected based on an adenosine A2B receptor model 
using the structure of bovine rhodopsin as a template. The expression levels of these mutants 
were determined by western blot analysis and the activation of the receptors was measured in 
the presence or absence of the following agonists NECA, CPA, CGS21680, IBMECA and 
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LUF5833. None of the mutant receptors displayed constitutive activity. On the contrary, most 
mutants had a reduced potency and/or efficacy, e.g. mutants N282Q, N282R, N286A, N286Q, 
N286R, and Y290F showed impaired activation and mutants Y290N, E14H, H280E, 
E14H/H280E, I61A, I61D and I61K could not be activated by any of the agonists tested. 
Among all the mutants constructed, only N282R and N286R receptors behaved similarly to 
the wild-type receptor. Moreover, mutant N286A reduced receptor expression and H280E and 
E14H/H280E abolished receptor expression. These results suggest an important role for the 
NxxxNPxxY motif and the potential salt bridge in receptor expression and activation. 
The recent publication of the 2-adrenergic receptor structure enabled us to construct a 
second model of the adenosine A2B receptor. Comparison of the two A2B receptor models 
based on these two different templates is also described in Chapter 5. The various effects 
caused by mutations in the NxxxNPxxY motif and the potential salt bridge of different 
receptors in both our experiments and from literature do suggest that receptor activation is a 
receptor-specific phenomenon. 
In Chapter 6 we provide a theoretical investigation of the treatment of disease-related 
constitutively active receptor mutations. Comparison of the characteristics of allosteric 
ligands with traditional orthosteric ligands using a two-state allosteric model predicts that 
allosteric ligands display a more complicated interaction with a receptor/endogenous ligand 
pair and are able to cooperatively modify receptor binding and function. As a result allosteric 
modulators may affect the level of constitutive activity without changing the potency of the 
endogenous ligand. Thus allosteric modulators may provide advantages over orthosteric 
ligands in the treatment of diseases caused by constitutively active GPCR mutations. 
Finally in Chapter 7, general conclusions about the research described in this thesis are 
drawn. This is also supplemented by an outlook on some potential aspects of research to be 
pursued, based upon the application of receptor models, pharmacology models and functional 
receptor assays. 
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amen attin  
In dit proefschrift wordt een gecombineerde aanpak besproken om aan de hand van de 
adenosine A2B receptor de constitutieve activiteit van aan G-eiwitten gekoppelde receptoren 
(GPCRs) te bestuderen en daarnaast de mogelijkheden te evalueren om ziekte-gerelateerde 
constitutief actieve receptoren te gebruiken als aangrijpingspunt voor behandeling. Daartoe is 
gebruik gemaakt van een expressiesysteem in gist tezamen met farmacologische en 
theoretische receptormodellen. 
In hoofdstuk 2 wordt een overzicht gegeven van de voordelen van het gebruik van gist 
als hulpmiddel om GPCRs te onderzoeken. Gemodificeerde gistcellen die kunnen 
communiceren met GPCRs afkomstig van zoogdieren zijn beschikbaar gekomen en bieden 
een heel geschikt systeem om gemuteerde receptoren tot expressie te brengen. Grote 
voordelen van gistcellen ten opzichte van zoogdiercellen zijn onder andere de eenvoudige 
kweek en hun karakteristieke eigenschap om maar n enkel plasmide op te nemen. Deze 
laatste eigenschap in combinatie met de robuuste meetmethode gebaseerd op gistgroei maakt 
deze gistcellen een ideaal testsysteem om de gemuteerde receptoren te bestuderen, of ze nu 
willekeurige dan wel plaatsspecifieke mutaties bevatten. In de hoofdstukken 3 t/m 5 is deze 
meetmethode gebaseerd op de groei van gist het voornaamste middel om de functionele 
eigenschappen van de willekeurig en plaatsspecifiek gemuteerde receptoren te onderzoeken. 
In de hoofdstukken 3 en 4 wordt dit gistsysteem gebruikt om invers agonisme van de 
adenosine A2B receptor van de mens te bestuderen. Allereerst zijn de constitutief actief 
gemuteerde (CAM) adenosine A2B receptoren van de mens gebruikt om onderscheid te maken 
tussen inverse agonisten en antagonisten voor de A2B receptor. Op basis hiervan werden de 
inverse agonisten ZM241385, DPCPX en MRS1706 ge dentificeerd en werd de volgorde van 
werkzaamheid bepaald. Bovendien werd een interessant systeemafhankelijk fenomeen 
opgemerkt, namelijk dat de intrinsieke activiteit van de inverse agonisten be nvloed wordt 
door de mate van constitutieve activiteit. De inverse agonisten bleken de grootste intrinsieke 
activiteit te vertonen op receptoren met een gemiddeld niveau van constitutieve activiteit. 
Om de relatie tussen de effectiviteit van een inverse agonist en de mate van constitutieve 
activiteit van de receptor verder te onderzoeken hebben we het two-state’ receptormodel 
ge ntroduceerd in hoofdstuk 3 en 4. Volgens dit two-state’ receptormodel bepalen zowel de 
receptor isomerisatieconstante (L) als de intrinsieke activiteit () van de inverse agonist de 
gevoeligheid waarmee de intrinsieke activiteit van de inverse agonist bepaald kan worden; dit 
wordt weerspiegeld in het waargenomen experimentele meetbereik. Het grootste 
experimentele meetbereik wordt verkregen met receptoren die een L waarde bezitten die 
gelijk is aan de omgekeerde wortel van . Onze experimenten laten zien dat gemuteerde 
receptoren met een gemiddeld niveau van constitutieve activiteit het grootste experimentele 
meetbereik hebben, terwijl mutanten met een lage constitutieve activiteit kleine experimentele 
meetbereiken hebben en mutanten met een hoge constitutieve activiteit niet reageren op de 
door ons geteste inverse agonisten. Op grond van deze bevindingen concluderen we dat 
receptoren met een gemiddeld niveau van constitutieve activiteit het meest gevoelige 
meetinstrument zullen zijn voor de detectie van inverse agonisten. 
In hoofdstuk 5 is de activering van de adenosine A2B receptor van de mens onderzocht. 
Plaatspecifieke mutaties zijn gebruikt om 15 gemuteerde A2B receptoren te maken waarmee 
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de rol van het NxxxNPxxY motief en de veronderstelde zoutbrug tussen het 
transmembranaire domein 1 (E14) en het transmembranaire domein 7 (H280) te bestuderen. 
De mutanten werden geselecteerd op basis van een adenosine A2B receptormodel met 
gebruikmaking van rhodopsine als matrijs. De expressieniveaus van deze mutanten werd 
bepaald met western blot analyse en de activering van de receptoren werd gemeten in de aan- 
en afwezigheid van de volgende agonisten: NECA, CPA, CGS21680, IBMECA en LUF5833. 
Geen van de gemuteerde receptoren vertoonde constitutieve activiteit. In tegendeel, de meeste 
mutanten hadden een verlaagde werkzaamheid en/of effectiviteit, dat wil zeggen de N282Q, 
N282R, N286A, N286Q, N286R en Y290F mutanten vertoonden een verminderde activering 
en de Y290N, E14H, H280E, E14H/H280E, I61A, I61D en I61K mutanten konden niet 
geactiveerd worden door de onderzochte agonisten. Van al deze gemaakte mutanten 
gedroegen alleen de N282R en de N286R receptoren zich vergelijkbaar aan de wild-type 
receptor. Bovendien vertoonde de N286A mutant een verlaagde receptorexpressie en was de 
expressie van de H280E en de E14H/H1280E receptor verdwenen. Deze resultaten suggereren 
een belangrijke rol voor het NxxxNPxxY motief en de veronderstelde zoutbrug in 
receptorexpressie en -activering. 
De recente structuuropheldering van de 2-adrenerge receptor heeft het ons mogelijk 
gemaakt om een tweede model voor de adenosine A2B receptor te construeren. Een 
vergelijking van de twee A2B receptormodellen gebaseerd op deze twee verschillende 
matrijzen is ook in hoofdstuk 5 beschreven. De verscheidene effecten die veroorzaakt worden 
door de mutaties in het NxxxNPxxY motief en de veronderstelde zoutbrug in verschillende 
receptoren, zowel in onze experimenten als in de literatuur, suggereren dat receptoractivering 
een receptor-specifiek fenomeen is. 
In hoofdstuk 6 doen we een theoretisch onderzoek naar de behandeling van 
ziektegerelateerde constitutief actieve receptormutaties. Een vergelijking van de 
eigenschappen van allostere liganden ten opzichte van traditionele orthostere liganden 
voorspelt op basis van het two-state’ allostere receptormodel dat allostere liganden een meer 
gecompliceerde interactie vertonen met de combinatie van receptor en endogeen ligand en dat 
ze in staat zijn om receptorbinding en receptorfunctie co peratief te modificeren. Daardoor 
kunnen allostere modulatoren de mate van constitutieve activiteit veranderen zonder dat de 
effectiviteit van het endogene ligand wijzigt. Met andere woorden, allostere modulatoren 
kunnen voordelen bieden ten opzichte van orthostere liganden in de behandeling van ziekten 
die veroorzaakt worden door constitutief actieve GPCR mutaties. 
Tot slot worden in hoofdstuk 7 algemene conclusies getrokken over het onderzoek zoals 
beschreven in dit proefschrift. Op basis van de toepassing van de receptor- en 
farmacologische modellen en functionele receptormeetmethoden wordt vooruitgeblikt naar 
verder onderzoek. 
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3-AT                       3-aminotriazole 
                              intrinsic efficacy 
BAY 60-6583         (2-[6-Amino-3,5-dicyano-4-(4-cyclopropylmethoxy-phenyl)–pyridin -2-   
ylsulfanyl]-acetamide) 
CAM                       constitutively active mutant 
CGS15943              9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine 
CGS21680              2-[4-(2-carboxyethyl)phenethylamino]-5’-N- ethylcarboxamidoadenosine 
CPA             N6-cyclopentyladenosine
DPCPX                   1,3-dipropyl-8-cyclopentylxanthine  
EC50                        Effective concentration (50%)   
GDP                        Guanosine diphosphate 
GPCR             G protein-coupled receptor 
GTP                Guanosine triphosphate 
IB-MECA     N6-(3-iodobenzyl)adenosine-5’-N-methyluronamide 
IC50     Inhibitory concentration (50%)
KA   equilibrium dissociation constant 
L     isomerization constant
MRS1706 N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3–dipropyl-1H - 
purin-8-yl)phenoxy]acetamide 
MRS1754                [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3 -dipropyl-1H 
-purin-8-yl)phenoxy] acetamide] 
MRE2029F20 [N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropy l-2,3,6,7-
tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide 
NECA             5’-N-ethylcarboxamidoadenosine 
OSIP339391            N-(2- 2-Phenyl-6-[4-(3-phenylpropyl)-piperazine-1-carbonyl] -7H -
pyrrolo[2,3-d]pyrimidin-4-ylamino -ethyl)-acetamide  
PD81,723                 (2-Amino-4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl) 
phenyl]methanone  
(S)-PHPNECA        (S)-2-phenylhydroxypropynyl-5'-N-ethylcarboxamidoadenosine  
wt  wild-type 
ZM 241385    (4-(2-[7-amino-2-(2-furyl 1,2,4 -triazolo 2,3-a 1,3,5 triazin-5-yl-
aminoethyl)phenol 
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TELL GE  
behorende bij het proefschrift 
Constitutive receptor activation and pharmacological modeling 
The adenosine A2B receptor as a prototype
1. To detect inverse agonists with low efficacy or to rank compounds based on their intrinsic 
efficacy, receptors with intermediate levels of constitutive activity provide a better test system 
than receptors with either a rather high constitutive activity or negligible constitutive activity. 
This thesis 
2. The assumption that the inhibitory effect of an inverse agonist will increase with an increase in 
constitutive activity of the receptors is valid only for highly efficacious inverse agonists. 
This thesis 
3. Although all class A receptors share a similar backbone consisting of 7 transmembrane 
domains linked by extracellular and intracellular loops, each receptor has its own characteristics. 
This thesis 
4. Unlike orthosteric ligands, the allosteric compounds are able to modulate independently the 
initial  activity and the maximal receptor response without affecting the potency of the 
endogenous ligands. 
This thesis 
5. It is believed that an inhibitory effect of an inverse agonist will increase with an increase in 
constitutive activity of the receptor it interacts with. However, this is not always true.  
Seifert and Wenzel-Seifert, Naunyn-Schmiedeberg’s Arch Pharmacol. 2002, 366:381-416; This thesis 
6. The three available ligand-bound GPCR structures suggest that there is no generally conserved 
receptor binding pocket. Rather, the pocket itself can vary in position and orientation, yielding 
more opportunity for receptor diversity and ligand selectivity. 
Jaakola et al., Science 2008
7. When compared to the 2AR crystal structure, all 2AR models based on the structure of 
rhodopsin were more similar to rhodopsin rather than 2AR. This is not entirely surprising but 
highlights a general shortcoming in homology models generated from a single structural template. 
Cherezov V, et al., Science. 2007, 318:1253-4
8. Receptor models can be used to simulate and fit data and yield quantitative parameters that can 
be used to measure drug activity, system responsiveness, and ligand behavior. However, the 
shortcoming of these models is that they require predefinition of the receptor species and this is 
not always obvious. 
Kenakin T.  J Recept Signal Transduct Res. 2008, 28:109-25 
9. Libraries are not made; they grow. 
Augustine Birrell 
10. It is a capital mistake to theorize before one has data. 
Sir Arthur Conan Doyle 
11. He who would distinguish the true from the false must have an adequate idea of what is true 
and false. 
Benedict
12. By indirections find directions out. 
William Shakespeare 
